<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceuticals (Basel)</journal-id><journal-id journal-id-type="pmc-domain-id">2102</journal-id><journal-id journal-id-type="pmc-domain">pharmaceuticals</journal-id><journal-id journal-id-type="publisher-id">pharmaceuticals</journal-id><journal-title-group><journal-title>Pharmaceuticals</journal-title></journal-title-group><issn pub-type="epub">1424-8247</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10610367</article-id><article-id pub-id-type="pmcid-ver">PMC10610367.1</article-id><article-id pub-id-type="pmcaid">10610367</article-id><article-id pub-id-type="pmcaiid">10610367</article-id><article-id pub-id-type="pmid">37895855</article-id><article-id pub-id-type="doi">10.3390/ph16101384</article-id><article-id pub-id-type="publisher-id">pharmaceuticals-16-01384</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Liu</surname><given-names initials="D">Dequan</given-names></name><xref rid="af1-pharmaceuticals-16-01384" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Che</surname><given-names initials="X">Xiangyu</given-names></name><xref rid="af1-pharmaceuticals-16-01384" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="X">Xiaoxi</given-names></name><xref rid="af2-pharmaceuticals-16-01384" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ma</surname><given-names initials="C">Chuanyu</given-names></name><xref rid="af1-pharmaceuticals-16-01384" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-16-01384" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="G">Guangzhen</given-names></name><xref rid="af1-pharmaceuticals-16-01384" ref-type="aff">1</xref><xref rid="c1-pharmaceuticals-16-01384" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Jimenez-Barbero</surname><given-names initials="J">Jesus</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-pharmaceuticals-16-01384"><label>1</label>Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China; <email>liudq@dmu.edu.cn</email> (D.L.); <email>chexiangyu@firsthosp-dmu.com</email> (X.C.)</aff><aff id="af2-pharmaceuticals-16-01384"><label>2</label>Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China; <email>wangxiaoxi@firsthosp-dmu.com</email></aff><author-notes><corresp id="c1-pharmaceuticals-16-01384"><label>*</label>Correspondence: <email>machuanyu@firsthosp-dmu.com</email> (C.M.); <email>wuguangzhen@firsthosp-dmu.com</email> (G.W.)</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>9</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>10</month><year>2023</year></pub-date><volume>16</volume><issue>10</issue><issue-id pub-id-type="pmc-issue-id">448079</issue-id><elocation-id>1384</elocation-id><history><date date-type="received"><day>02</day><month>9</month><year>2023</year></date><date date-type="rev-recd"><day>25</day><month>9</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>9</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>29</day><month>09</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>28</day><month>10</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-01-26 19:25:11.183"><day>26</day><month>01</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="pharmaceuticals-16-01384.pdf"/><abstract><p>This comprehensive review delves into the rapidly evolving arena of cancer vaccines. Initially, we examine the intricate constitution of the tumor microenvironment (TME), a dynamic factor that significantly influences tumor heterogeneity. Current research trends focusing on harnessing the TME for effective tumor vaccine treatments are also discussed. We then provide a detailed overview of the current state of research concerning tumor immunity and the mechanisms of tumor vaccines, describing the complex immunological processes involved. Furthermore, we conduct an exhaustive analysis of the contemporary research landscape of tumor vaccines, with a particular focus on peptide vaccines, DNA/RNA-based vaccines, viral-vector-based vaccines, dendritic-cell-based vaccines, and whole-cell-based vaccines. We analyze and summarize these categories of tumor vaccines, highlighting their individual advantages, limitations, and the factors influencing their effectiveness. In our survey of each category, we summarize commonly used tumor vaccines, aiming to provide readers with a more comprehensive understanding of the current state of tumor vaccine research. We then delve into an innovative strategy combining cancer vaccines with other therapies. By studying the effects of combining tumor vaccines with immune checkpoint inhibitors, radiotherapy, chemotherapy, targeted therapy, and oncolytic virotherapy, we establish that this approach can enhance overall treatment efficacy and offset the limitations of single-treatment approaches, offering patients more effective treatment options. Following this, we undertake a meticulous analysis of the entire process of personalized cancer vaccines, elucidating the intricate process from design, through research and production, to clinical application, thus helping readers gain a thorough understanding of its complexities. In conclusion, our exploration of tumor vaccines in this review aims to highlight their promising potential in cancer treatment. As research in this field continues to evolve, it undeniably holds immense promise for improving cancer patient outcomes.</p></abstract><kwd-group><kwd>TME</kwd><kwd>cancer immunology</kwd><kwd>oncology vaccines</kwd><kwd>combination therapies</kwd><kwd>personalized cancer vaccines</kwd></kwd-group><funding-group><award-group><funding-source>the Scientific Research Fund of the Liaoning Provincial Education Department</funding-source><award-id>LZ2020071</award-id></award-group><award-group><funding-source>the Doctoral Start-up Foundation of Liaoning Province</funding-source><award-id>2021-BS-209</award-id></award-group><award-group><funding-source>the Dalian Youth Science and Technology Star</funding-source><award-id>2021RQ010</award-id></award-group><funding-statement>This project was supported by the Scientific Research Fund of the Liaoning Provincial Education Department (No. LZ2020071), the Doctoral Start-Up Foundation of Liaoning Province (No. 2021-BS-209), and the Dalian Youth Science and Technology Star (No. 2021RQ010).</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-pharmaceuticals-16-01384"><title>1. Introduction</title><p>According to a comprehensive epidemiological survey conducted in 2020, malignancy persistently occupies the top position as the primary instigator of morbidity and mortality globally, with an alarming approximation of 19.3 million novel cancer incidences and nearly 10 million fatalities within that year [<xref rid="B1-pharmaceuticals-16-01384" ref-type="bibr">1</xref>]. The health and medical system confronts formidable challenges. However, a new hope in cancer treatment has emerged in the form of tumor vaccines. Tumor vaccines represent a breakthrough in oncology, leveraging immunotherapy principles to stimulate the body&#8217;s immune system against cancer, offering a more targeted approach with fewer side effects compared to conventional treatments like surgery, radiotherapy, and chemotherapy [<xref rid="B2-pharmaceuticals-16-01384" ref-type="bibr">2</xref>].</p><p>The evolution of cancer vaccines has unfolded over several decades, with each era marked by pivotal advancements (<xref rid="pharmaceuticals-16-01384-f001" ref-type="fig">Figure 1</xref>). The journey began in the late 19th century with William Coley, who developed Coley&#8217;s toxins after noticing that infections often induced tumor shrinkage in cancer patients [<xref rid="B3-pharmaceuticals-16-01384" ref-type="bibr">3</xref>]. This approach leveraged the immune system to fight cancer&#8212;a concept that was further expanded upon by Lewis Thomas and Frank Macfarlane Burnet in the mid-20th century, who introduced the ideas of cancer immunoediting and tumor immunity [<xref rid="B4-pharmaceuticals-16-01384" ref-type="bibr">4</xref>]. The dawn of clinically approved cancer vaccines arrived in 2010 with the FDA approval of sipuleucel-T, the first therapeutic cancer vaccine targeting prostate cancer [<xref rid="B5-pharmaceuticals-16-01384" ref-type="bibr">5</xref>]. The subsequent era, which continues to this day, is characterized by the development of modern cancer vaccines and checkpoint inhibitors, such as a combination therapy approved in 2021 for the treatment of lymphoma [<xref rid="B6-pharmaceuticals-16-01384" ref-type="bibr">6</xref>]. Currently, the development of cancer vaccines emphasizes personalization, with numerous strategies under investigation, including neoantigen vaccines, DNA/RNA vaccines, and viral vectors, aiming to tailor therapies to individual patients&#8217; tumors.</p><p>Delving into the mechanistic complexities, the tumor microenvironment (TME), within which tumors exist and evolve, plays a critical role in tumor progression. Consequently, the TME has emerged as a locus of scientific investigation in the arena of anticancer therapeutic drug evolution [<xref rid="B7-pharmaceuticals-16-01384" ref-type="bibr">7</xref>]. Serving as a testament to the innovation of contemporary medicine, tumor vaccines are meticulously contrived to exploit the innate and adaptive capacities of the host immune system to target aberrant cells. These pioneering formulations strategically modulate the TME, thereby judiciously minimizing the collateral devastation inflicted upon healthy tissues [<xref rid="B8-pharmaceuticals-16-01384" ref-type="bibr">8</xref>].</p><p>The field of cancer immunotherapy is experiencing significant advancements with the development of diverse tumor vaccines, each with its unique strengths and challenges. Peptide vaccines, though effective in initiating immune responses, often necessitate the use of adjuvants [<xref rid="B9-pharmaceuticals-16-01384" ref-type="bibr">9</xref>]. DNA/RNA-based vaccines allow for the endogenous production of antigens but face hurdles in terms of delivery and expression [<xref rid="B10-pharmaceuticals-16-01384" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceuticals-16-01384" ref-type="bibr">11</xref>]. Viral-vector-based vaccines can stimulate robust immune responses but are constrained by safety concerns and pre-existing immunity [<xref rid="B12-pharmaceuticals-16-01384" ref-type="bibr">12</xref>]. Although dendritic-cell-based vaccines can induce powerful responses, they entail complex production processes and variable patient responses [<xref rid="B13-pharmaceuticals-16-01384" ref-type="bibr">13</xref>]. Whole-cell-based vaccines, while leveraging entire tumor cells to trigger immune responses, grapple with production and standardization issues [<xref rid="B14-pharmaceuticals-16-01384" ref-type="bibr">14</xref>]. An in-depth understanding of these vaccines and their limitations is crucial for their effective deployment in cancer immunotherapy [<xref rid="B15-pharmaceuticals-16-01384" ref-type="bibr">15</xref>]. Current research, cognizant of the limited standalone efficacy of tumor vaccines, is seeking enhanced therapeutic outcomes through their combination with other treatments, such as immune checkpoint inhibitors, chemotherapy, radiotherapy, targeted therapy, and oncolytic virotherapy [<xref rid="B16-pharmaceuticals-16-01384" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceuticals-16-01384" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceuticals-16-01384" ref-type="bibr">18</xref>,<xref rid="B19-pharmaceuticals-16-01384" ref-type="bibr">19</xref>]. Simultaneously, the innovative domain of personalized cancer vaccines is gaining traction, offering a tailored immune response against individual-specific tumors [<xref rid="B8-pharmaceuticals-16-01384" ref-type="bibr">8</xref>]. Despite several challenges, including the complexity of neoantigen identification and resource-intensive production, advances in technology promise a faster and more affordable future for personalized cancer vaccines [<xref rid="B20-pharmaceuticals-16-01384" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceuticals-16-01384" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-16-01384" ref-type="bibr">22</xref>,<xref rid="B23-pharmaceuticals-16-01384" ref-type="bibr">23</xref>].</p><p>This review endeavors to provide a thorough and nuanced exploration of tumor vaccines, linking the foundational mechanisms to their practical clinical applications. As we scrutinize the mechanistic underpinnings of tumor vaccines, our focus is not only to underscore the pivotal role of the TME, but also to dissect the intricate interplay of vaccine mechanisms within this context. Transitioning to the clinical viewpoint, we aim to unravel the character of different tumor vaccines and probe into the state-of-the-art topics that are reshaping the field today. This encompasses the integration of tumor vaccines with other therapeutic methodologies, as well as the surge in pioneering research concerning personalized cancer vaccines. Our aspiration is to cultivate a well-rounded comprehension of tumor vaccines, thereby enriching the ongoing dialogue regarding their potential significance in the realm of cancer treatment.</p></sec><sec id="sec2-pharmaceuticals-16-01384"><title>2. Tumor Microenvironment</title><p>The tumor microenvironment (TME) is critical in the onset and progression of cancer and is a headache for scientists. It is not only dynamic but also incredibly complex, shaping tumor heterogeneity. The TME is a mixture of multiple cellular and non-cellular components such as cancer cells, stromal cells, immune cells, the extracellular matrix (ECM), and signaling molecules such as growth factors and cytokines [<xref rid="B24-pharmaceuticals-16-01384" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceuticals-16-01384" ref-type="bibr">25</xref>]. The ECM, a tangled web of proteins, glycoproteins, and proteoglycans, lends structure and shapes cell behavior via biochemical and biomechanical signals. When cancer alters the ECM&#8217;s composition, it can boost angiogenesis, immune evasion, and therapy resistance [<xref rid="B26-pharmaceuticals-16-01384" ref-type="bibr">26</xref>,<xref rid="B27-pharmaceuticals-16-01384" ref-type="bibr">27</xref>]. For example, increased ECM stiffness, as seen with lysyl oxidase (LOX) overexpression, promotes cellular proliferation and survival through mechanisms like focal adhesion kinase (FAK) activation, while also enhancing tumor invasiveness [<xref rid="B28-pharmaceuticals-16-01384" ref-type="bibr">28</xref>]. Similarly, an accumulation of hyaluronan, often linked to poor prognosis, can bolster tumor growth and facilitate immune evasion [<xref rid="B29-pharmaceuticals-16-01384" ref-type="bibr">29</xref>]. Altered expression of matrix metalloproteinases (MMPs) can remodel the ECM, favoring tumor invasion by releasing growth factors [<xref rid="B30-pharmaceuticals-16-01384" ref-type="bibr">30</xref>,<xref rid="B31-pharmaceuticals-16-01384" ref-type="bibr">31</xref>]. Furthermore, specific ECM proteins like elastin, laminin, tenascin-C, and periostin, when overexpressed, support tumor cell migration and survival [<xref rid="B32-pharmaceuticals-16-01384" ref-type="bibr">32</xref>]. Notably, changes in collagen orientation, resulting in aligned fibers, provide pathways for enhanced tumor cell migration, with such alignment often indicating a higher risk of metastasis [<xref rid="B33-pharmaceuticals-16-01384" ref-type="bibr">33</xref>]. The ECM is also involved in the secretion of various growth factors, like transforming growth factor-&#946; (TGF-&#946;), Interleukin-1&#946; (IL-1&#946;), IL-6, tumor necrosis factor-&#945; (TNF-&#945;), and vascular endothelial growth factor (VEGF), which are secreted by various cells of the TME and can initiate tumor cell growth, survival, migration, angiogenesis, and epithelial&#8211;mesenchymal transition (EMT). This is achieved by regulating their specific receptors and stimulating signaling pathways [<xref rid="B34-pharmaceuticals-16-01384" ref-type="bibr">34</xref>] (<xref rid="pharmaceuticals-16-01384-f002" ref-type="fig">Figure 2</xref>). This intricate interplay between the ECM and tumor cells not only propels cancer progression but also presents challenges in therapy due to factors like drug penetration barriers and the activation of cellular survival pathways.</p><p>Similarly, immune cell functions are shaped by a blend of elements. Tumor cells can secrete immunosuppressive cytokines and checkpoint ligands that modify the immune response [<xref rid="B35-pharmaceuticals-16-01384" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceuticals-16-01384" ref-type="bibr">36</xref>], while conditions like hypoxia and acidic pH, resulting from metabolic changes in tumors, can suppress immune activity [<xref rid="B37-pharmaceuticals-16-01384" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceuticals-16-01384" ref-type="bibr">38</xref>]. Concurrently, metabolic competition due to glucose consumption by tumors, alterations in the extracellular matrix, and the recruitment of immunosuppressive cells can inhibit effective immune responses [<xref rid="B39-pharmaceuticals-16-01384" ref-type="bibr">39</xref>]. Direct cell&#8211;cell interactions within the TME, the gut microbiome&#8217;s influence on tumor immunity, therapeutic interventions, and the presence of chronic inflammation further modulate the balance between pro-tumor and antitumor effects [<xref rid="B40-pharmaceuticals-16-01384" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceuticals-16-01384" ref-type="bibr">41</xref>]. The interplay of these factors determines the complex and dynamic nature of immune responses within the TME.</p><p>Regarding immune cells, such as tumor-associated macrophages (TAMs) and T cells, these cells can oscillate in both directions [<xref rid="B42-pharmaceuticals-16-01384" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceuticals-16-01384" ref-type="bibr">43</xref>]. They can either drive tumor growth or stop it. The TME phenotype and cytokines control the expression of all of these cellular and non-cellular components [<xref rid="B44-pharmaceuticals-16-01384" ref-type="bibr">44</xref>]. TAMs, crucial cells in the TME, possess the functional plasticity to either promote or inhibit tumor progression. This is greatly influenced by various cytokines that are present in the TME, leading TAMs to adopt one of two primary phenotypes: the classically activated (M1) macrophages, which have antitumor activity, and the alternatively activated (M2) macrophages which are typically pro-tumor [<xref rid="B45-pharmaceuticals-16-01384" ref-type="bibr">45</xref>]. Certain cytokines, such as interferon-&#947; (IFN-&#947;), which is mainly produced by T cells and NK cells, can drive TAMs towards the M1 phenotype. These M1 macrophages are characterized by their ability to present antigens, kill tumor cells, and produce pro-inflammatory cytokines like IL-12 and TNF-&#945;, thereby enhancing antitumor immunity [<xref rid="B45-pharmaceuticals-16-01384" ref-type="bibr">45</xref>]. TNF-&#945; also plays a role in inducing M1 polarization of macrophages, thereby increasing their tumoricidal activity [<xref rid="B46-pharmaceuticals-16-01384" ref-type="bibr">46</xref>]. However, other cytokines, such as IL-4 and IL-13, both of which are mainly produced by Th2 cells, can induce the polarization of macrophages towards the M2 phenotype, which is typically associated with tissue repair, immune regulation, and tumor promotion [<xref rid="B47-pharmaceuticals-16-01384" ref-type="bibr">47</xref>]. Similarly, IL-10, an anti-inflammatory cytokine, can also drive TAMs towards the M2 phenotype, resulting in macrophages that are generally immunosuppressive and produce factors such as VEGF and EGF, which promote tumor growth and angiogenesis [<xref rid="B45-pharmaceuticals-16-01384" ref-type="bibr">45</xref>]. Lastly, TGF-&#946; is known to induce M2 polarization and also has multiple pro-tumor effects, including promoting immune evasion, tissue remodeling, and angiogenesis [<xref rid="B48-pharmaceuticals-16-01384" ref-type="bibr">48</xref>].</p><p>T cells, especially cytotoxic T cells (CTLs) and helper T cells, are pivotal in antitumor immunity, with their activation, proliferation, and function being influenced by various cytokines in the TME. Several cytokines propel T cells to combat tumors. Interferon-&#947; (IFN-&#947;), primarily produced by Th1 cells and CTLs, enhances the cytotoxic activity of CTLs, promotes their tumor-killing ability, and increases the expression of MHC class I molecules on tumor cells, making them more susceptible to CTL-mediated killing [<xref rid="B49-pharmaceuticals-16-01384" ref-type="bibr">49</xref>]. IL-2 plays a crucial role in T cells&#8217; growth and differentiation, and it is often used in cancer immunotherapy to amplify the immune system&#8217;s capacity to fight cancer, mainly through promoting the proliferation and activation of CTLs and NK cells [<xref rid="B50-pharmaceuticals-16-01384" ref-type="bibr">50</xref>]. IL-12 steers the differentiation of naive T cells into Th1 cells, which generate IFN-&#947; and facilitate CTL-mediated tumor destruction [<xref rid="B51-pharmaceuticals-16-01384" ref-type="bibr">51</xref>]. On the other hand, some cytokines induce tumorigenesis. IL-10, an immunosuppressive cytokine, can hinder the function of effector T cells and antigen-presenting cells, potentially fostering tumor growth by curbing antitumor immunity [<xref rid="B52-pharmaceuticals-16-01384" ref-type="bibr">52</xref>]. TGF-&#946; can inhibit the function of T cells and other immune cells, contributing to tumor immune evasion. It also manifests pro-tumor effects in later cancer stages, promoting tumor cell invasion and metastasis, and initiating angiogenesis [<xref rid="B53-pharmaceuticals-16-01384" ref-type="bibr">53</xref>]. Lastly, IL-6 can aid in tumorigenesis by fostering chronic inflammation, cell survival, and angiogenesis, and it is involved in differentiating T cells into Th17 cells, which in certain contexts are implicated in promoting inflammation and tumor growth [<xref rid="B54-pharmaceuticals-16-01384" ref-type="bibr">54</xref>].</p><p>The TME offers promising therapeutic avenues in cancer treatment. Immunosuppressive cytokines like TGF-&#946;, when inhibited, may restore antitumor immune responses and curtail metastasis [<xref rid="B55-pharmaceuticals-16-01384" ref-type="bibr">55</xref>]. Although IL-10 generally suppresses TME immunity, its nuanced roles suggest potential benefits from modulating its levels, while the inhibition of angiogenic and immunosuppressive VEGF has birthed FDA-approved therapies like bevacizumab [<xref rid="B56-pharmaceuticals-16-01384" ref-type="bibr">56</xref>,<xref rid="B57-pharmaceuticals-16-01384" ref-type="bibr">57</xref>]. On the immunostimulatory front, IL-2, known to bolster T-cell growth, has seen therapeutic applications, albeit with side effects, and IL-12&#8217;s potent activation of immune cells hints at its combinatorial therapeutic potential [<xref rid="B58-pharmaceuticals-16-01384" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceuticals-16-01384" ref-type="bibr">59</xref>]. Additionally, checkpoint inhibitors targeting the PD-1/PD-L1 axis, such as pembrolizumab, rejuvenate exhausted T cells to counteract tumors [<xref rid="B60-pharmaceuticals-16-01384" ref-type="bibr">60</xref>].</p><p>Together, the TME significantly impacts the success of cancer vaccines. While vaccines aim to activate immune cells against tumor antigens, the TME&#8217;s immunosuppressive nature can stymie these activated T cells. Factors like altered tumor antigen presentation, reduced MHC molecule expression, and immune checkpoint expression further hinder vaccine-induced responses [<xref rid="B61-pharmaceuticals-16-01384" ref-type="bibr">61</xref>,<xref rid="B62-pharmaceuticals-16-01384" ref-type="bibr">62</xref>]. To enhance cancer vaccine efficacy, researchers are exploring combined therapies with checkpoint inhibitors, methods to reduce the numbers of immunosuppressive cells in the TME, strategies to breach the TME&#8217;s physical barriers, the incorporation of potent adjuvants, cytokine modulation, and the development of personalized vaccines tailored to individual tumor antigen profiles [<xref rid="B63-pharmaceuticals-16-01384" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceuticals-16-01384" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceuticals-16-01384" ref-type="bibr">65</xref>]. These multipronged strategies, targeting both the vaccine mechanism and the TME, are steering the direction of next-generation cancer therapies.</p></sec><sec id="sec3-pharmaceuticals-16-01384"><title>3. Oncology Vaccines</title><sec id="sec3dot1-pharmaceuticals-16-01384"><title>3.1. Cancer Immunology</title><p>Adaptive immunity, or acquired immunity, is a highly specific and long-lasting defense against pathogens and abnormal cells, and it is mainly managed by T and B lymphocytes [<xref rid="B66-pharmaceuticals-16-01384" ref-type="bibr">66</xref>]. This type of immunity is famous for its immunological memory, giving lasting protection against things that it has met before, like pathogens or antigens [<xref rid="B67-pharmaceuticals-16-01384" ref-type="bibr">67</xref>]. Studying adaptive immunity&#8217;s ins and outs has been vital for creating vaccines and targeted immunotherapies. These breakthroughs offer huge potential for preventing and treating a range of diseases, from infections and autoimmune disorders to cancers [<xref rid="B68-pharmaceuticals-16-01384" ref-type="bibr">68</xref>,<xref rid="B69-pharmaceuticals-16-01384" ref-type="bibr">69</xref>,<xref rid="B70-pharmaceuticals-16-01384" ref-type="bibr">70</xref>].</p><p>In cancer&#8217;s early stages, the immune system takes part in a process called immunosurveillance, where it hunts down and wipes out abnormal cells, stopping tumors from forming [<xref rid="B71-pharmaceuticals-16-01384" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceuticals-16-01384" ref-type="bibr">72</xref>]. But crafty cancer cells use different tricks to dodge the immune system, helping tumors grow and progress [<xref rid="B73-pharmaceuticals-16-01384" ref-type="bibr">73</xref>]. By studying these immune evasion tactics, scientists have come up with new immunotherapies like immune checkpoint inhibitors (ICIs) and adoptive cell transfer. These innovative treatments aim to boost the body&#8217;s ability to fight tumors and overcome cancer&#8217;s skill in dodging the immune system [<xref rid="B74-pharmaceuticals-16-01384" ref-type="bibr">74</xref>].</p><p>Immunotherapies, like ICIs and chimeric antigen receptor (CAR) T-cell therapy, have totally changed cancer treatment by using the immune system to fight cancer cells [<xref rid="B75-pharmaceuticals-16-01384" ref-type="bibr">75</xref>]. But even with these amazing advances, some patients do not respond well to immunotherapies, or they may even become resistant to them, which means that we still need to learn more about how the immune system and cancer interact [<xref rid="B76-pharmaceuticals-16-01384" ref-type="bibr">76</xref>]. Gaining this knowledge will help us create new immunotherapy strategies and find predictive biomarkers to make patient outcomes even better [<xref rid="B77-pharmaceuticals-16-01384" ref-type="bibr">77</xref>,<xref rid="B78-pharmaceuticals-16-01384" ref-type="bibr">78</xref>].</p></sec><sec id="sec3dot2-pharmaceuticals-16-01384"><title>3.2. Mechanism of Action</title><p>The fundamental function of cancer vaccines revolves around their capacity to mobilize both innate and adaptive immune responses for the identification, combat, and eradication of neoplastic cells [<xref rid="B20-pharmaceuticals-16-01384" ref-type="bibr">20</xref>]. The following discourse will undertake a comprehensive analysis of their intricate mechanisms of action (<xref rid="pharmaceuticals-16-01384-f003" ref-type="fig">Figure 3</xref>).</p><sec id="sec3dot2dot1-pharmaceuticals-16-01384"><title>3.2.1. Cellular Immunity</title><p>The procedure of eliciting a cellular immune response against cancer, exemplified by the use of cancer vaccines, is complex and sequential. It commences with the delivery of tumor antigens and concludes with the activation of humoral immunity. The following is a detailed breakdown of each phase in this process (<xref rid="pharmaceuticals-16-01384-f003" ref-type="fig">Figure 3</xref>A).</p><p>Introduction of tumor antigens: With cancer vaccines, we are referring to tumor antigens being introduced to antigen-presenting cells (APCs) like dendritic cells. Options include whole tumor cells, peptides, proteins, DNA, mRNA, or even dendritic cells loaded with tumor antigens or packing tumor-derived genetic material. Tumor vaccines play a role in this step. This crucial first step gets the ball rolling in the immune response against cancer [<xref rid="B18-pharmaceuticals-16-01384" ref-type="bibr">18</xref>,<xref rid="B79-pharmaceuticals-16-01384" ref-type="bibr">79</xref>].</p><p>Antigen processing and presentation: APCs capture, process, and present tumor-derived peptides on their surface. Dendritic cells efficiently cross-present exogenous antigens to both MHC class I and II molecules, activating both CD8+ cytotoxic T lymphocytes (CTLs) and CD4+ helper T cells [<xref rid="B18-pharmaceuticals-16-01384" ref-type="bibr">18</xref>,<xref rid="B80-pharmaceuticals-16-01384" ref-type="bibr">80</xref>].</p><p>Activation of T cells: Presentation of tumor antigens by APCs activates and expands antigen-specific T cells. T-cell activation requires antigen recognition via the T-cell receptor (TCR) and costimulatory signals provided by the interaction between costimulatory molecules on APCs and their receptors on T cells [<xref rid="B81-pharmaceuticals-16-01384" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceuticals-16-01384" ref-type="bibr">82</xref>].</p><p>CTLs and helper T cells in action: CTLs directly kill tumor cells by recognizing and binding to MHC class I molecules presenting tumor antigens, while helper T cells produce cytokines that support CTLs&#8217; activation, proliferation, and differentiation. CD4+ helper T cells also provide help to B cells, facilitating antibody production and enhancing the function of APCs and CTLs [<xref rid="B2-pharmaceuticals-16-01384" ref-type="bibr">2</xref>,<xref rid="B42-pharmaceuticals-16-01384" ref-type="bibr">42</xref>].</p><p>Stimulation of humoral immunity: Cancer vaccines induce the production of antigen-specific antibodies by B cells. These antibodies target and eliminate tumor cells [<xref rid="B15-pharmaceuticals-16-01384" ref-type="bibr">15</xref>,<xref rid="B83-pharmaceuticals-16-01384" ref-type="bibr">83</xref>].</p></sec><sec id="sec3dot2dot2-pharmaceuticals-16-01384"><title>3.2.2. Humoral Immunity</title><p>This procedure initiates with the recognition of tumor antigens and culminates in the implementation of effector functions mediated by antibodies. The following are the details of each stage in this process. (<xref rid="pharmaceuticals-16-01384-f003" ref-type="fig">Figure 3</xref>B).</p><p>Recognition of tumor antigens: Like with cellular immunity, tumor cells have tumor-associated antigens (TAAs) and tumor-specific antigens (TSAs) that the immune system can recognize [<xref rid="B84-pharmaceuticals-16-01384" ref-type="bibr">84</xref>].</p><p>Activation of B cells: B cells detect and recognize tumor antigens through their B-cell receptors (BCRs). Add in some costimulatory signals from helper T cells, and B cells are activated to multiply and differentiate [<xref rid="B72-pharmaceuticals-16-01384" ref-type="bibr">72</xref>].</p><p>Differentiation of B cells into plasma cells: After activation, B cells morph into plasma cells, specialized for producing vast quantities of antibodies specific to the recognized tumor antigens [<xref rid="B84-pharmaceuticals-16-01384" ref-type="bibr">84</xref>].</p><p>Production of antigen-specific antibodies: Plasma cells produce antigen-specific antibodies, which travel through the bloodstream and latch onto tumor antigens on cancer cells [<xref rid="B85-pharmaceuticals-16-01384" ref-type="bibr">85</xref>].</p><p>Effector functions of antibodies: Once bound, antibodies wield various strategies against tumor cells, such as the following: <list list-type="order"><list-item><p>Antibody-dependent cell-mediated cytotoxicity (ADCC) (<xref rid="pharmaceuticals-16-01384-f003" ref-type="fig">Figure 3</xref>A(1&#8211;3)): At the first stage, effector cell recruitment: Fc-receptor-bearing immune cells, like natural killer (NK) cells, macrophages, and neutrophils, are drawn to the tumor site via interactions between their Fc receptors and the Fc segment of the antibody bound to the malignant cell [<xref rid="B86-pharmaceuticals-16-01384" ref-type="bibr">86</xref>,<xref rid="B87-pharmaceuticals-16-01384" ref-type="bibr">87</xref>]. At the next stage, formation of immunological synapses, degranulation, and release of cytotoxic molecules: Immunological synapses are formed when Fc receptors on effector cells interact with the Fc portion of cancer-bound antibodies, enabling the targeted release of cytotoxic molecules [<xref rid="B88-pharmaceuticals-16-01384" ref-type="bibr">88</xref>]. Effector cell degranulation ensues, culminating in cancer cell elimination via perforin and granzymes [<xref rid="B89-pharmaceuticals-16-01384" ref-type="bibr">89</xref>]. Finally, phagocytosis: Post-apoptosis, macrophages engulf the cancerous debris, facilitating clearance and preventing the dissemination of harmful cellular components [<xref rid="B90-pharmaceuticals-16-01384" ref-type="bibr">90</xref>].</p></list-item><list-item><p>Complement-dependent cytotoxicity (CDC) (<xref rid="pharmaceuticals-16-01384-f003" ref-type="fig">Figure 3</xref>B(1&#8211;4)): At the first stage, complement activation and cascade: Bound antibodies&#8217; Fc portions engage C1q (complement component 1, q subcomponent), instigating the classical complement pathway and the formation of the C3 convertase enzyme complex [<xref rid="B91-pharmaceuticals-16-01384" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceuticals-16-01384" ref-type="bibr">92</xref>]. At the next stage, membrane attack complex (MAC) assembly: Complement protein cleavage and activation yield the MAC, comprising C5b, C6, C7, C8, and C9 [<xref rid="B93-pharmaceuticals-16-01384" ref-type="bibr">93</xref>]. After that, cell lysis: MACs perforate cancer cell membranes, causing uncontrolled ion and water movement, cellular lysis, and death [<xref rid="B93-pharmaceuticals-16-01384" ref-type="bibr">93</xref>]. Finally, opsonization and phagocytosis: Cancer cells are targeted for destruction by phagocytes when complement activation promotes opsonization [<xref rid="B92-pharmaceuticals-16-01384" ref-type="bibr">92</xref>].</p></list-item><list-item><p>Neutralization of growth factors and inhibition of signaling pathways: Antibodies obstruct tumor cell proliferation-promoting growth factors and impede signaling pathways that are crucial for cancer cell survival and invasion [<xref rid="B15-pharmaceuticals-16-01384" ref-type="bibr">15</xref>].</p></list-item></list></p></sec></sec></sec><sec id="sec4-pharmaceuticals-16-01384"><title>4. Types and Characteristics of Cancer Vaccines</title><sec id="sec4dot1-pharmaceuticals-16-01384"><title>4.1. Peptide Vaccines </title><p>Peptide vaccines represent a potential cancer immunotherapy approach that employs short amino acid sequences originating from tumor-specific or tumor-associated antigens (TAAs) to evoke targeted immune reactions against malignant cells [<xref rid="B94-pharmaceuticals-16-01384" ref-type="bibr">94</xref>]. TAAs, including differentiation antigens, overexpressed antigens, cancer/testis antigens, and mutated antigens, present feasible targets for multiple immunotherapeutic techniques, such as cancer vaccines, adoptive T-cell therapies, and immune checkpoint inhibitors [<xref rid="B95-pharmaceuticals-16-01384" ref-type="bibr">95</xref>,<xref rid="B96-pharmaceuticals-16-01384" ref-type="bibr">96</xref>]. Peptide vaccines offer several benefits, including ease of synthesis, specificity, and a favorable safety profile due to their reduced likelihood of triggering autoimmune responses compared to whole-protein or live attenuated vaccines [<xref rid="B97-pharmaceuticals-16-01384" ref-type="bibr">97</xref>,<xref rid="B98-pharmaceuticals-16-01384" ref-type="bibr">98</xref>]. Nevertheless, they encounter limitations such as suboptimal immunogenicity, rapid in vivo degradation, weak CD4+ T-cell responses, and challenges pertaining to immune evasion and tumor-induced immune suppression [<xref rid="B97-pharmaceuticals-16-01384" ref-type="bibr">97</xref>]. To tackle these limitations, strategies encompass the incorporation of adjuvants, peptide sequence optimization, utilization of carriers to enhance stability and immunogenicity, and the combination of peptide vaccines with other immunotherapies [<xref rid="B94-pharmaceuticals-16-01384" ref-type="bibr">94</xref>].</p><p>At present, the relatively mature peptide vaccines include Nelipepimut-S (NeuVax), CIMAvax-EGF, and MUC1-based peptide vaccines. Nelipepimut-S, also known as NeuVax, is a peptide vaccine targeting HER2/neu-expressing cancer cells, primarily focusing on early-stage HER2 1+ and 2+ breast cancer patients who are ineligible for standard HER2 therapies [<xref rid="B99-pharmaceuticals-16-01384" ref-type="bibr">99</xref>]. It combines the E75 peptide from HER2/neu with GM-CSF as an adjuvant for a heightened immune response [<xref rid="B100-pharmaceuticals-16-01384" ref-type="bibr">100</xref>]. Although its scope may cover other HER2/neu cancers like ovarian and gastric cancers, its clinical development hit snags [<xref rid="B101-pharmaceuticals-16-01384" ref-type="bibr">101</xref>]. Recent phase III trial results show that Nelipepimut-S still exhibits good efficacy and tolerability in breast cancer patients [<xref rid="B102-pharmaceuticals-16-01384" ref-type="bibr">102</xref>]. Similarly, CIMAvax-EGF, targeting the epidermal growth factor for non-small-cell lung cancer (NSCLC), merges recombinant EGF with a protein carrier. It has shown promise in prolonging the lives of late-stage lung cancer patients, with phase III trials completed [<xref rid="B103-pharmaceuticals-16-01384" ref-type="bibr">103</xref>,<xref rid="B104-pharmaceuticals-16-01384" ref-type="bibr">104</xref>]. Additionally, MUC1-based peptide vaccines focus on the aberrantly expressed glycoprotein in cancers like breast and pancreatic cancers [<xref rid="B105-pharmaceuticals-16-01384" ref-type="bibr">105</xref>]. Though some have reached phase I and II trials, with promising safety and immune indicators, eliciting robust clinical responses remains complex, leading to the exploration of combination therapies [<xref rid="B106-pharmaceuticals-16-01384" ref-type="bibr">106</xref>,<xref rid="B107-pharmaceuticals-16-01384" ref-type="bibr">107</xref>]. Collectively, these vaccines represent cutting-edge cancer treatment approaches, each with its unique targets and development stages.</p></sec><sec id="sec4dot2-pharmaceuticals-16-01384"><title>4.2. DNA/RNA-Based Vaccines</title><p>DNA/RNA-based tumor vaccines operate on the principle of delivering genetic material that encodes tumor antigens to host cells. This approach, leveraging various vectors such as viral vectors, lipid nanoparticles, or naked nucleic acids, stimulates the immune system to recognize and destroy cancer cells, leading to an adaptive immune response [<xref rid="B108-pharmaceuticals-16-01384" ref-type="bibr">108</xref>]. Compared to traditional methods, these vaccines confer several advantages, including safety, ease of manufacture, robust immune response induction, and amenability to modifications. They also afford the possibility of personalization to cater to each patient&#8217;s unique tumor profile [<xref rid="B109-pharmaceuticals-16-01384" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceuticals-16-01384" ref-type="bibr">110</xref>]. Despite their promise, challenges such as the efficient delivery and uptake of DNA/RNA into cells, the risk of autoimmune responses, and the constraints of cost and time for personalization pose significant hurdles [<xref rid="B111-pharmaceuticals-16-01384" ref-type="bibr">111</xref>,<xref rid="B112-pharmaceuticals-16-01384" ref-type="bibr">112</xref>,<xref rid="B113-pharmaceuticals-16-01384" ref-type="bibr">113</xref>].</p><p>However, recent advances, including several vaccines in clinical trials and technological progress enhancing the efficacy of vaccine delivery, are encouraging [<xref rid="B114-pharmaceuticals-16-01384" ref-type="bibr">114</xref>]. The field looks forward to leveraging advancements in genomic sequencing, bioinformatics, and nanotechnology to surmount current limitations, aspiring to blend these potent vaccines with other immunotherapeutic strategies for comprehensive cancer eradication [<xref rid="B115-pharmaceuticals-16-01384" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceuticals-16-01384" ref-type="bibr">116</xref>]. Among them, techniques such as lipid nanoparticles (LNPs), which have been seminal for mRNA COVID-19 vaccines, are being adapted for cancer vaccine development to boost the delivery of tumor-specific antigens [<xref rid="B117-pharmaceuticals-16-01384" ref-type="bibr">117</xref>,<xref rid="B118-pharmaceuticals-16-01384" ref-type="bibr">118</xref>]. Electroporation and viral vectors (like adenoviruses) enhance the uptake of DNA/RNA, while non-viral nanocarriers and microneedle patches aim to augment this delivery without inducing strong anti-vector responses [<xref rid="B119-pharmaceuticals-16-01384" ref-type="bibr">119</xref>,<xref rid="B120-pharmaceuticals-16-01384" ref-type="bibr">120</xref>]. To mitigate autoimmune risks, researchers emphasize tumor-specific antigen selection, sequence optimization to reduce cross-reactivity, and transient expression techniques, such as those inherent to mRNA vaccines [<xref rid="B121-pharmaceuticals-16-01384" ref-type="bibr">121</xref>,<xref rid="B122-pharmaceuticals-16-01384" ref-type="bibr">122</xref>]. Furthermore, tolerance-breaking adjuvants and nanoparticles tailored for targeted delivery are being harnessed to fine-tune the immune response, maximizing antitumor efficacy while minimizing collateral damage to healthy tissues [<xref rid="B121-pharmaceuticals-16-01384" ref-type="bibr">121</xref>,<xref rid="B123-pharmaceuticals-16-01384" ref-type="bibr">123</xref>]. Collectively, these innovations underscore the evolving landscape of cancer vaccine design, balancing potent tumor targeting with patient safety. CV9104 is an mRNA-based cancer vaccine targeting prostate cancer [<xref rid="B124-pharmaceuticals-16-01384" ref-type="bibr">124</xref>]. Its development reached a phase II trial for metastatic castration-resistant prostate cancer (mCRPC) [<xref rid="B124-pharmaceuticals-16-01384" ref-type="bibr">124</xref>]. This vaccine represents the innovative utilization of mRNA in oncology.</p></sec><sec id="sec4dot3-pharmaceuticals-16-01384"><title>4.3. Viral-Vector-Based Vaccines</title><p>Viral-vector-based tumor vaccines are a promising development in cancer immunotherapy [<xref rid="B11-pharmaceuticals-16-01384" ref-type="bibr">11</xref>]. These vaccines leverage the innate ability of viruses to infiltrate host cells and efficiently deliver tumor antigens, sparking an intense, targeted immune response [<xref rid="B125-pharmaceuticals-16-01384" ref-type="bibr">125</xref>,<xref rid="B126-pharmaceuticals-16-01384" ref-type="bibr">126</xref>,<xref rid="B127-pharmaceuticals-16-01384" ref-type="bibr">127</xref>]. This approach prompts host cells to produce tumor-specific or associated antigens after infection, resulting in these antigens being displayed to T cells and subsequently initiating a robust defense against tumor cells [<xref rid="B128-pharmaceuticals-16-01384" ref-type="bibr">128</xref>]. One of the significant advantages of these vaccines is their capacity to trigger potent cellular and humoral immune responses. They can also be engineered to express numerous tumor antigens, extending their range and enhancing the potency of the immune response [<xref rid="B129-pharmaceuticals-16-01384" ref-type="bibr">129</xref>,<xref rid="B130-pharmaceuticals-16-01384" ref-type="bibr">130</xref>]. Despite these benefits, certain challenges need to be addressed, such as the impact of pre-existing immunity to the viral vector and the logistical issues associated with large-scale production [<xref rid="B131-pharmaceuticals-16-01384" ref-type="bibr">131</xref>,<xref rid="B132-pharmaceuticals-16-01384" ref-type="bibr">132</xref>].</p><p>Among these challenges, pre-existing immunity to viral vectors poses a significant challenge for their use in tumor vaccines, as the immune system might neutralize the vector before its therapeutic action [<xref rid="B133-pharmaceuticals-16-01384" ref-type="bibr">133</xref>]. To counteract this, researchers are exploring a range of strategies: using rare or novel viral vectors with limited human exposure, pseudotyping to change viral envelope proteins, employing a heterologous prime&#8211;boost strategy with different vectors, making genetic modifications to the viral capsid to reduce recognizability, co-administering with immune modulators to transiently suppress certain immune responses, opting for non-intravenous delivery routes like intratumoral administration to avoid high antibody concentrations, and adjusting dosages, either by using a high vector dose to overcome neutralization or by administering repeated low doses to evade immune detection [<xref rid="B134-pharmaceuticals-16-01384" ref-type="bibr">134</xref>,<xref rid="B135-pharmaceuticals-16-01384" ref-type="bibr">135</xref>,<xref rid="B136-pharmaceuticals-16-01384" ref-type="bibr">136</xref>,<xref rid="B137-pharmaceuticals-16-01384" ref-type="bibr">137</xref>]. Additionally, adjuvants are being explored to shift the focus of the immune response from the vector to the delivered tumor antigen [<xref rid="B138-pharmaceuticals-16-01384" ref-type="bibr">138</xref>,<xref rid="B139-pharmaceuticals-16-01384" ref-type="bibr">139</xref>]. These multifaceted approaches aim to optimize the efficacy of viral-vector-based tumor vaccines in the face of pre-existing immunity.</p><p>OncoVEXGM-CSF, or T-VEC, is an oncolytic HSV-1 vaccine modified for tumor selectivity and GM-CSF production, primarily targeting melanoma [<xref rid="B140-pharmaceuticals-16-01384" ref-type="bibr">140</xref>]. It gained FDA approval for unresectable recurrent melanoma following a successful phase III trial [<xref rid="B140-pharmaceuticals-16-01384" ref-type="bibr">140</xref>]. CG0070, another adenovirus-based vaccine, was engineered for selective replication in Rb-pathway-defective cancer cells and targets bladder cancer [<xref rid="B141-pharmaceuticals-16-01384" ref-type="bibr">141</xref>]. LV305, a lentivirus-based vaccine, delivers the NY-ESO-1 antigen gene to dendritic cells, aiming at NY-ESO-1-expressing cancers like melanoma and sarcoma [<xref rid="B142-pharmaceuticals-16-01384" ref-type="bibr">142</xref>]. JX-594, or Pexa-Vec, a vaccinia-virus-based vaccine, is modified to express GM-CSF and selectively target cancer cells with high thymidine kinase activity, and it has undergone several trials, including a phase III trial for hepatocellular carcinoma [<xref rid="B143-pharmaceuticals-16-01384" ref-type="bibr">143</xref>,<xref rid="B144-pharmaceuticals-16-01384" ref-type="bibr">144</xref>,<xref rid="B145-pharmaceuticals-16-01384" ref-type="bibr">145</xref>]. These represent innovative intersections of virotherapy and immunotherapy in oncology.</p></sec><sec id="sec4dot4-pharmaceuticals-16-01384"><title>4.4. Dendritic-Cell-Based Vaccines</title><p>Dendritic cells (DCs), instrumental in mediating the immune response by linking the innate and adaptive immune systems, and vital in antigen presentation and subsequent T-cell activation, have found substantial relevance in cancer immunotherapy strategies [<xref rid="B18-pharmaceuticals-16-01384" ref-type="bibr">18</xref>,<xref rid="B146-pharmaceuticals-16-01384" ref-type="bibr">146</xref>]. This stems from DC-based cancer vaccines, which employ DCs loaded with tumor-associated antigens (TAAs) to prompt a robust immune response against cancer cells [<xref rid="B147-pharmaceuticals-16-01384" ref-type="bibr">147</xref>]. The approaches for loading these DCs with TAAs are multifaceted, ranging from the use of tumor lysates and synthetic peptides to mRNA encoding tumor antigens [<xref rid="B148-pharmaceuticals-16-01384" ref-type="bibr">148</xref>]. Clinical trials have highlighted the promise of these DC-based vaccines in a variety of cancers. Despite this exciting potential, challenges persist, including technical difficulties in DC vaccine production, vaccine potency variations, the immunosuppressive tumor microenvironment, and the lack of reliable biomarkers for patient selection [<xref rid="B149-pharmaceuticals-16-01384" ref-type="bibr">149</xref>]. However, recent advancements in personalized cancer immunotherapy, such as neoantigen-based vaccines, present promising opportunities for DC-based vaccines, and combining these with other treatments may enhance their efficacy [<xref rid="B8-pharmaceuticals-16-01384" ref-type="bibr">8</xref>]. In a recent study, researchers introduced a metabolic glycan labeling technique using azido sugars for the enhancement of DC vaccines [<xref rid="B150-pharmaceuticals-16-01384" ref-type="bibr">150</xref>]. This method not only boosts DC activation and antigen presentation but also facilitates the efficient conjugation of cytokines [<xref rid="B150-pharmaceuticals-16-01384" ref-type="bibr">150</xref>]. Furthermore, it holds promise for broad applications across various tumors, provides a platform for modulating interactions between DCs and other immune cells, and amplifies the antitumor efficacy of dendritic cell vaccines.</p><p>Outstanding representatives include Provenge and DCVax-L. Provenge (sipuleucel-T) is an FDA-approved autologous cellular immunotherapy for advanced prostate cancer [<xref rid="B5-pharmaceuticals-16-01384" ref-type="bibr">5</xref>]. It uses a patient&#8217;s peripheral blood mononuclear cells (PBMCs) exposed to a fusion protein, PA2024, which combines an antigen from prostate cancer cells with an immune activator, GM-CSF, priming an immune response against prostate cancer cells expressing the antigen [<xref rid="B151-pharmaceuticals-16-01384" ref-type="bibr">151</xref>,<xref rid="B152-pharmaceuticals-16-01384" ref-type="bibr">152</xref>,<xref rid="B153-pharmaceuticals-16-01384" ref-type="bibr">153</xref>,<xref rid="B154-pharmaceuticals-16-01384" ref-type="bibr">154</xref>,<xref rid="B155-pharmaceuticals-16-01384" ref-type="bibr">155</xref>]. On the other hand, DCVax-L is an autologous dendritic cell vaccine for glioblastoma multiforme (GBM) [<xref rid="B156-pharmaceuticals-16-01384" ref-type="bibr">156</xref>]. The vaccine is prepared by loading a patient&#8217;s dendritic cells with tumor lysate from their own tumor tissue, enabling the immune system to recognize and attack corresponding cancer cells [<xref rid="B156-pharmaceuticals-16-01384" ref-type="bibr">156</xref>]. Both vaccines harness dendritic cells to target cancer, but their clinical journeys and disease targets differ (<xref rid="pharmaceuticals-16-01384-t001" ref-type="table">Table 1</xref>).</p></sec><sec id="sec4dot5-pharmaceuticals-16-01384"><title>4.5. Whole-Cell-Based Vaccines</title><p>Whole-cell-based vaccines offer a comprehensive approach to cancer immunotherapy by incorporating a vast array of tumor-associated antigens to stimulate a potent immune response. Mechanistically, these vaccines utilize irradiated tumor cells (autologous or allogeneic) to expose the immune system to the full antigenic repertoire of the tumor [<xref rid="B157-pharmaceuticals-16-01384" ref-type="bibr">157</xref>], leading to the induction of specific and polyvalent immune responses against a range of tumor antigens [<xref rid="B158-pharmaceuticals-16-01384" ref-type="bibr">158</xref>]. This strategy presents a broad spectrum of known and unknown tumor antigens, avoiding antigen loss or downregulation&#8212;a typical escape mechanism employed by tumors [<xref rid="B157-pharmaceuticals-16-01384" ref-type="bibr">157</xref>]&#8212;and bypassing the need to identify specific antigens for each patient, which can be time-consuming and costly [<xref rid="B159-pharmaceuticals-16-01384" ref-type="bibr">159</xref>]. However, there are limitations. The production of autologous whole-cell vaccines can be labor-intensive and personalized, necessitating the isolation and culture of tumor cells from each patient [<xref rid="B159-pharmaceuticals-16-01384" ref-type="bibr">159</xref>]. These vaccines often require co-administration with adjuvants or immunomodulatory agents to boost their immunogenicity, given that the immunosuppressive tumor microenvironment can limit vaccine efficacy [<xref rid="B8-pharmaceuticals-16-01384" ref-type="bibr">8</xref>,<xref rid="B159-pharmaceuticals-16-01384" ref-type="bibr">159</xref>]. Concerns also linger about potential autoimmunity induced by self-antigens in the vaccine formulation [<xref rid="B158-pharmaceuticals-16-01384" ref-type="bibr">158</xref>]. Thus, while whole-cell-based vaccines offer a promising approach to cancer immunotherapy, further optimization and refinement of these strategies are required to address these challenges and limitations.</p><p>Representatives include GVAX, Canvaxin, and Oncophage. GVAX is a whole-cell tumor vaccine, utilizing tumor cells genetically modified to secrete GM-CSF (an immune stimulant), and has been explored for cancers like pancreatic and prostate cancers, with mixed outcomes in later-phase trials [<xref rid="B160-pharmaceuticals-16-01384" ref-type="bibr">160</xref>,<xref rid="B161-pharmaceuticals-16-01384" ref-type="bibr">161</xref>]. Canvaxin, aimed at melanoma, combines irradiated autologous and allogeneic melanoma cells with the BCG adjuvant, but it failed to show significant survival benefits in a phase III trial for advanced melanoma [<xref rid="B115-pharmaceuticals-16-01384" ref-type="bibr">115</xref>,<xref rid="B162-pharmaceuticals-16-01384" ref-type="bibr">162</xref>]. Oncophage (Vitespen) is derived from patient-specific tumor heat shock proteins (HSPs) and primarily targets renal-cell carcinoma and melanoma [<xref rid="B163-pharmaceuticals-16-01384" ref-type="bibr">163</xref>,<xref rid="B164-pharmaceuticals-16-01384" ref-type="bibr">164</xref>]. It completed phase III trials with mixed results but secured approval in Russia for the treatment of kidney cancer [<xref rid="B165-pharmaceuticals-16-01384" ref-type="bibr">165</xref>]. While these vaccines showcase varied cancer immunotherapy strategies, each has faced challenges in late-stage clinical evaluations. (<xref rid="pharmaceuticals-16-01384-t001" ref-type="table">Table 1</xref>)</p><table-wrap position="anchor" id="pharmaceuticals-16-01384-t001" orientation="portrait"><object-id pub-id-type="pii">pharmaceuticals-16-01384-t001_Table 1</object-id><label>Table 1</label><caption><p>Below is a tabular list of various tumor vaccines in the last decade.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Types of Tumor Vaccines</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Strengths</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Weaknesses</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Examples</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mechanisms of Action</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Effects</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Limitations</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Peptide vaccines</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Specific to tumor antigens</p></list-item><list-item><p>Low toxicity</p></list-item><list-item><p>Easily synthesized and scalable</p></list-item></list>
</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Limited to known antigens</p></list-item><list-item><p>May not induce a robust immune response alone</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Nelipepimut-S (NeuVax)</td><td align="center" valign="middle" rowspan="1" colspan="1">HER2-derived peptide vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Activation of T-cell response</td><td align="center" valign="middle" rowspan="1" colspan="1">Limited overall survival improvement</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B166-pharmaceuticals-16-01384" ref-type="bibr">166</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">CIMAvax-EGF</td><td align="center" valign="middle" rowspan="1" colspan="1">EGF-based peptide vaccine</td><td align="center" valign="middle" rowspan="1" colspan="1">Inhibition of EGF signaling</td><td align="center" valign="middle" rowspan="1" colspan="1">No direct tumor targeting</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B103-pharmaceuticals-16-01384" ref-type="bibr">103</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MUC1-based peptide vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Targeting MUC1 tumor-associated antigens</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Enhanced immune response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heterogeneous patient response</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-pharmaceuticals-16-01384" ref-type="bibr">167</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">DNA/RNA-based vaccines</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Can encode multiple antigens</p></list-item><list-item><p>Flexibility in design</p></list-item><list-item><p>Stable and easy to produce</p></list-item></list>
</td><td align="left" valign="middle" rowspan="1" colspan="1">
<list list-type="order"><list-item><p>Delivery into cells can be challenging</p></list-item><list-item><p>Risk of integration (for DNA)</p></list-item><list-item><p>May induce autoimmune responses</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">CV9104 (CureVac)</td><td align="center" valign="middle" rowspan="1" colspan="1">Uses mRNA to encode six antigens overexpressed in prostate cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">Induced antigen-specific immune responses in early clinical trials</td><td align="center" valign="middle" rowspan="1" colspan="1">Efficacy in late-stage trials yet to be established; possibility of inducing autoimmune responses</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B168-pharmaceuticals-16-01384" ref-type="bibr">168</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Viral-vector-based vaccines</td><td rowspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Efficient cell entry and expression</p></list-item><list-item><p>Can induce strong immune responses</p></list-item></list>
</td><td rowspan="3" align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Pre-existing immunity to the viral vector can reduce effectiveness</p></list-item><list-item><p>Potential for off-target effects</p></list-item></list>
</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Adenovirus-based vaccines (OncoVEXGM-CSF, CG0070)</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Adenoviruses are modified to express a tumor-specific antigen or an immunomodulatory molecule; these stimulate an immune response against the tumor</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Effective in stimulating an immune response against the tumor</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">Immune response to the viral vector can limit repeat dosing</td><td align="center" valign="middle" style="border-top:solid thin" rowspan="1" colspan="1">[<xref rid="B169-pharmaceuticals-16-01384" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Lentivirus-based vaccines (LV305)</td><td align="center" valign="middle" rowspan="1" colspan="1">Lentiviruses are engineered to deliver tumor-specific antigens to dendritic cells to stimulate a T-cell response</td><td align="center" valign="middle" rowspan="1" colspan="1">Successful in initiating T-cell responses</td><td align="center" valign="middle" rowspan="1" colspan="1">Safety concerns over integration into the host genome</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B23-pharmaceuticals-16-01384" ref-type="bibr">23</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinia-virus-based vaccines<break/>(JX-594)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vaccinia viruses are genetically engineered to express a tumor antigen and/or immunostimulatory molecule; they can directly lyse cancer cells</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed antitumor activity and were well tolerated in clinical trials</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Immune response to the viral vector can limit its effectiveness</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B170-pharmaceuticals-16-01384" ref-type="bibr">170</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Dendritic-cell-based vaccines</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Tailored to individual patients</p></list-item><list-item><p>Induce potent T-cell responses</p></list-item></list>
</td><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Labor-intensive and costly production</p></list-item><list-item><p>Requires patient-specific infrastructure</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">Provenge (Sipuleucel-T)</td><td align="center" valign="middle" rowspan="1" colspan="1">The patient&#8217;s own dendritic cells are exposed to a fusion protein (prostatic acid phosphatase linked to an immune cell stimulating factor)</td><td align="center" valign="middle" rowspan="1" colspan="1">Extended overall survival in metastatic castration-resistant prostate cancer</td><td align="center" valign="middle" rowspan="1" colspan="1">Limited clinical benefits, high cost, and complex manufacturing process</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B5-pharmaceuticals-16-01384" ref-type="bibr">5</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DCVax-L</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Autologous dendritic cells are pulsed with tumor lysate</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Prolonged progression-free survival in glioblastoma multiforme (GBM) patients</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not FDA-approved; requires personalized manufacturing</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B171-pharmaceuticals-16-01384" ref-type="bibr">171</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Whole-cell-based vaccines</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Broad range of tumor antigens presented</p></list-item><list-item><p>Mimics natural infection</p></list-item></list>
</td><td rowspan="3" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">
<list list-type="order"><list-item><p>Complex manufacturing</p></list-item><list-item><p>Potential for tumor cell growth if not fully inactivated</p></list-item></list>
</td><td align="center" valign="middle" rowspan="1" colspan="1">GVAX</td><td align="center" valign="middle" rowspan="1" colspan="1">Utilizes autologous/allogeneic tumor cells that have been genetically modified to secrete the immune-stimulating cytokine GM-CSF</td><td align="center" valign="middle" rowspan="1" colspan="1">Demonstrated a significant immune response against cancer, studied in various types of cancer, including pancreatic and prostate cancers</td><td align="center" valign="middle" rowspan="1" colspan="1">Production can be labor-intensive and personalized; often requires co-administration with adjuvants or other immunomodulatory agents to enhance their immunogenicity</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B159-pharmaceuticals-16-01384" ref-type="bibr">159</xref>,<xref rid="B172-pharmaceuticals-16-01384" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">Canvaxin</td><td align="center" valign="middle" rowspan="1" colspan="1">Allogeneic melanoma cells mixed with Bacillus Calmette&#8211;Gu&#233;rin (BCG) to stimulate immune response</td><td align="center" valign="middle" rowspan="1" colspan="1">Intended for melanoma treatment, but development discontinued due to insufficient effectiveness</td><td align="center" valign="middle" rowspan="1" colspan="1">Limited efficacy; potential for BCG-related side effects</td><td align="center" valign="middle" rowspan="1" colspan="1">[<xref rid="B173-pharmaceuticals-16-01384" ref-type="bibr">173</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Oncophage (Vitespen)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Uses heat shock proteins (gp96) derived from the patient&#8217;s tumor as an autologous vaccine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Showed efficacy in extending disease-free survival in certain patients with kidney cancer and melanoma</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Not universally effective; personalized manufacturing can be labor-intensive</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-pharmaceuticals-16-01384" ref-type="bibr">174</xref>,<xref rid="B175-pharmaceuticals-16-01384" ref-type="bibr">175</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p>The preceding table encapsulates seminal instances of assorted classifications of cancer vaccines, encompassing peptide-based, DNA/RNA-based, viral-vector-based, dendritic-cell-based, and whole-cell-based vaccines. Each paradigm is delineated in exhaustive detail, supplemented by pertinent bibliographical citations for subsequent scholarly inquiry.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec4dot6-pharmaceuticals-16-01384"><title>4.6. Another Cancer Vaccine Therapy: In Situ Cancer Vaccines</title><p>In situ cancer vaccines represent a therapeutic approach where the tumor inside a patient&#8217;s body is directly targeted to serve as its own vaccine [<xref rid="B63-pharmaceuticals-16-01384" ref-type="bibr">63</xref>]. Rather than extracting tumor cells for external processing and reintroduction, in situ vaccines stimulate the immune system by damaging the tumor in its native environment [<xref rid="B63-pharmaceuticals-16-01384" ref-type="bibr">63</xref>]. As the tumor cells die, they release antigens, which are then recognized by the immune system. Often, this is achieved by injecting immune-stimulating agents or oncolytic viruses into the tumor [<xref rid="B176-pharmaceuticals-16-01384" ref-type="bibr">176</xref>,<xref rid="B177-pharmaceuticals-16-01384" ref-type="bibr">177</xref>]. This not only aims to destroy the immediate tumor but also primes the immune system to recognize and combat tumor cells elsewhere in the body [<xref rid="B176-pharmaceuticals-16-01384" ref-type="bibr">176</xref>]. In situ cancer vaccines have shown promise in preliminary studies.</p></sec><sec id="sec4dot7-pharmaceuticals-16-01384"><title>4.7. Influencing Factors of Tumor Vaccines</title><p>Boosting the power of cancer vaccines is a top priority for researchers, who are diving deep into adjuvants and combination therapies to ramp up immune responses, outsmart tumor immune evasion, and prevent cancers from coming back [<xref rid="B178-pharmaceuticals-16-01384" ref-type="bibr">178</xref>,<xref rid="B179-pharmaceuticals-16-01384" ref-type="bibr">179</xref>]. The efficacy of cancer vaccines hinges on several factors, including picking the right antigens, choosing the adjuvants wisely, and using the best delivery systems [<xref rid="B2-pharmaceuticals-16-01384" ref-type="bibr">2</xref>]. Antigen selection is of paramount significance. The antigens should be specific to the tumor, or associated with it, so that the immune response zeroes in on cancer cells without harming healthy tissues [<xref rid="B180-pharmaceuticals-16-01384" ref-type="bibr">180</xref>]. Plus, the chosen antigens need to be highly immunogenic and able to stimulate both CD8+ cytotoxic T cells and CD4+ helper T cells for a strong, long-lasting attack against tumors [<xref rid="B15-pharmaceuticals-16-01384" ref-type="bibr">15</xref>]. Adjuvants help by making cancer vaccines more immunogenic. They stimulate the innate immune system, encourage antigen uptake by APCs, and help activate and expand antigen-specific T cells [<xref rid="B181-pharmaceuticals-16-01384" ref-type="bibr">181</xref>,<xref rid="B182-pharmaceuticals-16-01384" ref-type="bibr">182</xref>]. There are different types of adjuvants, like alum, toll-like receptor (TLR) agonists, and cytokines, each with unique mechanisms of action and varying effectiveness [<xref rid="B183-pharmaceuticals-16-01384" ref-type="bibr">183</xref>,<xref rid="B184-pharmaceuticals-16-01384" ref-type="bibr">184</xref>]. The latest research shows that TLR agonists, such as TLR9 and TLR7/8 agonists, have shown promise by bolstering antigen-presenting cells and intensifying immune responses [<xref rid="B185-pharmaceuticals-16-01384" ref-type="bibr">185</xref>]. Researchers have developed a nanosystem that can inhibit a process called MerTK-mediated efferocytosis. This inhibition leads to the release of immunogenic contents into the tumor microenvironment, potentially boosting the body&#8217;s natural defenses against the tumor [<xref rid="B186-pharmaceuticals-16-01384" ref-type="bibr">186</xref>]. Similarly, STING agonists enhance dendritic cell activity, boosting T-cell responses against tumors [<xref rid="B187-pharmaceuticals-16-01384" ref-type="bibr">187</xref>,<xref rid="B188-pharmaceuticals-16-01384" ref-type="bibr">188</xref>]. Oncolytic viruses, while serving as direct antitumor agents, also act as adjuvants by releasing tumor antigens within an inflammatory milieu [<xref rid="B132-pharmaceuticals-16-01384" ref-type="bibr">132</xref>]. These recent breakthroughs encapsulate the dynamic progression in adjuvant research, aiming to optimize the immune system&#8217;s potency against tumors.</p></sec></sec><sec id="sec5-pharmaceuticals-16-01384"><title>5. Combination Therapies</title><p>Combining cancer vaccines with other therapies has emerged as a promising strategy to enhance the overall therapeutic efficacy and overcome the limitations of single-agent treatments [<xref rid="B189-pharmaceuticals-16-01384" ref-type="bibr">189</xref>]. Cancer vaccines, which aim to stimulate a patient&#8217;s immune system to recognize and attack tumor cells, may benefit from being combined with other immunotherapies, such as immune checkpoint inhibitors, to boost immune responses and counteract immunosuppressive mechanisms within the tumor microenvironment (TME) [<xref rid="B190-pharmaceuticals-16-01384" ref-type="bibr">190</xref>].</p><p>Several types of combination therapies involving cancer vaccines and other treatment modalities have been explored in recent years, such as combining cancer vaccines with chemotherapy, targeted therapies, and radiation therapy [<xref rid="B189-pharmaceuticals-16-01384" ref-type="bibr">189</xref>]. These combination approaches hold significant promise for optimizing cancer treatment outcomes and providing more effective, personalized therapy options for patients [<xref rid="B74-pharmaceuticals-16-01384" ref-type="bibr">74</xref>].</p><sec id="sec5dot1-pharmaceuticals-16-01384"><title>5.1. Cancer Vaccine + Immune Checkpoint Inhibitors</title><p>These vaccines can be combined with other treatments to enhance their effectiveness. Immune checkpoint inhibitors like pembrolizumab (Keytruda), nivolumab (Opdivo), and ipilimumab (Yervoy) disable immune checkpoints, thereby unleashing a more potent attack on cancer cells [<xref rid="B191-pharmaceuticals-16-01384" ref-type="bibr">191</xref>,<xref rid="B192-pharmaceuticals-16-01384" ref-type="bibr">192</xref>,<xref rid="B193-pharmaceuticals-16-01384" ref-type="bibr">193</xref>,<xref rid="B194-pharmaceuticals-16-01384" ref-type="bibr">194</xref>]. This combination hopes to enhance recognition of cancer cells (via the vaccine) and amplify the immune response (via the checkpoint inhibitors) [<xref rid="B5-pharmaceuticals-16-01384" ref-type="bibr">5</xref>,<xref rid="B178-pharmaceuticals-16-01384" ref-type="bibr">178</xref>].</p><p>This combined approach has shown promise in preclinical models and early clinical trials by generating tumor-specific T cells and preventing their exhaustion [<xref rid="B195-pharmaceuticals-16-01384" ref-type="bibr">195</xref>]. The mechanism behind these effects is that cancer vaccines aim to boost T cells&#8217; recognition of tumor antigens, but this immune response can be dampened by the tumor&#8217;s evasion mechanisms [<xref rid="B196-pharmaceuticals-16-01384" ref-type="bibr">196</xref>]. Enter immune checkpoint inhibitors, which block inhibitory checkpoints (PD-1 and CTLA-4) on T cells, essentially &#8220;releasing the brakes&#8221; and amplifying their antitumor activity [<xref rid="B197-pharmaceuticals-16-01384" ref-type="bibr">197</xref>]. By combining cancer vaccines, which enhance the number of tumor-recognizing T cells, with checkpoint inhibitors that ensure that these T cells are not suppressed, there is a synergistic boost in the antitumor immune response. Preliminary studies suggest that this combination augments tumor attack, potentially leading to improved patient outcomes [<xref rid="B198-pharmaceuticals-16-01384" ref-type="bibr">198</xref>,<xref rid="B199-pharmaceuticals-16-01384" ref-type="bibr">199</xref>,<xref rid="B200-pharmaceuticals-16-01384" ref-type="bibr">200</xref>,<xref rid="B201-pharmaceuticals-16-01384" ref-type="bibr">201</xref>].</p></sec><sec id="sec5dot2-pharmaceuticals-16-01384"><title>5.2. Cancer Vaccine + Chemotherapy</title><p>Chemotherapy is a destructive force against cancer cells, hindering their growth and division, but may also inadvertently harm rapidly dividing normal cells such as those in bone marrow, the digestive tract, and skin [<xref rid="B202-pharmaceuticals-16-01384" ref-type="bibr">202</xref>]. The potential synergy between cancer vaccines and chemotherapy arises from some chemotherapeutic agents inducing immunogenic cell death, increasing the visibility of dying cancer cells to the immune system and potentially enhancing the efficacy of cancer vaccines [<xref rid="B203-pharmaceuticals-16-01384" ref-type="bibr">203</xref>]. Several chemotherapeutic agents have been identified to potentially enhance the efficacy of cancer vaccines due to their immunomodulatory effects. For instance, cyclophosphamide and temozolomide can deplete immune-suppressing regulatory T cells (Tregs), creating a more receptive tumor environment for vaccine action [<xref rid="B204-pharmaceuticals-16-01384" ref-type="bibr">204</xref>]. Docetaxel, used for cancers like breast and prostate cancers, can bolster antigen presentation, thereby enhancing immune recognition of tumor cells [<xref rid="B205-pharmaceuticals-16-01384" ref-type="bibr">205</xref>]. Gemcitabine targets and reduces myeloid-derived suppressor cells (MDSCs) [<xref rid="B206-pharmaceuticals-16-01384" ref-type="bibr">206</xref>]. When combined with cancer vaccines, these agents can modify the tumor environment, diminish immune suppression, or amplify the immune response against tumors, although the choice of combination depends on multiple factors, including cancer type and patient health [<xref rid="B203-pharmaceuticals-16-01384" ref-type="bibr">203</xref>].</p><p>However, there are substantial challenges to this approach. Determining the optimal timing and dosage of chemotherapy in relation to cancer vaccines remains a complex task [<xref rid="B159-pharmaceuticals-16-01384" ref-type="bibr">159</xref>]. The side effects of both chemotherapy and cancer vaccines, including chemotherapy&#8217;s often severe systemic side effects such as fatigue, infection, hair loss, and nausea, are a significant concern [<xref rid="B207-pharmaceuticals-16-01384" ref-type="bibr">207</xref>]. Furthermore, the treatment&#8217;s responsiveness is limited, as not all cancer types respond well to chemotherapy or cancer vaccines, with variability in individual patient responses adding to the complexity of treatment plans [<xref rid="B208-pharmaceuticals-16-01384" ref-type="bibr">208</xref>,<xref rid="B209-pharmaceuticals-16-01384" ref-type="bibr">209</xref>]. Additionally, the complexity of the tumor microenvironment, which can evolve various mechanisms to resist or evade treatment, may limit the effectiveness of these combined therapies [<xref rid="B210-pharmaceuticals-16-01384" ref-type="bibr">210</xref>].</p></sec><sec id="sec5dot3-pharmaceuticals-16-01384"><title>5.3. Cancer Vaccine + Radiotherapy</title><p>Radiotherapy employs high-energy particles or waves, such as X-rays, gamma rays, electron beams, or protons, to annihilate or damage cancer cells. This radiation induces small breaks in the DNA inside cells, inhibiting their growth and division, and eventually leading to their death [<xref rid="B211-pharmaceuticals-16-01384" ref-type="bibr">211</xref>]. When combined with tumor vaccines, these treatments might produce a synergistic effect, with radiotherapy potentially leading to the release of cancer cell antigens and stimulating the immune system, thereby enhancing the effectiveness of cancer vaccines [<xref rid="B212-pharmaceuticals-16-01384" ref-type="bibr">212</xref>,<xref rid="B213-pharmaceuticals-16-01384" ref-type="bibr">213</xref>,<xref rid="B214-pharmaceuticals-16-01384" ref-type="bibr">214</xref>]. Research indicates that radiotherapy exerts both cytotoxic and immunomodulatory effects on the tumor microenvironment. Beyond directly damaging tumor cells, RT induces immunogenic cell death, leading to the release of damage-associated molecular patterns (DAMPs) [<xref rid="B215-pharmaceuticals-16-01384" ref-type="bibr">215</xref>]. These DAMPs serve as &#8220;danger signals&#8221;, enhancing dendritic cell function and fostering antitumor immune responses. Concurrently, radiotherapy damages the tumor vasculature, increasing its permeability due to direct effects on endothelial cells and the upregulated release of VEGF from irradiated tumor cells [<xref rid="B215-pharmaceuticals-16-01384" ref-type="bibr">215</xref>,<xref rid="B216-pharmaceuticals-16-01384" ref-type="bibr">216</xref>]. This can lead to both transient improvements in oxygen and nutrient delivery and enhanced immune cell infiltration into the tumor.</p><p>However, this combination approach has its limitations. Not all patients or cancer types respond well to either radiotherapy or cancer vaccines, making the efficacy of this approach unclear in a broad population [<xref rid="B217-pharmaceuticals-16-01384" ref-type="bibr">217</xref>]. The optimal timing and dosage of radiotherapy relative to cancer vaccines are not well understood, posing a risk of radiotherapy killing immune cells stimulated by the vaccine, and thereby reducing the effectiveness of the treatment [<xref rid="B218-pharmaceuticals-16-01384" ref-type="bibr">218</xref>]. Both treatments can cause side effects, such as skin changes, fatigue, and other symptoms for radiotherapy, and usually mild but possibly flu-like symptoms for cancer vaccines [<xref rid="B63-pharmaceuticals-16-01384" ref-type="bibr">63</xref>], and some tumors may develop resistance to radiotherapy, which could limit the effectiveness of this combined approach [<xref rid="B219-pharmaceuticals-16-01384" ref-type="bibr">219</xref>].</p></sec><sec id="sec5dot4-pharmaceuticals-16-01384"><title>5.4. Cancer Vaccine + Targeted Therapy</title><p>Compared to cancer vaccines, targeted therapies obstruct specific proteins or processes that aid in cancer growth and progression, offering a more cancer-cell-selective approach compared to traditional chemotherapy and resulting in fewer side effects. Notable targeted therapies include small-molecule inhibitors, like Gleevec (imatinib), and monoclonal antibodies, like Herceptin (trastuzumab) [<xref rid="B220-pharmaceuticals-16-01384" ref-type="bibr">220</xref>,<xref rid="B221-pharmaceuticals-16-01384" ref-type="bibr">221</xref>,<xref rid="B222-pharmaceuticals-16-01384" ref-type="bibr">222</xref>]. When utilized in combination, targeted therapies aim to inhibit cancer cells&#8217; proliferation and survival, rendering the cancer cells more susceptible to the immune response provoked by the cancer vaccine. Studies have revealed the potential of this combination, with targeted therapies able to modulate the tumor microenvironment, thereby possibly enhancing the effectiveness of the vaccine-stimulated immune response [<xref rid="B223-pharmaceuticals-16-01384" ref-type="bibr">223</xref>] and helping to prevent or delay resistance to targeted therapies [<xref rid="B2-pharmaceuticals-16-01384" ref-type="bibr">2</xref>]. However, challenges and limitations remain, including the development of resistance to targeted therapies over time [<xref rid="B224-pharmaceuticals-16-01384" ref-type="bibr">224</xref>], potential side effects ranging from mild skin rashes or diarrhea to severe liver toxicity or heart problems [<xref rid="B225-pharmaceuticals-16-01384" ref-type="bibr">225</xref>], limited responsiveness in certain cancer types or patients [<xref rid="B208-pharmaceuticals-16-01384" ref-type="bibr">208</xref>], and the complex and not fully understood interaction effects between cancer vaccines and targeted therapies, which could potentially interfere with the vaccine-stimulated immune response [<xref rid="B16-pharmaceuticals-16-01384" ref-type="bibr">16</xref>].</p></sec><sec id="sec5dot5-pharmaceuticals-16-01384"><title>5.5. Cancer Vaccine + Oncolytic Virotherapy</title><p>Oncolytic virotherapy constitutes a novel paradigm in the therapeutic approach towards malignant neoplasms, exhibiting a mechanism of action that distinguishes it from traditional tumor vaccines. It capitalizes on the unique capabilities of selected or genetically engineered viruses, which are orchestrated to specifically target and eradicate neoplastic cells [<xref rid="B19-pharmaceuticals-16-01384" ref-type="bibr">19</xref>,<xref rid="B226-pharmaceuticals-16-01384" ref-type="bibr">226</xref>]. Upon administration, these oncolytic viruses infiltrate the patient&#8217;s system, subjugating cancerous cells and commandeering their biological machinery for viral replication, consequently leading to cell lysis [<xref rid="B227-pharmaceuticals-16-01384" ref-type="bibr">227</xref>,<xref rid="B228-pharmaceuticals-16-01384" ref-type="bibr">228</xref>]. This lysogenic cycle not only facilitates direct oncolysis but also liberates tumor-specific antigens, providing a catalyst for the patient&#8217;s immune system to mount an anticancer response&#8212;an underpinning that is shared with the concept of tumor vaccines [<xref rid="B132-pharmaceuticals-16-01384" ref-type="bibr">132</xref>]. This dual-action mechanism that harmonizes direct cellular destruction with immune activation embodies a promising pathway in the realm of cancer therapy. The dual-action mechanism encompasses direct tumor cell lysis, releasing tumor-associated antigens, and the unveiling of damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). These elements activate both the innate and adaptive arms of the immune system, enhancing antitumor responses. As newly assembled viral entities continue their onslaught against other malignant cells, a self-propagating cycle is established.</p><p>Recent advancements in this burgeoning field have entailed the exploration of diverse oncolytic virus models, such as the <italic toggle="yes">Parapoxvirus ovis</italic> model, known to induce an immunogenic form of cell death termed pyroptosis [<xref rid="B229-pharmaceuticals-16-01384" ref-type="bibr">229</xref>]. Scientific investigations have also scrutinized the immunostimulatory effects of these bioengineered viruses and combinational therapeutic strategies that kindle pyroptosis, consequently fostering potent antitumor activity [<xref rid="B230-pharmaceuticals-16-01384" ref-type="bibr">230</xref>,<xref rid="B231-pharmaceuticals-16-01384" ref-type="bibr">231</xref>,<xref rid="B232-pharmaceuticals-16-01384" ref-type="bibr">232</xref>]. These engineered viruses have some potential in the delivery of antitumor drugs [<xref rid="B233-pharmaceuticals-16-01384" ref-type="bibr">233</xref>]. Pioneering therapeutic strategies, such as the KISIMA/VSV-GP heterologous prime&#8211;boost methodology and the development of adenovirus-based tumor vaccines, have further emphasized the potential of oncolytic virotherapy as a formidable armament in the arsenal of cancer immunotherapy [<xref rid="B234-pharmaceuticals-16-01384" ref-type="bibr">234</xref>].</p><p>Cancer vaccines and oncolytic virotherapy offer a potential synergistic approach for cancer treatment. Cancer vaccines introduce cancer-specific antigens into the body, training the immune system to recognize and attack cells displaying these antigens [<xref rid="B5-pharmaceuticals-16-01384" ref-type="bibr">5</xref>]. Concurrently, oncolytic virotherapy uses engineered viruses that selectively infect and eliminate cancer cells, subsequently releasing tumor antigens and new viral particles that can infect nearby cancer cells, thereby stimulating an immune response [<xref rid="B19-pharmaceuticals-16-01384" ref-type="bibr">19</xref>]. In combination, the cancer vaccine&#8217;s potential enhancement of the immune response, coupled with the direct cellular damage from the oncolytic virus, could increase therapeutic effectiveness. Initial studies suggest that this combination can result in a more robust and long-lasting immune response against tumors, even potentially overcoming some immune evasion tactics employed by cancer cells [<xref rid="B235-pharmaceuticals-16-01384" ref-type="bibr">235</xref>]. Nevertheless, this approach is not without limitations. The immune system could respond to the oncolytic virus, reducing its cancer-killing effectiveness [<xref rid="B236-pharmaceuticals-16-01384" ref-type="bibr">236</xref>]. Additionally, delivering both oncolytic viruses and cancer vaccines to the tumor site, particularly in solid tumors, is challenging [<xref rid="B237-pharmaceuticals-16-01384" ref-type="bibr">237</xref>]. The diverse nature of cancers and variability in patient responses can limit the overall responsiveness of this combined therapy [<xref rid="B238-pharmaceuticals-16-01384" ref-type="bibr">238</xref>]. Finally, safety is a significant concern, as both oncolytic virotherapy and cancer vaccines can cause side effects, with the former potentially leading to severe or life-threatening reactions in rare instances [<xref rid="B239-pharmaceuticals-16-01384" ref-type="bibr">239</xref>]. Recent advancements will change this domain. Viruses are now engineered for heightened tumor specificity, some are armed with therapeutic genes to turn tumors into producers of anticancer agents, and combinations with treatments like immune checkpoint inhibitors are showing synergistic effects [<xref rid="B240-pharmaceuticals-16-01384" ref-type="bibr">240</xref>,<xref rid="B241-pharmaceuticals-16-01384" ref-type="bibr">241</xref>]. Moreover, refined genetic engineering techniques have improved the safety profiles of these oncolytic viruses, making them more amenable for therapeutic applications [<xref rid="B242-pharmaceuticals-16-01384" ref-type="bibr">242</xref>,<xref rid="B243-pharmaceuticals-16-01384" ref-type="bibr">243</xref>]. This means that they have reduced virulence in non-target tissues and minimized side effects.</p></sec></sec><sec id="sec6-pharmaceuticals-16-01384"><title>6. Personalized Cancer Vaccines</title><p>Personalized cancer vaccine therapy is an innovative approach that tailors cancer treatment to a patient&#8217;s unique tumor profile. The process can be outlined as follows (<xref rid="pharmaceuticals-16-01384-f004" ref-type="fig">Figure 4</xref>).</p><sec id="sec6dot1-pharmaceuticals-16-01384"><title>6.1. Tumor Sample Collection</title><p>A critical step in this process is the collection of tumor samples, which provide the essential genetic material needed to tailor the vaccine to the individual&#8217;s specific cancer [<xref rid="B244-pharmaceuticals-16-01384" ref-type="bibr">244</xref>]. The latest research advances have highlighted the importance of obtaining high-quality, well-preserved samples through minimally invasive techniques such as fine-needle aspiration or core-needle biopsy [<xref rid="B245-pharmaceuticals-16-01384" ref-type="bibr">245</xref>]. Additionally, there is a growing emphasis on collecting tumor samples at multiple timepoints throughout the course of treatment to account for the inherent heterogeneity of tumors and the potential for evolving cancer mutations [<xref rid="B246-pharmaceuticals-16-01384" ref-type="bibr">246</xref>]. The integration of these cutting-edge technologies and best practices in tumor sample collection is essential for maximizing the success of personalized cancer vaccine therapy [<xref rid="B20-pharmaceuticals-16-01384" ref-type="bibr">20</xref>].</p></sec><sec id="sec6dot2-pharmaceuticals-16-01384"><title>6.2. Sequencing and Analysis</title><p>Sequencing and analysis empower researchers and clinicians to identify tumor-specific mutations and neoantigens that may function as potential therapeutic targets [<xref rid="B20-pharmaceuticals-16-01384" ref-type="bibr">20</xref>]. The development of next-generation sequencing (NGS) technologies, such as whole-exome and whole-genome sequencing, has greatly sped up the process and increased the precision of pinpointing tumor-specific mutations [<xref rid="B177-pharmaceuticals-16-01384" ref-type="bibr">177</xref>,<xref rid="B247-pharmaceuticals-16-01384" ref-type="bibr">247</xref>]. Concurrently, innovative computational approaches like machine learning algorithms and in silico prediction tools have emerged to forecast neoantigens with high immunogenicity, thereby expediting the selection of optimal vaccine candidates [<xref rid="B244-pharmaceuticals-16-01384" ref-type="bibr">244</xref>,<xref rid="B248-pharmaceuticals-16-01384" ref-type="bibr">248</xref>,<xref rid="B249-pharmaceuticals-16-01384" ref-type="bibr">249</xref>]. Moreover, incorporating multi-omics data, which include transcriptomics, proteomics, and epigenomics, offers a more comprehensive understanding of the tumor microenvironment and its influence on the effectiveness of personalized cancer vaccine therapy [<xref rid="B250-pharmaceuticals-16-01384" ref-type="bibr">250</xref>]. These advancements in sequencing and analysis have markedly improved our capacity to develop customized cancer vaccines, and they further emphasize the significance of multidisciplinary collaboration within the cancer immunotherapy field.</p></sec><sec id="sec6dot3-pharmaceuticals-16-01384"><title>6.3. Neoantigen Selection</title><p>Neoantigen selection is vital for eliciting a robust and effective immune response [<xref rid="B20-pharmaceuticals-16-01384" ref-type="bibr">20</xref>,<xref rid="B21-pharmaceuticals-16-01384" ref-type="bibr">21</xref>]. Factors considered in the selection process include the binding affinity of the neoantigen to major histocompatibility complex (MHC) molecules, the immunogenicity of the epitope, and the likelihood of generating T-cell receptor (TCR) recognition [<xref rid="B251-pharmaceuticals-16-01384" ref-type="bibr">251</xref>,<xref rid="B252-pharmaceuticals-16-01384" ref-type="bibr">252</xref>]. Recent studies have also highlighted the importance of incorporating multi-omics data to ensure that the chosen neoantigens are effectively processed and presented on the cell surface [<xref rid="B250-pharmaceuticals-16-01384" ref-type="bibr">250</xref>]. By combining these innovative approaches, researchers have substantially improved the process of neoantigen selection, bolstering the potential for successful personalized cancer vaccine therapy.</p></sec><sec id="sec6dot4-pharmaceuticals-16-01384"><title>6.4. Vaccine Design</title><p>Vaccine design directly influences the efficacy of the immune response against tumor cells [<xref rid="B8-pharmaceuticals-16-01384" ref-type="bibr">8</xref>]. Recent research advances have led to the development of various vaccine platforms, including peptide-based, nucleic-acid-based (DNA or RNA), viral-vector-based, and dendritic-cell-based vaccines, each with their own set of advantages and challenges [<xref rid="B8-pharmaceuticals-16-01384" ref-type="bibr">8</xref>,<xref rid="B21-pharmaceuticals-16-01384" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-16-01384" ref-type="bibr">22</xref>]. The selection of appropriate adjuvants and delivery systems is essential for enhancing the immunogenicity of the vaccine and promoting the activation and expansion of tumor-specific T cells [<xref rid="B253-pharmaceuticals-16-01384" ref-type="bibr">253</xref>]. Innovative techniques such as liposomal and nanoparticle-based delivery systems have shown promise in improving vaccine stability, cellular uptake, and antigen presentation [<xref rid="B254-pharmaceuticals-16-01384" ref-type="bibr">254</xref>]. The swift pace of advancements in vaccine design methodologies, in conjunction with a burgeoning understanding of the tumor microenvironment and immune system, has notably augmented the potential of personalized cancer vaccine therapy, laying the groundwork for more effective and targeted cancer treatments.</p></sec><sec id="sec6dot5-pharmaceuticals-16-01384"><title>6.5. Vaccine Production</title><p>The high quality of production in personalized cancer vaccine therapy is indispensable for ensuring the delivery of efficacious and safe treatment options to patients [<xref rid="B22-pharmaceuticals-16-01384" ref-type="bibr">22</xref>]. Noteworthy innovations in the production process encompass the incorporation of automation and process optimization to curtail the manufacturing duration and boost scalability [<xref rid="B255-pharmaceuticals-16-01384" ref-type="bibr">255</xref>]. Furthermore, the utilization of continuous manufacturing processes and the establishment of modular facilities have amplified flexibility and adaptability in vaccine production, thereby streamlining the supply chain for personalized therapies [<xref rid="B256-pharmaceuticals-16-01384" ref-type="bibr">256</xref>]. To ensure product quality, regulatory agencies have enforced good manufacturing practices (GMPs) and stringent quality control measures. The integration of advanced bioinformatics tools has also contributed to the acceleration of vaccine development and production, enabling more rapid clinical translation and patient access [<xref rid="B110-pharmaceuticals-16-01384" ref-type="bibr">110</xref>]. As the field of personalized cancer vaccine therapy continues to expand, further innovations in vaccine production technologies and processes will be vital to meeting the growing demand and ensuring the timely delivery of these tailored treatments.</p></sec><sec id="sec6dot6-pharmaceuticals-16-01384"><title>6.6. Vaccine Administration</title><p>Vaccine administration directly impacts the induction of a robust immune response against tumor cells. The latest research advances have led to the exploration of various routes of administration, including subcutaneous, intradermal, intramuscular, and intranodal, with each route presenting unique benefits and challenges for different vaccine platforms [<xref rid="B257-pharmaceuticals-16-01384" ref-type="bibr">257</xref>,<xref rid="B258-pharmaceuticals-16-01384" ref-type="bibr">258</xref>]. The choice of administration route can influence the vaccine&#8217;s biodistribution, antigen presentation, and subsequent immune response [<xref rid="B23-pharmaceuticals-16-01384" ref-type="bibr">23</xref>]. Researchers are also investigating the optimal dosing and scheduling of these personalized vaccines to maximize their efficacy while minimizing potential adverse effects [<xref rid="B21-pharmaceuticals-16-01384" ref-type="bibr">21</xref>,<xref rid="B259-pharmaceuticals-16-01384" ref-type="bibr">259</xref>]. Recent studies have delved into the synergistic effects of merging personalized cancer vaccines with other immunotherapies to amplify therapeutic outcomes and surmount immune resistance [<xref rid="B260-pharmaceuticals-16-01384" ref-type="bibr">260</xref>].</p><p>As the realm of personalized cancer vaccine therapy continues to expand, a nuanced understanding of the optimal administration strategies, including route, dosage, and scheduling, will be pivotal for maximizing the therapeutic potential of these individualized treatments.</p></sec><sec id="sec6dot7-pharmaceuticals-16-01384"><title>6.7. Immune Response Activation</title><p>The activation of the immune response is a central objective in personalized cancer vaccine therapy, aiming to instigate a robust and specific immune response against tumor cells expressing neoantigens. Recent research strides have provided a more comprehensive understanding of the mechanisms underpinning the activation of both innate and adaptive immune responses [<xref rid="B20-pharmaceuticals-16-01384" ref-type="bibr">20</xref>]. Personalized cancer vaccines endeavor to prime the immune system by presenting tumor-specific neoantigens to antigen-presenting cells (APCs) such as dendritic cells, which subsequently activate cytotoxic T lymphocytes (CTLs) to target and eliminate tumor cells [<xref rid="B22-pharmaceuticals-16-01384" ref-type="bibr">22</xref>,<xref rid="B178-pharmaceuticals-16-01384" ref-type="bibr">178</xref>,<xref rid="B261-pharmaceuticals-16-01384" ref-type="bibr">261</xref>]. A key facet of immune response activation lies in the optimization of vaccine design, thereby amplifying the immunogenicity of the vaccine and fostering the expansion of tumor-specific T cells [<xref rid="B262-pharmaceuticals-16-01384" ref-type="bibr">262</xref>].</p><p>Recent investigations have probed into combining personalized cancer vaccines with other immunotherapies to augment the antitumor immune response and counter the immune evasion strategies utilized by cancer cells [<xref rid="B260-pharmaceuticals-16-01384" ref-type="bibr">260</xref>]. As the realm of personalized cancer vaccine therapy progresses, a deeper comprehension of immune response activation and its modulation will be indispensable for maximizing the therapeutic potential of these tailored treatments.</p></sec><sec id="sec6dot8-pharmaceuticals-16-01384"><title>6.8. Monitoring and Evaluation</title><p>Monitoring and evaluation are integral to ensuring the safety, efficacy, and optimization of these individualized treatments. Recent research breakthroughs have resulted in the development of comprehensive methodologies to assess both immune response and clinical outcomes in patients receiving personalized cancer vaccines [<xref rid="B21-pharmaceuticals-16-01384" ref-type="bibr">21</xref>,<xref rid="B22-pharmaceuticals-16-01384" ref-type="bibr">22</xref>]. Essential parameters for evaluating the immunological response include monitoring the expansion of vaccine-specific T cells, the production of cytokines, and the infiltration of immune cells into the tumor microenvironment [<xref rid="B258-pharmaceuticals-16-01384" ref-type="bibr">258</xref>]. These evaluations furnish invaluable insights into the vaccine&#8217;s capacity to activate and modulate the immune system.</p><p>Clinical evaluation entails tracking objective responses, such as reduction in tumor size, progression-free survival, and overall survival, while also considering the patients&#8217; quality of life [<xref rid="B23-pharmaceuticals-16-01384" ref-type="bibr">23</xref>,<xref rid="B263-pharmaceuticals-16-01384" ref-type="bibr">263</xref>]. As personalized cancer vaccines are often administered in combination with other immunotherapies, it is crucial to identify synergistic effects and ascertain the optimal treatment regimen [<xref rid="B260-pharmaceuticals-16-01384" ref-type="bibr">260</xref>,<xref rid="B264-pharmaceuticals-16-01384" ref-type="bibr">264</xref>].</p><p>Moreover, monitoring and evaluating safety profiles is imperative for identifying and managing potential adverse effects associated with personalized cancer vaccines, such as autoimmune reactions or systemic inflammation [<xref rid="B109-pharmaceuticals-16-01384" ref-type="bibr">109</xref>]. The ongoing refinement of monitoring and evaluation strategies will contribute to maximizing the therapeutic potential and safety of personalized cancer vaccine therapies, thereby enhancing patient outcomes.</p></sec><sec id="sec6dot9-pharmaceuticals-16-01384"><title>6.9. Follow-Up, Maintenance, and Patient Education and Support</title><p>Continuous follow-up empowers healthcare professionals to monitor patients&#8217; responses to therapy, assess potential adverse effects, and make necessary adjustments to treatment plans [<xref rid="B21-pharmaceuticals-16-01384" ref-type="bibr">21</xref>,<xref rid="B265-pharmaceuticals-16-01384" ref-type="bibr">265</xref>]. Maintenance therapy, including administering booster vaccinations or adjusting combination therapies, is pivotal for maintaining the antitumor immune response and preventing cancer recurrence [<xref rid="B22-pharmaceuticals-16-01384" ref-type="bibr">22</xref>,<xref rid="B74-pharmaceuticals-16-01384" ref-type="bibr">74</xref>].</p><p>Patient education forms a key aspect of personalized cancer vaccine therapy, as it enables patients to make informed decisions about their treatment and manage potential side effects [<xref rid="B257-pharmaceuticals-16-01384" ref-type="bibr">257</xref>]. Patients should be well informed about potential adverse effects of the treatment and the importance of promptly reporting these to their healthcare providers [<xref rid="B109-pharmaceuticals-16-01384" ref-type="bibr">109</xref>,<xref rid="B261-pharmaceuticals-16-01384" ref-type="bibr">261</xref>]. Moreover, the emotional and psychological wellbeing of patients can significantly influence their response to treatment, underscoring the need for comprehensive support systems. This may include mental health counseling, peer support groups, and resources for family members, creating an environment that nurtures the patient&#8217;s resilience and determination [<xref rid="B266-pharmaceuticals-16-01384" ref-type="bibr">266</xref>]. As personalized cancer vaccine therapy continues to progress, it is crucial to maintain an integrated approach that addresses all facets of patient care, including follow-up, maintenance, education, and support. This holistic approach can maximize the therapeutic potential of personalized cancer vaccines and lead to improved patient outcomes [<xref rid="B267-pharmaceuticals-16-01384" ref-type="bibr">267</xref>].</p></sec><sec id="sec6dot10-pharmaceuticals-16-01384"><title>6.10. Data Collection and Analysis</title><p>Data collection and analysis stand as the cornerstones of personalized cancer vaccine development and evaluation. Recent strides in high-throughput sequencing technologies, computational methodologies, and bioinformatics have ushered in a new era, enabling researchers to more precisely identify and prioritize neoantigens, craft personalized vaccines, and keep track of immune responses [<xref rid="B20-pharmaceuticals-16-01384" ref-type="bibr">20</xref>,<xref rid="B22-pharmaceuticals-16-01384" ref-type="bibr">22</xref>,<xref rid="B258-pharmaceuticals-16-01384" ref-type="bibr">258</xref>]. Furthermore, the application of machine learning algorithms and artificial intelligence has emerged as a powerful tool to navigate the complexity of these data landscapes. This technology bolsters our capacity to predict the immunogenicity of neoantigens and assess the effectiveness of personalized cancer vaccines [<xref rid="B252-pharmaceuticals-16-01384" ref-type="bibr">252</xref>]. Standardized data collection and analysis protocols are paramount to ensure reproducibility, facilitate comparisons across studies, and promote the development of robust and reliable personalized cancer vaccine therapies [<xref rid="B23-pharmaceuticals-16-01384" ref-type="bibr">23</xref>].</p></sec><sec id="sec6dot11-pharmaceuticals-16-01384"><title>6.11. Integration with Other Therapies</title><p>The integration of personalized cancer vaccines with other therapeutic modalities offers an intriguing avenue in the realm of cancer treatment. By combining different treatment modalities, we can potentially augment therapeutic efficacy, surmount resistance mechanisms, and ultimately improve patient outcomes. Recent scientific findings highlight the potential synergistic effects of marrying personalized cancer vaccines with other forms of immunotherapies. Notably, ICIs, which target immunosuppressive pathways like PD-1 (programmed cell death protein 1), PD-L1 (programmed cell death ligand 1), and CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), have shown promising results in combination with personalized cancer vaccines [<xref rid="B109-pharmaceuticals-16-01384" ref-type="bibr">109</xref>]. The rationale behind this combination is that the vaccine can stimulate a specific antitumor immune response, while ICIs can further enhance the function and persistence of tumor-specific T cells [<xref rid="B191-pharmaceuticals-16-01384" ref-type="bibr">191</xref>].</p><p>Additionally, personalized cancer vaccines can be combined with conventional therapies, such as chemotherapy and radiotherapy, to induce immunogenic cell death and release tumor-associated antigens, creating a more conducive environment for the activation of vaccine-induced immune responses [<xref rid="B139-pharmaceuticals-16-01384" ref-type="bibr">139</xref>]. Furthermore, combining personalized cancer vaccines with targeted therapies, such as kinase inhibitors or monoclonal antibodies, has shown promise in preclinical models by modulating the tumor microenvironment and improving immune cell infiltration [<xref rid="B265-pharmaceuticals-16-01384" ref-type="bibr">265</xref>,<xref rid="B268-pharmaceuticals-16-01384" ref-type="bibr">268</xref>].</p></sec><sec id="sec6dot12-pharmaceuticals-16-01384"><title>6.12. Expanding Applications</title><p>The exploration of personalized cancer vaccine therapy applications continues to surge, unlocking new possibilities for cancer treatment across a diverse range of tumor types and stages. Groundbreaking studies have revealed the potential and effectiveness of tailored cancer vaccines against melanoma, glioblastoma, and non-small-cell lung cancer [<xref rid="B22-pharmaceuticals-16-01384" ref-type="bibr">22</xref>,<xref rid="B263-pharmaceuticals-16-01384" ref-type="bibr">263</xref>]. Aside from solid tumors, there is growing evidence of personalized cancer vaccines proving promising against hematological malignancies such as acute myeloid leukemia (AML) and multiple myeloma (MM) [<xref rid="B269-pharmaceuticals-16-01384" ref-type="bibr">269</xref>,<xref rid="B270-pharmaceuticals-16-01384" ref-type="bibr">270</xref>]. Furthermore, researchers are delving into the possibility of implementing personalized cancer vaccines during earlier disease stages, or as supplementary therapy after surgery or radiotherapy, with the ultimate goal of preventing relapse or disease progression [<xref rid="B126-pharmaceuticals-16-01384" ref-type="bibr">126</xref>].</p><p>As the development of personalized cancer vaccine therapy progresses, gaining a comprehensive understanding of the factors impacting vaccine effectiveness&#8212;including the tumor microenvironment, individual immune responses, and the dynamic interplay among various treatment approaches&#8212;becomes essential in extending its application scope. Unrelenting research and innovation are indispensable for harnessing the full therapeutic capacity of personalized cancer vaccines and enhancing outcomes for a wide spectrum of cancer patients. The world of clinical trials is abuzz with personalized cancer vaccines and neoantigen-targeting therapies [<xref rid="B271-pharmaceuticals-16-01384" ref-type="bibr">271</xref>,<xref rid="B272-pharmaceuticals-16-01384" ref-type="bibr">272</xref>]. Challenges exist, such as optimizing vaccine design and manufacturing, plus pinpointing the patients most likely to benefit from personalized immunotherapies [<xref rid="B195-pharmaceuticals-16-01384" ref-type="bibr">195</xref>,<xref rid="B273-pharmaceuticals-16-01384" ref-type="bibr">273</xref>]. Add in resistance mechanisms, sky-high costs, and complex production, and suddenly these groundbreaking treatments seem less accessible and affordable. So, the cancer immunotherapy research needs to zero in on resistance, refine neoantigen identification tech, and make personalized therapies more cost-effective and scalable [<xref rid="B274-pharmaceuticals-16-01384" ref-type="bibr">274</xref>]. This is where multi-omics approaches and AI come into play, helping to precisely stratify patients and craft combination therapies that boost efficacy while minimizing side effects [<xref rid="B75-pharmaceuticals-16-01384" ref-type="bibr">75</xref>]. Tackling these challenges and embracing emerging technologies will be the key to revolutionizing cancer treatment and offering new hope to countless patients.</p></sec></sec><sec sec-type="conclusions" id="sec7-pharmaceuticals-16-01384"><title>7. Conclusions</title><p>The future prospects of tumor vaccines combined with other treatment modalities are compelling, driven by advances in our understanding of the tumor microenvironment and the immune system&#8217;s interaction with cancer [<xref rid="B275-pharmaceuticals-16-01384" ref-type="bibr">275</xref>]. Enhanced delivery and efficacy of tumor vaccines could be achievable with the development of nanotechnology and advanced drug delivery systems, which increase the stability and targeting of tumor antigens and immune adjuvants, enhancing their immunogenicity when combined with other treatments [<xref rid="B276-pharmaceuticals-16-01384" ref-type="bibr">276</xref>]. Another promising avenue is the combination of tumor vaccines with adoptive cellular therapies such as CAR-T cells, where the vaccine&#8217;s ability to induce a broad immune response could complement the direct cytotoxic effect of engineered T cells [<xref rid="B277-pharmaceuticals-16-01384" ref-type="bibr">277</xref>]. Continual clinical trials and progressive insights into cancer immunology underline the burgeoning promise of tumor vaccines in concert with other treatments [<xref rid="B278-pharmaceuticals-16-01384" ref-type="bibr">278</xref>].</p><p>Personalized cancer vaccines are another exciting frontier in cancer therapy, capitalizing on advancements in our understanding of the immune system and cancer genomics to deliver highly individualized treatments. The development of predictive biomarkers and novel imaging techniques may enhance the efficacy of personalized cancer vaccines by facilitating real-time monitoring of patient responses, enabling timely adjustments to treatment strategies [<xref rid="B279-pharmaceuticals-16-01384" ref-type="bibr">279</xref>]. Rapid progress in genomics, bioinformatics, and manufacturing technologies has streamlined the process of identifying neoantigens and producing personalized vaccines, potentially making these treatments available to a larger number of patients [<xref rid="B280-pharmaceuticals-16-01384" ref-type="bibr">280</xref>]. With continued research and technological innovation, personalized vaccines potentially signify a significant breakthrough in cancer treatment [<xref rid="B281-pharmaceuticals-16-01384" ref-type="bibr">281</xref>].</p><p>Meanwhile, we must acknowledge significant persisting challenges, such as the high cost and logistical complexity of producing individualized vaccines, the necessity for more comprehensive clinical trials to thoroughly appraise their effectiveness, and the fact that not all patients&#8217; tumors harbor identifiable neoantigens [<xref rid="B258-pharmaceuticals-16-01384" ref-type="bibr">258</xref>]. Furthermore, potential issues such as determining the optimal timing and sequencing of combination therapies, managing possible side effects and immune-related toxicities, and addressing issues of cost and accessibility cannot be overlooked [<xref rid="B197-pharmaceuticals-16-01384" ref-type="bibr">197</xref>]. Despite these hurdles, the potential for leveraging the inherent capabilities of the immune system in combatting tumors is distinctly promising, hinting at a future marked by enhanced patient prognostic outcomes.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>G.W. provided the idea for the article. D.L. conducted the initial research and participated in the writing. C.M. and X.W. reviewed and revised the manuscript. X.C. contributed to the revision process. All authors contributed to the manuscript and approved the submitted version. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>Data sharing is not applicable..</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no known competing financial interest or personal relationships that could have appeared to influence the work reported in this paper.</p></notes><glossary><title>Abbreviations</title><array orientation="portrait"><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">ADCC</td><td align="left" valign="middle" rowspan="1" colspan="1">Antibody-dependent cell-mediated cytotoxicity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">AML</td><td align="left" valign="middle" rowspan="1" colspan="1">Acute myeloid leukemia</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">APC</td><td align="left" valign="middle" rowspan="1" colspan="1">Antigen-presenting cell</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">BCRs</td><td align="left" valign="middle" rowspan="1" colspan="1">B-cell receptors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAR</td><td align="left" valign="middle" rowspan="1" colspan="1">Chimeric antigen receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CAR-Ts</td><td align="left" valign="middle" rowspan="1" colspan="1">Chimeric antigen receptor T cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CDC</td><td align="left" valign="middle" rowspan="1" colspan="1">Complement-dependent cytotoxicity</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTLA-4</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytotoxic T-lymphocyte-associated protein 4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">CTLs</td><td align="left" valign="middle" rowspan="1" colspan="1">Cytotoxic T cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DAMPs</td><td align="left" valign="middle" rowspan="1" colspan="1">Damage-associated molecular patterns</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">DCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Dendritic cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ECM</td><td align="left" valign="middle" rowspan="1" colspan="1">Extracellular matrix</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">EGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Epidermal growth factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FAK</td><td align="left" valign="middle" rowspan="1" colspan="1">Focal adhesion kinase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">FDA</td><td align="left" valign="middle" rowspan="1" colspan="1">Food and Drug Administration</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">GBM</td><td align="left" valign="middle" rowspan="1" colspan="1">Glioblastoma multiforme</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">ICIs</td><td align="left" valign="middle" rowspan="1" colspan="1">Immune checkpoint inhibitors</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IFN-&#947;</td><td align="left" valign="middle" rowspan="1" colspan="1">Interferon-&#947;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">IL</td><td align="left" valign="middle" rowspan="1" colspan="1">Interleukin</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LNPs</td><td align="left" valign="middle" rowspan="1" colspan="1">Lipid nanoparticles</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">LOX</td><td align="left" valign="middle" rowspan="1" colspan="1">Lysyl oxidase</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">M1</td><td align="left" valign="middle" rowspan="1" colspan="1">Classically activated macrophages</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">M2</td><td align="left" valign="middle" rowspan="1" colspan="1">Alternatively activated macrophages</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MAC</td><td align="left" valign="middle" rowspan="1" colspan="1">Membrane attack complex</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">mCRPC</td><td align="left" valign="middle" rowspan="1" colspan="1">Metastatic castration-resistant prostate cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">M-CSF</td><td align="left" valign="middle" rowspan="1" colspan="1">Macrophage colony-stimulating factor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MDSCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Myeloid-derived suppressor cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MHC</td><td align="left" valign="middle" rowspan="1" colspan="1">Major histocompatibility complex</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MM</td><td align="left" valign="middle" rowspan="1" colspan="1">Multiple myeloma</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">MMPs</td><td align="left" valign="middle" rowspan="1" colspan="1">Matrix metalloproteinases</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NGS</td><td align="left" valign="middle" rowspan="1" colspan="1">Next-generation sequencing</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NK</td><td align="left" valign="middle" rowspan="1" colspan="1">Natural killer cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">NSCLC</td><td align="left" valign="middle" rowspan="1" colspan="1">Non-small-cell lung cancer</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PAMPs</td><td align="left" valign="middle" rowspan="1" colspan="1">Pathogen-associated molecular patterns</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PBMCs</td><td align="left" valign="middle" rowspan="1" colspan="1">Peripheral blood mononuclear cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD-1</td><td align="left" valign="middle" rowspan="1" colspan="1">Programmed cell death protein 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">PD-L1</td><td align="left" valign="middle" rowspan="1" colspan="1">Programmed cell death ligand 1</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAAs</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor-associated antigens</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TAMs</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor-associated macrophages</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TCR</td><td align="left" valign="middle" rowspan="1" colspan="1">T-cell receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TGF-&#946;</td><td align="left" valign="middle" rowspan="1" colspan="1">Transforming growth factor-&#946;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Th</td><td align="left" valign="middle" rowspan="1" colspan="1">Helper T cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TLR</td><td align="left" valign="middle" rowspan="1" colspan="1">Toll-like receptor</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TME</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor microenvironment</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TNF-&#945;</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor necrosis factor-&#945;</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tregs</td><td align="left" valign="middle" rowspan="1" colspan="1">Regulatory T cells</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">TSAs</td><td align="left" valign="middle" rowspan="1" colspan="1">Tumor-specific antigens</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">VEGF</td><td align="left" valign="middle" rowspan="1" colspan="1">Vascular endothelial growth factor</td></tr></tbody></array></glossary><ref-list><title>References</title><ref id="B1-pharmaceuticals-16-01384"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ferlay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Siegel</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Laversanne</surname><given-names>M.</given-names></name><name name-style="western"><surname>Soerjomataram</surname><given-names>I.</given-names></name><name name-style="western"><surname>Jemal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bray</surname><given-names>F.</given-names></name></person-group><article-title>Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries</article-title><source>CA Cancer J. Clin.</source><year>2021</year><volume>71</volume><fpage>209</fpage><lpage>249</lpage><pub-id pub-id-type="doi">10.3322/caac.21660</pub-id><pub-id pub-id-type="pmid">33538338</pub-id></element-citation></ref><ref id="B2-pharmaceuticals-16-01384"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Coukos</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dranoff</surname><given-names>G.</given-names></name></person-group><article-title>Cancer immunotherapy comes of age</article-title><source>Nature</source><year>2011</year><volume>480</volume><fpage>480</fpage><lpage>489</lpage><pub-id pub-id-type="doi">10.1038/nature10673</pub-id><pub-id pub-id-type="pmid">22193102</pub-id><pub-id pub-id-type="pmcid">PMC3967235</pub-id></element-citation></ref><ref id="B3-pharmaceuticals-16-01384"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiemann</surname><given-names>B.</given-names></name><name name-style="western"><surname>Starnes</surname><given-names>C.O.</given-names></name></person-group><article-title>Coley&#8217;s toxins, tumor necrosis factor and cancer research: A historical perspective</article-title><source>Pharmacol. Ther.</source><year>1994</year><volume>64</volume><fpage>529</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1016/0163-7258(94)90023-X</pub-id><pub-id pub-id-type="pmid">7724661</pub-id></element-citation></ref><ref id="B4-pharmaceuticals-16-01384"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burnet</surname><given-names>M.</given-names></name></person-group><article-title>Cancer-A Biological Approach: III Viruses Associated with Neoplastic Conditions</article-title><source>Br. Med. J.</source><year>1957</year><volume>1</volume><fpage>841</fpage><pub-id pub-id-type="doi">10.1136/bmj.1.5023.841</pub-id><pub-id pub-id-type="pmid">13413231</pub-id><pub-id pub-id-type="pmcid">PMC1973618</pub-id></element-citation></ref><ref id="B5-pharmaceuticals-16-01384"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kantoff</surname><given-names>P.W.</given-names></name><name name-style="western"><surname>Higano</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Shore</surname><given-names>N.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>E.</given-names></name><name name-style="western"><surname>Small</surname><given-names>E.J.</given-names></name></person-group><article-title>Sipuleucel T immunotherapy for CRPC</article-title><source>N. Engl. J.</source><year>2010</year><volume>363</volume><fpage>411</fpage><lpage>422</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa1001294</pub-id><pub-id pub-id-type="pmid">20818862</pub-id></element-citation></ref><ref id="B6-pharmaceuticals-16-01384"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neelapu</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Locke</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Lekakis</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Miklos</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Jacobson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Braunschweig</surname><given-names>I.</given-names></name><name name-style="western"><surname>Oluwole</surname><given-names>O.O.</given-names></name><name name-style="western"><surname>Siddiqi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>2531</fpage><lpage>2544</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1707447</pub-id><pub-id pub-id-type="pmid">29226797</pub-id><pub-id pub-id-type="pmcid">PMC5882485</pub-id></element-citation></ref><ref id="B7-pharmaceuticals-16-01384"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Quail</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>J.A.</given-names></name></person-group><article-title>Microenvironmental regulation of tumor progression and metastasis</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1423</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1038/nm.3394</pub-id><pub-id pub-id-type="pmid">24202395</pub-id><pub-id pub-id-type="pmcid">PMC3954707</pub-id></element-citation></ref><ref id="B8-pharmaceuticals-16-01384"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>T&#252;reci</surname><given-names>&#214;.</given-names></name></person-group><article-title>Personalized vaccines for cancer immunotherapy</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>1355</fpage><lpage>1360</lpage><pub-id pub-id-type="doi">10.1126/science.aar7112</pub-id><pub-id pub-id-type="pmid">29567706</pub-id></element-citation></ref><ref id="B9-pharmaceuticals-16-01384"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malonis</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Vergnolle</surname><given-names>O.</given-names></name></person-group><article-title>Peptide-Based Vaccines: Current Progress and Future Challenges</article-title><source>Chem. Rev.</source><year>2020</year><volume>120</volume><fpage>3210</fpage><lpage>3229</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.9b00472</pub-id><pub-id pub-id-type="pmid">31804810</pub-id><pub-id pub-id-type="pmcid">PMC7094793</pub-id></element-citation></ref><ref id="B10-pharmaceuticals-16-01384"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saade</surname><given-names>F.</given-names></name><name name-style="western"><surname>Petrovsky</surname><given-names>N.</given-names></name></person-group><article-title>Technologies for enhanced efficacy of DNA vaccines</article-title><source>Expert Rev. Vaccines</source><year>2012</year><volume>11</volume><fpage>189</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1586/erv.11.188</pub-id><pub-id pub-id-type="pmid">22309668</pub-id><pub-id pub-id-type="pmcid">PMC3293989</pub-id></element-citation></ref><ref id="B11-pharmaceuticals-16-01384"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines-a new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="B12-pharmaceuticals-16-01384"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cecilia Larocca</surname><given-names>B.S.</given-names></name><name name-style="western"><surname>Schlom</surname><given-names>J.</given-names></name></person-group><article-title>Viral Vector Y Based Therapeutic Cancer Vaccines</article-title><source>Cancer J.</source><year>2011</year><volume>17</volume><fpage>359</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1097/PPO.0b013e3182325e63</pub-id><pub-id pub-id-type="pmid">21952287</pub-id><pub-id pub-id-type="pmcid">PMC3207353</pub-id></element-citation></ref><ref id="B13-pharmaceuticals-16-01384"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bubenik</surname><given-names>J.</given-names></name></person-group><article-title>Dendritic cell-based cancer vaccines</article-title><source>Folia Biol.</source><year>1999</year><volume>45</volume><fpage>71</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">10730892</pub-id></element-citation></ref><ref id="B14-pharmaceuticals-16-01384"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Gruijl</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Van Den Eertwegh</surname><given-names>A.J.M.</given-names></name><name name-style="western"><surname>Pinedo</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Scheper</surname><given-names>R.J.</given-names></name></person-group><article-title>Whole-cell cancer vaccination: From autologous to allogeneic tumor- and dendritic cell-based vaccines</article-title><source>Cancer Immunol. Immunother.</source><year>2008</year><volume>57</volume><fpage>1569</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1007/s00262-008-0536-z</pub-id><pub-id pub-id-type="pmid">18523771</pub-id><pub-id pub-id-type="pmcid">PMC2491427</pub-id></element-citation></ref><ref id="B15-pharmaceuticals-16-01384"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gaudernack</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gerritsen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Huber</surname><given-names>C.</given-names></name><name name-style="western"><surname>Parmiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Scholl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thatcher</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wagstaff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zielinski</surname><given-names>C.</given-names></name><name name-style="western"><surname>Faulkner</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Therapeutic vaccines for cancer: An overview of clinical trials</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2014</year><volume>11</volume><fpage>509</fpage><lpage>524</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2014.111</pub-id><pub-id pub-id-type="pmid">25001465</pub-id></element-citation></ref><ref id="B16-pharmaceuticals-16-01384"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buqu&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents</article-title><source>Cancer Cell</source><year>2015</year><volume>28</volume><fpage>690</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.10.012</pub-id><pub-id pub-id-type="pmid">26678337</pub-id></element-citation></ref><ref id="B17-pharmaceuticals-16-01384"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharabi</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>M.</given-names></name><name name-style="western"><surname>DeWeese</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>C.G.</given-names></name></person-group><article-title>Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy</article-title><source>Lancet Oncol.</source><year>2015</year><volume>16</volume><fpage>e498</fpage><lpage>e509</lpage><pub-id pub-id-type="doi">10.1016/S1470-2045(15)00007-8</pub-id><pub-id pub-id-type="pmid">26433823</pub-id></element-citation></ref><ref id="B18-pharmaceuticals-16-01384"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palucka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name></person-group><article-title>Cancer immunotherapy via dendritic cells</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>265</fpage><lpage>277</lpage><pub-id pub-id-type="doi">10.1038/nrc3258</pub-id><pub-id pub-id-type="pmid">22437871</pub-id><pub-id pub-id-type="pmcid">PMC3433802</pub-id></element-citation></ref><ref id="B19-pharmaceuticals-16-01384"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.C.</given-names></name></person-group><article-title>Oncolytic virotherapy</article-title><source>Nat. Biotechnol.</source><year>2012</year><volume>30</volume><fpage>658</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1038/nbt.2287</pub-id><pub-id pub-id-type="pmid">22781695</pub-id><pub-id pub-id-type="pmcid">PMC3888062</pub-id></element-citation></ref><ref id="B20-pharmaceuticals-16-01384"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schumacher</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name></person-group><article-title>Neoantigens in cancer immunotherapy</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4971</pub-id><pub-id pub-id-type="pmid">25838375</pub-id></element-citation></ref><ref id="B21-pharmaceuticals-16-01384"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ott</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Keskin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Shukla</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bozym</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Luoma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Peter</surname><given-names>L.</given-names></name><etal/></person-group><article-title>An immunogenic personal neoantigen vaccine for patients with melanoma</article-title><source>Nature</source><year>2017</year><volume>547</volume><fpage>217</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1038/nature22991</pub-id><pub-id pub-id-type="pmid">28678778</pub-id><pub-id pub-id-type="pmcid">PMC5577644</pub-id></element-citation></ref><ref id="B22-pharmaceuticals-16-01384"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keskin</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Anandappa</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tirosh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mathewson</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Li</surname><given-names>S.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>G.</given-names></name><name name-style="western"><surname>Giobbie-Hurder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Felt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gjini</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial</article-title><source>Nature</source><year>2019</year><volume>565</volume><fpage>234</fpage><lpage>239</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0792-9</pub-id><pub-id pub-id-type="pmid">30568305</pub-id><pub-id pub-id-type="pmcid">PMC6546179</pub-id></element-citation></ref><ref id="B23-pharmaceuticals-16-01384"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kranz</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name><name name-style="western"><surname>Haas</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kreiter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Loquai</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reuter</surname><given-names>K.C.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vascotto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Hefesha</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy</article-title><source>Nature</source><year>2016</year><volume>534</volume><fpage>396</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1038/nature18300</pub-id><pub-id pub-id-type="pmid">27281205</pub-id></element-citation></ref><ref id="B24-pharmaceuticals-16-01384"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanahan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Weinberg</surname><given-names>R.A.</given-names></name></person-group><article-title>Hallmarks of cancer: The next generation</article-title><source>Cell</source><year>2011</year><volume>144</volume><fpage>646</fpage><lpage>674</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.02.013</pub-id><pub-id pub-id-type="pmid">21376230</pub-id></element-citation></ref><ref id="B25-pharmaceuticals-16-01384"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balkwill</surname><given-names>F.R.</given-names></name><name name-style="western"><surname>Capasso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hagemann</surname><given-names>T.</given-names></name></person-group><article-title>The tumor microenvironment at a glance</article-title><source>J. Cell Sci.</source><year>2012</year><volume>125</volume><fpage>5591</fpage><lpage>5596</lpage><pub-id pub-id-type="doi">10.1242/jcs.116392</pub-id><pub-id pub-id-type="pmid">23420197</pub-id></element-citation></ref><ref id="B26-pharmaceuticals-16-01384"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naci</surname><given-names>D.</given-names></name><name name-style="western"><surname>El Azreq</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Chetoui</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lauden</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sigaux</surname><given-names>F.</given-names></name><name name-style="western"><surname>Charron</surname><given-names>D.</given-names></name><name name-style="western"><surname>Al-Daccak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Aoudjit</surname><given-names>F.</given-names></name></person-group><article-title>&#945;2&#946;1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK)</article-title><source>J. Biol. Chem.</source><year>2012</year><volume>287</volume><fpage>17065</fpage><lpage>17076</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.349365</pub-id><pub-id pub-id-type="pmid">22457358</pub-id><pub-id pub-id-type="pmcid">PMC3366820</pub-id></element-citation></ref><ref id="B27-pharmaceuticals-16-01384"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joyce</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>J.W.</given-names></name></person-group><article-title>Microenvironmental regulation of metastasis</article-title><source>Nat. Rev. Cancer</source><year>2009</year><volume>9</volume><fpage>239</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/nrc2618</pub-id><pub-id pub-id-type="pmid">19279573</pub-id><pub-id pub-id-type="pmcid">PMC3251309</pub-id></element-citation></ref><ref id="B28-pharmaceuticals-16-01384"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Laczko</surname><given-names>R.</given-names></name><name name-style="western"><surname>Szauter</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Hollosi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Muranyi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Molnar</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>K.S.K.</given-names></name><name name-style="western"><surname>Hinek</surname><given-names>A.</given-names></name><name name-style="western"><surname>Csiszar</surname><given-names>K.</given-names></name></person-group><article-title>Active lysyl oxidase (LOX) correlates with focal adhesion kinase (FAK)/paxillin activation and migration in invasive astrocytes</article-title><source>Neuropathol. Appl. Neurobiol.</source><year>2007</year><volume>33</volume><fpage>631</fpage><lpage>643</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2990.2007.00858.x</pub-id><pub-id pub-id-type="pmid">17931358</pub-id></element-citation></ref><ref id="B29-pharmaceuticals-16-01384"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Caon</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bartolini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Parnigoni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Carav&#224;</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moretto</surname><given-names>P.</given-names></name><name name-style="western"><surname>Viola</surname><given-names>M.</given-names></name><name name-style="western"><surname>Karousou</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vigetti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Passi</surname><given-names>A.</given-names></name></person-group><article-title>Revisiting the hallmarks of cancer: The role of hyaluronan</article-title><source>Semin. Cancer Biol.</source><year>2019</year><volume>62</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2019.07.007</pub-id><pub-id pub-id-type="pmid">31319162</pub-id></element-citation></ref><ref id="B30-pharmaceuticals-16-01384"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jab&#322;o&#324;ska-Trypu&#263;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Matejczyk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rosochacki</surname><given-names>S.</given-names></name></person-group><article-title>Matrix metalloproteinases (MMPs), the main extracellular matrix (ECM) enzymes in collagen degradation, as a target for anticancer drugs</article-title><source>J. Enzym. Inhib. Med. Chem.</source><year>2016</year><volume>31</volume><fpage>177</fpage><lpage>183</lpage><pub-id pub-id-type="doi">10.3109/14756366.2016.1161620</pub-id><pub-id pub-id-type="pmid">27028474</pub-id></element-citation></ref><ref id="B31-pharmaceuticals-16-01384"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niland</surname><given-names>S.</given-names></name><name name-style="western"><surname>Riscanevo</surname><given-names>A.X.</given-names></name><name name-style="western"><surname>Eble</surname><given-names>J.A.</given-names></name></person-group><article-title>Matrix metalloproteinases shape the tumor microenvironment in cancer progression</article-title><source>Int. J. Mol. Sci.</source><year>2022</year><volume>23</volume><elocation-id>146</elocation-id><pub-id pub-id-type="doi">10.3390/ijms23010146</pub-id><pub-id pub-id-type="pmid">35008569</pub-id><pub-id pub-id-type="pmcid">PMC8745566</pub-id></element-citation></ref><ref id="B32-pharmaceuticals-16-01384"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lepucki</surname><given-names>A.</given-names></name><name name-style="western"><surname>Orli&#324;ska</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mielczarek-Palacz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kabut</surname><given-names>J.</given-names></name><name name-style="western"><surname>Olczyk</surname><given-names>P.</given-names></name><name name-style="western"><surname>Komosi&#324;ska-Vassev</surname><given-names>K.</given-names></name></person-group><article-title>The Role of Extracellular Matrix Proteins in Breast Cancer</article-title><source>J. Clin. Med.</source><year>2022</year><volume>11</volume><elocation-id>1250</elocation-id><pub-id pub-id-type="doi">10.3390/jcm11051250</pub-id><pub-id pub-id-type="pmid">35268340</pub-id><pub-id pub-id-type="pmcid">PMC8911242</pub-id></element-citation></ref><ref id="B33-pharmaceuticals-16-01384"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azimzade</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Saberi</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Sahimi</surname><given-names>M.</given-names></name></person-group><article-title>Regulation of migration of chemotactic tumor cells by the spatial distribution of collagen fiber orientation</article-title><source>Phys. Rev. E</source><year>2019</year><volume>99</volume><fpage>062414</fpage><pub-id pub-id-type="doi">10.1103/PhysRevE.99.062414</pub-id><pub-id pub-id-type="pmid">31330715</pub-id></element-citation></ref><ref id="B34-pharmaceuticals-16-01384"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carmeliet</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.K.</given-names></name></person-group><article-title>Molecular mechanisms and clinical applications of angiogenesis</article-title><source>Nature</source><year>2011</year><volume>473</volume><fpage>298</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1038/nature10144</pub-id><pub-id pub-id-type="pmid">21593862</pub-id><pub-id pub-id-type="pmcid">PMC4049445</pub-id></element-citation></ref><ref id="B35-pharmaceuticals-16-01384"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Associated with anti-PD-1 Response</article-title><source>Nature</source><year>2019</year><volume>560</volume><fpage>382</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0392-8</pub-id><pub-id pub-id-type="pmid">30089911</pub-id><pub-id pub-id-type="pmcid">PMC6095740</pub-id></element-citation></ref><ref id="B36-pharmaceuticals-16-01384"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Lan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zou</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>Y.</given-names></name></person-group><article-title>Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment</article-title><source>Int. Immunopharmacol.</source><year>2020</year><volume>88</volume><fpage>106939</fpage><pub-id pub-id-type="doi">10.1016/j.intimp.2020.106939</pub-id><pub-id pub-id-type="pmid">33182039</pub-id></element-citation></ref><ref id="B37-pharmaceuticals-16-01384"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Multhoff</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vaupel</surname><given-names>P.</given-names></name></person-group><article-title>Hypoxia compromises anti-cancer immune responses</article-title><source>Adv. Exp. Med. Biol.</source><year>2020</year><volume>1232</volume><fpage>131</fpage><lpage>143</lpage><pub-id pub-id-type="pmid">31893404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-3-030-34461-0_18</pub-id></element-citation></ref><ref id="B38-pharmaceuticals-16-01384"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boedtkjer</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pedersen</surname><given-names>S.F.</given-names></name></person-group><article-title>The Acidic Tumor Microenvironment as a Driver of Cancer</article-title><source>Annu. Rev. Physiol.</source><year>2020</year><volume>82</volume><fpage>103</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1146/annurev-physiol-021119-034627</pub-id><pub-id pub-id-type="pmid">31730395</pub-id></element-citation></ref><ref id="B39-pharmaceuticals-16-01384"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roman-Trufero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Auner</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>C.M.</given-names></name></person-group><article-title>Multiple myeloma metabolism&#8212;A treasure trove of therapeutic targets?</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>897862</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.897862</pub-id><pub-id pub-id-type="pmid">36072593</pub-id><pub-id pub-id-type="pmcid">PMC9441940</pub-id></element-citation></ref><ref id="B40-pharmaceuticals-16-01384"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gopalakrishnan</surname><given-names>V.</given-names></name><name name-style="western"><surname>Helmink</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Reuben</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wargo</surname><given-names>J.A.</given-names></name></person-group><article-title>The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy</article-title><source>Cancer Cell.</source><year>2018</year><volume>33</volume><fpage>570</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2018.03.015</pub-id><pub-id pub-id-type="pmid">29634945</pub-id><pub-id pub-id-type="pmcid">PMC6529202</pub-id></element-citation></ref><ref id="B41-pharmaceuticals-16-01384"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>P.</given-names></name></person-group><article-title>Gut microbiome and cancer immunotherapy</article-title><source>Cancer Lett.</source><year>2019</year><volume>447</volume><fpage>41</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.01.015</pub-id><pub-id pub-id-type="pmid">30684593</pub-id></element-citation></ref><ref id="B42-pharmaceuticals-16-01384"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gajewski</surname><given-names>T.F.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.X.</given-names></name></person-group><article-title>Innate and adaptive immune cells in the tumor microenvironment</article-title><source>Nat. Immunol.</source><year>2013</year><volume>14</volume><fpage>1014</fpage><lpage>1022</lpage><pub-id pub-id-type="doi">10.1038/ni.2703</pub-id><pub-id pub-id-type="pmid">24048123</pub-id><pub-id pub-id-type="pmcid">PMC4118725</pub-id></element-citation></ref><ref id="B43-pharmaceuticals-16-01384"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fridman</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Pag&#232;s</surname><given-names>F.</given-names></name><name name-style="western"><surname>Saut&#768;s-Fridman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Galon</surname><given-names>J.</given-names></name></person-group><article-title>The immune contexture in human tumours: Impact on clinical outcome</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>298</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1038/nrc3245</pub-id><pub-id pub-id-type="pmid">22419253</pub-id></element-citation></ref><ref id="B44-pharmaceuticals-16-01384"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalluri</surname><given-names>R.</given-names></name></person-group><article-title>The biology and function of fibroblasts in cancer</article-title><source>Nat. Rev. Cancer</source><year>2016</year><volume>16</volume><fpage>582</fpage><lpage>598</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.73</pub-id><pub-id pub-id-type="pmid">27550820</pub-id></element-citation></ref><ref id="B45-pharmaceuticals-16-01384"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mantovani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sozzani</surname><given-names>S.</given-names></name><name name-style="western"><surname>Locati</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allavena</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sica</surname><given-names>A.</given-names></name></person-group><article-title>Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes</article-title><source>Trends Immunol.</source><year>2002</year><volume>23</volume><fpage>549</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/S1471-4906(02)02302-5</pub-id><pub-id pub-id-type="pmid">12401408</pub-id></element-citation></ref><ref id="B46-pharmaceuticals-16-01384"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Koelwyn</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Quail</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>White</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>L.W.</given-names></name></person-group><article-title>Exercise-dependent regulation of the tumour microenvironment</article-title><source>Nat. Rev. Cancer</source><year>2017</year><volume>17</volume><fpage>620</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1038/nrc.2017.78</pub-id><pub-id pub-id-type="pmid">28943640</pub-id></element-citation></ref><ref id="B47-pharmaceuticals-16-01384"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>S.</given-names></name></person-group><article-title>Alternative activation of macrophages</article-title><source>Nat. Rev. Immunol.</source><year>2003</year><volume>3</volume><fpage>23</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1038/nri978</pub-id><pub-id pub-id-type="pmid">12511873</pub-id></element-citation></ref><ref id="B48-pharmaceuticals-16-01384"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pickup</surname><given-names>M.</given-names></name><name name-style="western"><surname>Novitskiy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Moses</surname><given-names>H.L.</given-names></name></person-group><article-title>The roles of TGF&#946; in the tumour microenvironment</article-title><source>Nat. Rev. Cancer</source><year>2013</year><volume>13</volume><fpage>788</fpage><lpage>799</lpage><pub-id pub-id-type="doi">10.1038/nrc3603</pub-id><pub-id pub-id-type="pmid">24132110</pub-id><pub-id pub-id-type="pmcid">PMC4025940</pub-id></element-citation></ref><ref id="B49-pharmaceuticals-16-01384"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schroder</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hertzog</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Ravasi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hume</surname><given-names>D.A.</given-names></name></person-group><article-title>Interferon-&#947;: An overview of signals, mechanisms and functions</article-title><source>J. Leukoc Biol.</source><year>2004</year><volume>75</volume><fpage>163</fpage><lpage>189</lpage><pub-id pub-id-type="doi">10.1189/jlb.0603252</pub-id><pub-id pub-id-type="pmid">14525967</pub-id></element-citation></ref><ref id="B50-pharmaceuticals-16-01384"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name></person-group><article-title>IL-2: The First Effective Immunotherapy for Human Cancer</article-title><source>J. Immunol.</source><year>2014</year><volume>192</volume><fpage>5451</fpage><lpage>5458</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1490019</pub-id><pub-id pub-id-type="pmid">24907378</pub-id><pub-id pub-id-type="pmcid">PMC6293462</pub-id></element-citation></ref><ref id="B51-pharmaceuticals-16-01384"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trinchieri</surname><given-names>G.</given-names></name></person-group><article-title>Interleukin-12 and the regulation of innate resistance and adaptive immunity</article-title><source>Nat. Rev. Immunol.</source><year>2003</year><volume>3</volume><fpage>133</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/nri1001</pub-id><pub-id pub-id-type="pmid">12563297</pub-id></element-citation></ref><ref id="B52-pharmaceuticals-16-01384"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Cantor</surname><given-names>H.</given-names></name></person-group><article-title>CD4 T-cell subsets and tumor immunity: The helpful and the not-so-helpful</article-title><source>Cancer Immunol. Res.</source><year>2014</year><volume>2</volume><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0216</pub-id><pub-id pub-id-type="pmid">24778273</pub-id></element-citation></ref><ref id="B53-pharmaceuticals-16-01384"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>David</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Massagu&#233;</surname><given-names>J.</given-names></name></person-group><article-title>Contextual determinants of TGF&#946; action in development, immunity and cancer</article-title><source>Nat. Rev. Mol. Cell Biol.</source><year>2018</year><volume>19</volume><fpage>419</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/s41580-018-0007-0</pub-id><pub-id pub-id-type="pmid">29643418</pub-id><pub-id pub-id-type="pmcid">PMC7457231</pub-id></element-citation></ref><ref id="B54-pharmaceuticals-16-01384"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>O&#8217;Keefe</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Grandis</surname><given-names>J.R.</given-names></name></person-group><article-title>Targeting the IL-6/JAK/STAT3 signalling axis in cancer</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2018</year><volume>15</volume><fpage>234</fpage><lpage>248</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2018.8</pub-id><pub-id pub-id-type="pmid">29405201</pub-id><pub-id pub-id-type="pmcid">PMC5858971</pub-id></element-citation></ref><ref id="B55-pharmaceuticals-16-01384"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Streel</surname><given-names>G.</given-names></name><name name-style="western"><surname>Lucas</surname><given-names>S.</given-names></name></person-group><article-title>Targeting immunosuppression by TGF-&#946;1 for cancer immunotherapy</article-title><source>Biochem. Pharmacol.</source><year>2021</year><volume>192</volume><elocation-id>114697</elocation-id><pub-id pub-id-type="doi">10.1016/j.bcp.2021.114697</pub-id><pub-id pub-id-type="pmid">34302795</pub-id><pub-id pub-id-type="pmcid">PMC8484859</pub-id></element-citation></ref><ref id="B56-pharmaceuticals-16-01384"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cattin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fellay</surname><given-names>B.</given-names></name><name name-style="western"><surname>Pradervand</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trojan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ruhstaller</surname><given-names>T.</given-names></name><name name-style="western"><surname>R&#252;egg</surname><given-names>C.</given-names></name><name name-style="western"><surname>F&#252;rstenberger</surname><given-names>G.</given-names></name></person-group><article-title>Bevacizumab specifically decreases elevated levels of circulating KIT+CD11b+ cells and IL-10 in metastatic breast cancer patients</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>11137</fpage><lpage>11150</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.7097</pub-id><pub-id pub-id-type="pmid">26840567</pub-id><pub-id pub-id-type="pmcid">PMC4905463</pub-id></element-citation></ref><ref id="B57-pharmaceuticals-16-01384"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bolandi</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Abdolmaleki</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Assarehzadegan</surname><given-names>M.A.</given-names></name></person-group><article-title>Bevacizumab regulates inflammatory cytokines and inhibits VEGFR2 signaling pathway in an ovalbumin-induced rat model of airway hypersensitivity</article-title><source>Inflammopharmacology</source><year>2021</year><volume>29</volume><fpage>683</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1007/s10787-021-00798-8</pub-id><pub-id pub-id-type="pmid">33742375</pub-id></element-citation></ref><ref id="B58-pharmaceuticals-16-01384"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arenas-Ramirez</surname><given-names>N.</given-names></name><name name-style="western"><surname>Woytschak</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boyman</surname><given-names>O.</given-names></name></person-group><article-title>Interleukin-2: Biology, Design and Application</article-title><source>Trends. Immunol.</source><year>2015</year><volume>36</volume><fpage>763</fpage><lpage>777</lpage><pub-id pub-id-type="doi">10.1016/j.it.2015.10.003</pub-id><pub-id pub-id-type="pmid">26572555</pub-id></element-citation></ref><ref id="B59-pharmaceuticals-16-01384"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prochazkova</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pokorna</surname><given-names>K.</given-names></name><name name-style="western"><surname>Holan</surname><given-names>V.</given-names></name></person-group><article-title>IL-12 inhibits the TGF-&#946;-dependent T cell developmental programs and skews the TGF-&#946;-induced differentiation into a Th1-like direction</article-title><source>Immunobiology</source><year>2012</year><volume>217</volume><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2011.07.032</pub-id><pub-id pub-id-type="pmid">21903294</pub-id></element-citation></ref><ref id="B60-pharmaceuticals-16-01384"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kwok</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yau</surname><given-names>T.C.C.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Tse</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kwong</surname><given-names>Y.L.</given-names></name></person-group><article-title>Pembrolizumab (Keytruda)</article-title><source>Hum. Vaccines Immunother.</source><year>2016</year><volume>12</volume><fpage>2777</fpage><lpage>2789</lpage><pub-id pub-id-type="doi">10.1080/21645515.2016.1199310</pub-id><pub-id pub-id-type="pmcid">PMC5137544</pub-id><pub-id pub-id-type="pmid">27398650</pub-id></element-citation></ref><ref id="B61-pharmaceuticals-16-01384"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lei</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.-K.</given-names></name><name name-style="western"><surname>Du</surname><given-names>W.-X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>R.-G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>H.-B.</given-names></name></person-group><article-title>Immune cells within the tumor microenvironment: Biological functions and roles in cancer immunotherapy</article-title><source>Cancer Lett.</source><year>2020</year><volume>470</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2019.11.009</pub-id><pub-id pub-id-type="pmid">31730903</pub-id></element-citation></ref><ref id="B62-pharmaceuticals-16-01384"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Zocca</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Ehrnrooth</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.E.W.</given-names></name></person-group><article-title>The changing landscape of therapeutic cancer vaccines-novel platforms and neoantigen identification</article-title><source>Clin. Cancer Res.</source><year>2021</year><volume>27</volume><fpage>689</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-0245</pub-id><pub-id pub-id-type="pmid">33122346</pub-id></element-citation></ref><ref id="B63-pharmaceuticals-16-01384"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saxena</surname><given-names>M.</given-names></name><name name-style="western"><surname>van der Burg</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name><name name-style="western"><surname>Bhardwaj</surname><given-names>N.</given-names></name></person-group><article-title>Therapeutic cancer vaccines</article-title><source>Nat. Rev. Cancer</source><year>2021</year><volume>21</volume><fpage>360</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/s41568-021-00346-0</pub-id><pub-id pub-id-type="pmid">33907315</pub-id></element-citation></ref><ref id="B64-pharmaceuticals-16-01384"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prendergast</surname><given-names>G.C.</given-names></name></person-group><article-title>Cancer vaccines: A brief overview</article-title><source>Methods Mol. Biol.</source><year>2016</year><volume>1403</volume><fpage>755</fpage><lpage>761</lpage><pub-id pub-id-type="pmid">27076165</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-1-4939-3387-7_43</pub-id></element-citation></ref><ref id="B65-pharmaceuticals-16-01384"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>W.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Exhausted CD8+ T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy</article-title><source>Front. Immunol.</source><year>2021</year><volume>11</volume><fpage>622509</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.622509</pub-id><pub-id pub-id-type="pmid">33633741</pub-id><pub-id pub-id-type="pmcid">PMC7902023</pub-id></element-citation></ref><ref id="B66-pharmaceuticals-16-01384"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swain</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>McKinstry</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Strutt</surname><given-names>T.M.</given-names></name></person-group><article-title>Expanding roles for CD4+ T cells in immunity to viruses</article-title><source>Nat. Rev. Immunol.</source><year>2012</year><volume>12</volume><fpage>136</fpage><lpage>148</lpage><pub-id pub-id-type="doi">10.1038/nri3152</pub-id><pub-id pub-id-type="pmid">22266691</pub-id><pub-id pub-id-type="pmcid">PMC3764486</pub-id></element-citation></ref><ref id="B67-pharmaceuticals-16-01384"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sallusto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Araki</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>From vaccines to memory and back</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>451</fpage><lpage>463</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.008</pub-id><pub-id pub-id-type="pmid">21029957</pub-id><pub-id pub-id-type="pmcid">PMC3760154</pub-id></element-citation></ref><ref id="B68-pharmaceuticals-16-01384"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Swartz</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>G.L.</given-names></name></person-group><article-title>Engineering synthetic vaccines using cues from natural immunity</article-title><source>Nat. Mater.</source><year>2013</year><volume>12</volume><fpage>978</fpage><lpage>990</lpage><pub-id pub-id-type="doi">10.1038/nmat3775</pub-id><pub-id pub-id-type="pmid">24150416</pub-id><pub-id pub-id-type="pmcid">PMC3928825</pub-id></element-citation></ref><ref id="B69-pharmaceuticals-16-01384"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pulendran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ahmed</surname><given-names>R.</given-names></name></person-group><article-title>Immunological mechanisms of vaccination</article-title><source>Nat. Immunol.</source><year>2011</year><volume>12</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmid">21739679</pub-id><pub-id pub-id-type="pmcid">PMC3253344</pub-id></element-citation></ref><ref id="B70-pharmaceuticals-16-01384"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weiner</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Surana</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name></person-group><article-title>Monoclonal antibodies: Versatile platforms for cancer immunotherapy</article-title><source>Nat. Rev. Immunol.</source><year>2010</year><volume>10</volume><fpage>317</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/nri2744</pub-id><pub-id pub-id-type="pmid">20414205</pub-id><pub-id pub-id-type="pmcid">PMC3508064</pub-id></element-citation></ref><ref id="B71-pharmaceuticals-16-01384"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunn</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Bruce</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Ikeda</surname><given-names>H.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name></person-group><article-title>Cancer immunoediting: From immunosurveillance to tumor escape</article-title><source>Nat. Immunol.</source><year>2002</year><volume>3</volume><fpage>991</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1038/ni1102-991</pub-id><pub-id pub-id-type="pmid">12407406</pub-id></element-citation></ref><ref id="B72-pharmaceuticals-16-01384"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittal</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gubin</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>M.J.</given-names></name></person-group><article-title>New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape</article-title><source>Curr. Opin. Immunol.</source><year>2014</year><volume>27</volume><fpage>16</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2014.01.004</pub-id><pub-id pub-id-type="pmid">24531241</pub-id><pub-id pub-id-type="pmcid">PMC4388310</pub-id></element-citation></ref><ref id="B73-pharmaceuticals-16-01384"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vinay</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ryan</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Pawelec</surname><given-names>G.</given-names></name><name name-style="western"><surname>Talib</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Stagg</surname><given-names>J.</given-names></name><name name-style="western"><surname>Elkord</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lichtor</surname><given-names>T.</given-names></name><name name-style="western"><surname>Decker</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Whelan</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kumara</surname><given-names>H.M.C.S.</given-names></name><etal/></person-group><article-title>Immune evasion in cancer: Mechanistic basis and therapeutic strategies</article-title><source>Semin. Cancer Biol.</source><year>2015</year><volume>35</volume><fpage>S185</fpage><lpage>S198</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2015.03.004</pub-id><pub-id pub-id-type="pmid">25818339</pub-id></element-citation></ref><ref id="B74-pharmaceuticals-16-01384"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>J.D.</given-names></name></person-group><article-title>Cancer immunotherapy using checkpoint blockade</article-title><source>Science</source><year>2018</year><volume>359</volume><fpage>1350</fpage><lpage>1355</lpage><pub-id pub-id-type="doi">10.1126/science.aar4060</pub-id><pub-id pub-id-type="pmid">29567705</pub-id><pub-id pub-id-type="pmcid">PMC7391259</pub-id></element-citation></ref><ref id="B75-pharmaceuticals-16-01384"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name></person-group><article-title>Elements of cancer immunity and the cancer-immune set point</article-title><source>Nature</source><year>2017</year><volume>541</volume><fpage>321</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1038/nature21349</pub-id><pub-id pub-id-type="pmid">28102259</pub-id></element-citation></ref><ref id="B76-pharmaceuticals-16-01384"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bruni</surname><given-names>D.</given-names></name></person-group><article-title>Approaches to treat immune hot, altered and cold tumours with combination immunotherapies</article-title><source>Nat. Rev. Drug Discov.</source><year>2019</year><volume>18</volume><fpage>197</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1038/s41573-018-0007-y</pub-id><pub-id pub-id-type="pmid">30610226</pub-id></element-citation></ref><ref id="B77-pharmaceuticals-16-01384"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Mlecnik</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bindea</surname><given-names>G.</given-names></name><name name-style="western"><surname>Angell</surname><given-names>H.K.</given-names></name><name name-style="western"><surname>Berger</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lagorce</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lugli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zlobec</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hartmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bifulco</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Towards the introduction of the &#8220;Immunoscore&#8221; in the classification of malignant tumours</article-title><source>J. Pathol.</source><year>2014</year><volume>232</volume><fpage>199</fpage><lpage>209</lpage><pub-id pub-id-type="doi">10.1002/path.4287</pub-id><pub-id pub-id-type="pmid">24122236</pub-id><pub-id pub-id-type="pmcid">PMC4255306</pub-id></element-citation></ref><ref id="B78-pharmaceuticals-16-01384"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topalian</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Taube</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name></person-group><article-title>Neoadjuvant checkpoint blockade for cancer immunotherapy</article-title><source>Science</source><year>2020</year><volume>367</volume><fpage>6477</fpage><pub-id pub-id-type="doi">10.1126/science.aax0182</pub-id><pub-id pub-id-type="pmcid">PMC7789854</pub-id><pub-id pub-id-type="pmid">32001626</pub-id></element-citation></ref><ref id="B79-pharmaceuticals-16-01384"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finn</surname><given-names>O.J.</given-names></name></person-group><article-title>Cancer vaccines: Between the idea and the reality</article-title><source>Nat. Rev. Immunol.</source><year>2003</year><volume>3</volume><fpage>630</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.1038/nri1150</pub-id><pub-id pub-id-type="pmid">12974478</pub-id></element-citation></ref><ref id="B80-pharmaceuticals-16-01384"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cella</surname><given-names>M.</given-names></name><name name-style="western"><surname>Engering</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pinet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Pieters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lanzavecchia</surname><given-names>A.</given-names></name></person-group><article-title>Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells</article-title><source>Nature</source><year>1997</year><volume>388</volume><fpage>782</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1038/42030</pub-id><pub-id pub-id-type="pmid">9285591</pub-id></element-citation></ref><ref id="B81-pharmaceuticals-16-01384"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Flies</surname><given-names>D.B.</given-names></name></person-group><article-title>Molecular mechanisms of T cell co-stimulation and co-inhibition</article-title><source>Nat. Rev. Immunol.</source><year>2013</year><volume>13</volume><fpage>227</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/nri3405</pub-id><pub-id pub-id-type="pmid">23470321</pub-id><pub-id pub-id-type="pmcid">PMC3786574</pub-id></element-citation></ref><ref id="B82-pharmaceuticals-16-01384"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Cancer immunotherapy: Moving beyond current vaccines</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>909</fpage><lpage>915</lpage><pub-id pub-id-type="doi">10.1038/nm1100</pub-id><pub-id pub-id-type="pmid">15340416</pub-id><pub-id pub-id-type="pmcid">PMC1435696</pub-id></element-citation></ref><ref id="B83-pharmaceuticals-16-01384"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name></person-group><article-title>Antibody therapy of cancer</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>278</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1038/nrc3236</pub-id><pub-id pub-id-type="pmid">22437872</pub-id></element-citation></ref><ref id="B84-pharmaceuticals-16-01384"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Old</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>M.J.</given-names></name></person-group><article-title>Cancer immunoediting: Integrating immunity&#8217;s roles in cancer suppression and promotion</article-title><source>Science</source><year>2011</year><volume>331</volume><fpage>1565</fpage><lpage>1570</lpage><pub-id pub-id-type="doi">10.1126/science.1203486</pub-id><pub-id pub-id-type="pmid">21436444</pub-id></element-citation></ref><ref id="B85-pharmaceuticals-16-01384"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schroeder</surname><given-names>H.W.</given-names></name><name name-style="western"><surname>Cavacini</surname><given-names>L.</given-names></name></person-group><article-title>Structure and function of immunoglobulins</article-title><source>J. Allergy Clin. Immunol.</source><year>2010</year><volume>125</volume><issue>(Suppl. 2)</issue><fpage>S41</fpage><lpage>S52</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2009.09.046</pub-id><pub-id pub-id-type="pmid">20176268</pub-id><pub-id pub-id-type="pmcid">PMC3670108</pub-id></element-citation></ref><ref id="B86-pharmaceuticals-16-01384"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golay</surname><given-names>J.</given-names></name><name name-style="western"><surname>Introna</surname><given-names>M.</given-names></name></person-group><article-title>Mechanism of action of therapeutic monoclonal antibodies: Promises and pitfalls of in vitro and in vivo assays</article-title><source>Arch. Biochem. Biophys.</source><year>2012</year><volume>526</volume><fpage>146</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2012.02.011</pub-id><pub-id pub-id-type="pmid">22387378</pub-id></element-citation></ref><ref id="B87-pharmaceuticals-16-01384"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nimmerjahn</surname><given-names>F.</given-names></name><name name-style="western"><surname>Ravetch</surname><given-names>J.V.</given-names></name></person-group><article-title>Fc&#947; receptors as regulators of immune responses</article-title><source>Nat. Rev. Immunol.</source><year>2008</year><volume>8</volume><fpage>34</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1038/nri2206</pub-id><pub-id pub-id-type="pmid">18064051</pub-id></element-citation></ref><ref id="B88-pharmaceuticals-16-01384"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Orange</surname><given-names>J.S.</given-names></name></person-group><article-title>Formation and function of the lytic NK-cell immunological synapse</article-title><source>Nat. Rev. Immunol.</source><year>2008</year><volume>8</volume><fpage>713</fpage><lpage>725</lpage><pub-id pub-id-type="doi">10.1038/nri2381</pub-id><pub-id pub-id-type="pmid">19172692</pub-id><pub-id pub-id-type="pmcid">PMC2772177</pub-id></element-citation></ref><ref id="B89-pharmaceuticals-16-01384"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bryceson</surname><given-names>Y.T.</given-names></name><name name-style="western"><surname>March</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Ljunggren</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Long</surname><given-names>E.O.</given-names></name></person-group><article-title>Activation, coactivation, and costimulation of resting human natural killer cells</article-title><source>Immunol. Rev.</source><year>2006</year><volume>214</volume><fpage>73</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2006.00457.x</pub-id><pub-id pub-id-type="pmid">17100877</pub-id><pub-id pub-id-type="pmcid">PMC3845883</pub-id></element-citation></ref><ref id="B90-pharmaceuticals-16-01384"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greenberg</surname><given-names>S.</given-names></name><name name-style="western"><surname>Grinstein</surname><given-names>S.</given-names></name></person-group><article-title>Phagocytosis and innate immunity Greenberg and Grinstein 137</article-title><source>Sci. Rep.</source><year>2002</year><volume>14</volume><fpage>136</fpage><lpage>145</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0952-7915(01)00309-0</pub-id><pub-id pub-id-type="pmid">11790544</pub-id></element-citation></ref><ref id="B91-pharmaceuticals-16-01384"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dunkelberger</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Song</surname><given-names>W.C.</given-names></name></person-group><article-title>Complement and its role in innate and adaptive immune responses</article-title><source>Cell Res.</source><year>2010</year><volume>20</volume><fpage>34</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1038/cr.2009.139</pub-id><pub-id pub-id-type="pmid">20010915</pub-id></element-citation></ref><ref id="B92-pharmaceuticals-16-01384"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ricklin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hajishengallis</surname><given-names>G.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lambris</surname><given-names>J.D.</given-names></name></person-group><article-title>Complement: A key system for immune surveillance and homeostasis</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>785</fpage><lpage>797</lpage><pub-id pub-id-type="doi">10.1038/ni.1923</pub-id><pub-id pub-id-type="pmid">20720586</pub-id><pub-id pub-id-type="pmcid">PMC2924908</pub-id></element-citation></ref><ref id="B93-pharmaceuticals-16-01384"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>B.P.</given-names></name></person-group><article-title>The membrane attack complex as an inflammatory trigger</article-title><source>Immunobiology</source><year>2016</year><volume>221</volume><fpage>747</fpage><lpage>751</lpage><pub-id pub-id-type="doi">10.1016/j.imbio.2015.04.006</pub-id><pub-id pub-id-type="pmid">25956457</pub-id></element-citation></ref><ref id="B94-pharmaceuticals-16-01384"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schumacher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Bunse</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pusch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sahm</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wiestler</surname><given-names>B.</given-names></name><name name-style="western"><surname>Quandt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Menn</surname><given-names>O.</given-names></name><name name-style="western"><surname>Osswald</surname><given-names>M.</given-names></name><name name-style="western"><surname>Oezen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>M.</given-names></name><etal/></person-group><article-title>A vaccine targeting mutant IDH1 induces antitumour immunity</article-title><source>Nature</source><year>2014</year><volume>512</volume><fpage>324</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1038/nature13387</pub-id><pub-id pub-id-type="pmid">25043048</pub-id></element-citation></ref><ref id="B95-pharmaceuticals-16-01384"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coulie</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Van Den Eynde</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Van Der Bruggen</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boon</surname><given-names>T.</given-names></name></person-group><article-title>Tumour antigens recognized by T lymphocytes: At the core of cancer immunotherapy</article-title><source>Nat. Rev. Cancer</source><year>2014</year><volume>14</volume><fpage>135</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1038/nrc3670</pub-id><pub-id pub-id-type="pmid">24457417</pub-id></element-citation></ref><ref id="B96-pharmaceuticals-16-01384"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name><name name-style="western"><surname>Van Hall</surname><given-names>T.</given-names></name><name name-style="western"><surname>Arens</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Van Der Burg</surname><given-names>S.H.</given-names></name></person-group><article-title>Therapeutic cancer vaccines</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>3401</fpage><lpage>3412</lpage><pub-id pub-id-type="doi">10.1172/JCI80009</pub-id><pub-id pub-id-type="pmid">26214521</pub-id><pub-id pub-id-type="pmcid">PMC4588240</pub-id></element-citation></ref><ref id="B97-pharmaceuticals-16-01384"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melief</surname><given-names>C.J.M.</given-names></name><name name-style="western"><surname>Van der Burg</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Toes</surname><given-names>R.E.M.</given-names></name><name name-style="western"><surname>Ossendorp</surname><given-names>F.</given-names></name><name name-style="western"><surname>Offringa</surname><given-names>R.</given-names></name></person-group><article-title>Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes</article-title><source>Immunol. Rev.</source><year>2002</year><volume>188</volume><fpage>177</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1034/j.1600-065X.2002.18816.x</pub-id><pub-id pub-id-type="pmid">12445291</pub-id></element-citation></ref><ref id="B98-pharmaceuticals-16-01384"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jiang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.N.</given-names></name></person-group><article-title>Editorial: Research, Development and Clinical Trials for Peptide-Based Vaccines</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>894989</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.894989</pub-id><pub-id pub-id-type="pmid">35529849</pub-id><pub-id pub-id-type="pmcid">PMC9074893</pub-id></element-citation></ref><ref id="B99-pharmaceuticals-16-01384"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneble</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Berry</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Trappey</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Ponniah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mittendorf</surname><given-names>E.</given-names></name><name name-style="western"><surname>Peoples</surname><given-names>G.E.</given-names></name></person-group><article-title>The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax<sup>TM</sup>) in breast cancer patients at risk for recurrence: Correlation of immunologic data with clinical response</article-title><source>Immunotherapy</source><year>2014</year><volume>6</volume><fpage>519</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.2217/imt.14.22</pub-id><pub-id pub-id-type="pmid">24896623</pub-id></element-citation></ref><ref id="B100-pharmaceuticals-16-01384"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chick</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Clifton</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Vreeland</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Hickerson</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Bohan</surname><given-names>P.M.K.</given-names></name><name name-style="western"><surname>McCarthy</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Litton</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Alatrash</surname><given-names>G.</given-names></name><name name-style="western"><surname>Murthy</surname><given-names>R.K.</given-names></name><etal/></person-group><article-title>Subgroup analysis of nelipepimut-S plus GM-CSF combined with trastuzumab versus trastuzumab alone to prevent recurrences in patients with high-risk, HER2 low-expressing breast cancer</article-title><source>Clin. Immunol.</source><year>2021</year><volume>225</volume><fpage>108679</fpage><pub-id pub-id-type="doi">10.1016/j.clim.2021.108679</pub-id><pub-id pub-id-type="pmid">33485895</pub-id></element-citation></ref><ref id="B101-pharmaceuticals-16-01384"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clifton</surname><given-names>G.T.</given-names></name><name name-style="western"><surname>Peoples</surname><given-names>G.E.</given-names></name><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name></person-group><article-title>The development and use of the E75 (HER2 369-377) peptide vaccine</article-title><source>Future Oncol.</source><year>2016</year><volume>12</volume><fpage>1321</fpage><lpage>1329</lpage><pub-id pub-id-type="doi">10.2217/fon-2015-0054</pub-id><pub-id pub-id-type="pmid">27044454</pub-id><pub-id pub-id-type="pmcid">PMC6040084</pub-id></element-citation></ref><ref id="B102-pharmaceuticals-16-01384"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Melisko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hiller</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Bondarenko</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brunt</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Sergii</surname><given-names>G.</given-names></name><name name-style="western"><surname>Petrakova</surname><given-names>K.</given-names></name><name name-style="western"><surname>Peoples</surname><given-names>G.E.</given-names></name></person-group><article-title>Efficacy and safety analysis of nelipepimut-S vaccine to prevent breast cancer recurrence: A randomized, multicenter, phase III clinical trial</article-title><source>Clin. Cancer Res.</source><year>2019</year><volume>25</volume><fpage>4248</fpage><lpage>4254</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-2867</pub-id><pub-id pub-id-type="pmid">31036542</pub-id></element-citation></ref><ref id="B103-pharmaceuticals-16-01384"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodriguez</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Popa</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mart&#237;nez</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Santiesteban</surname><given-names>E.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>T.</given-names></name><name name-style="western"><surname>Amador</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Fleytas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Acosta</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Otero</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients</article-title><source>Clin. Cancer Res.</source><year>2016</year><volume>22</volume><fpage>3782</fpage><lpage>3790</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-15-0855</pub-id><pub-id pub-id-type="pmid">26927662</pub-id></element-citation></ref><ref id="B104-pharmaceuticals-16-01384"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tagliamento</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rijavec</surname><given-names>E.</given-names></name><name name-style="western"><surname>Barletta</surname><given-names>G.</given-names></name><name name-style="western"><surname>Biello</surname><given-names>F.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grossi</surname><given-names>F.</given-names></name><name name-style="western"><surname>Genova</surname><given-names>C.</given-names></name></person-group><article-title>CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine</article-title><source>Expert Opin. Biol. Ther.</source><year>2018</year><volume>18</volume><fpage>829</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1080/14712598.2018.1492539</pub-id><pub-id pub-id-type="pmid">29936901</pub-id></element-citation></ref><ref id="B105-pharmaceuticals-16-01384"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hanisch</surname><given-names>F.G.</given-names></name></person-group><article-title>Design of a MUC1-based cancer vaccine</article-title><source>Biochem. Soc. Trans.</source><year>2005</year><volume>33</volume><fpage>705</fpage><lpage>708</lpage><pub-id pub-id-type="doi">10.1042/BST0330705</pub-id><pub-id pub-id-type="pmid">16042579</pub-id></element-citation></ref><ref id="B106-pharmaceuticals-16-01384"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cen</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>H.</given-names></name></person-group><article-title>A review on development of MUC1-based cancer vaccine</article-title><source>Biomed. Pharmacother.</source><year>2020</year><volume>132</volume><elocation-id>110888</elocation-id><pub-id pub-id-type="doi">10.1016/j.biopha.2020.110888</pub-id><pub-id pub-id-type="pmid">33113416</pub-id></element-citation></ref><ref id="B107-pharmaceuticals-16-01384"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor-Papadimitriou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Burchell</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Graham</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beatson</surname><given-names>R.</given-names></name></person-group><article-title>Latest developments in MUC1 immunotherapy</article-title><source>Biochem. Soc. Trans.</source><year>2018</year><volume>46</volume><fpage>659</fpage><lpage>668</lpage><pub-id pub-id-type="doi">10.1042/BST20170400</pub-id><pub-id pub-id-type="pmid">29784646</pub-id><pub-id pub-id-type="pmcid">PMC6008591</pub-id></element-citation></ref><ref id="B108-pharmaceuticals-16-01384"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahm</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Colluru</surname><given-names>V.T.</given-names></name><name name-style="western"><surname>McNeel</surname><given-names>D.G.</given-names></name></person-group><article-title>DNA vaccines for prostate cancer</article-title><source>Pharmacol. Ther.</source><year>2017</year><volume>174</volume><fpage>27</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.02.016</pub-id><pub-id pub-id-type="pmid">28185916</pub-id><pub-id pub-id-type="pmcid">PMC5429198</pub-id></element-citation></ref><ref id="B109-pharmaceuticals-16-01384"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sahin</surname><given-names>U.</given-names></name><name name-style="western"><surname>Derhovanessian</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kloke</surname><given-names>B.-P.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>P.</given-names></name><name name-style="western"><surname>L&#246;wer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bukur</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tadmor</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Luxemburger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Schr&#246;rs</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer</article-title><source>Nature</source><year>2017</year><volume>547</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1038/nature23003</pub-id><pub-id pub-id-type="pmid">28678784</pub-id></element-citation></ref><ref id="B110-pharmaceuticals-16-01384"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kreiter</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vormehr</surname><given-names>M.</given-names></name><name name-style="western"><surname>van de Roemer</surname><given-names>N.</given-names></name><name name-style="western"><surname>Diken</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#246;wer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Diekmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Boegel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schr&#246;rs</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vascotto</surname><given-names>F.</given-names></name><name name-style="western"><surname>Castle</surname><given-names>J.C.</given-names></name><etal/></person-group><article-title>Mutant MHC class II epitopes drive therapeutic immune responses to cancer</article-title><source>Nature</source><year>2015</year><volume>520</volume><fpage>692</fpage><lpage>696</lpage><pub-id pub-id-type="doi">10.1038/nature14426</pub-id><pub-id pub-id-type="pmid">25901682</pub-id><pub-id pub-id-type="pmcid">PMC4838069</pub-id></element-citation></ref><ref id="B111-pharmaceuticals-16-01384"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name></person-group><article-title>RNA modification in mRNA cancer vaccines</article-title><source>Clin. Exp. Med.</source><year>2023</year><volume>14</volume><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s10238-023-01020-5</pub-id><pub-id pub-id-type="pmid">36788153</pub-id><pub-id pub-id-type="pmcid">PMC9928499</pub-id></element-citation></ref><ref id="B112-pharmaceuticals-16-01384"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kuai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ochyl</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Bahjat</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Schwendeman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>J.J.</given-names></name></person-group><article-title>Designer vaccine nanodiscs for personalized cancer immunotherapy</article-title><source>Nat. Mater.</source><year>2017</year><volume>16</volume><fpage>489</fpage><lpage>498</lpage><pub-id pub-id-type="doi">10.1038/nmat4822</pub-id><pub-id pub-id-type="pmid">28024156</pub-id><pub-id pub-id-type="pmcid">PMC5374005</pub-id></element-citation></ref><ref id="B113-pharmaceuticals-16-01384"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Su</surname><given-names>C.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sham</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Immune Gene-Viral Therapy with Triplex Efficacy Mediated by Oncolytic Adenovirus Carrying an Interferon-&#947; Gene Yields Efficient Antitumor Activity in Immunodeficient and Immunocompetent Mice</article-title><source>Mol. Ther.</source><year>2006</year><volume>13</volume><fpage>918</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2005.12.011</pub-id><pub-id pub-id-type="pmid">16497559</pub-id></element-citation></ref><ref id="B114-pharmaceuticals-16-01384"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>M.A.</given-names></name></person-group><article-title>Transgene FDNA vaccines: A review</article-title><source>J. Intern. Med.</source><year>2003</year><volume>253</volume><fpage>402</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2796.2003.01140.x</pub-id><pub-id pub-id-type="pmid">12653868</pub-id></element-citation></ref><ref id="B115-pharmaceuticals-16-01384"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blass</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ott</surname><given-names>P.A.</given-names></name></person-group><article-title>Advances in the development of personalized neoantigen-based therapeutic cancer vaccines</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2021</year><volume>18</volume><fpage>215</fpage><lpage>229</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-00460-2</pub-id><pub-id pub-id-type="pmid">33473220</pub-id><pub-id pub-id-type="pmcid">PMC7816749</pub-id></element-citation></ref><ref id="B116-pharmaceuticals-16-01384"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma</article-title><source>Mol. Ther.</source><year>2018</year><volume>26</volume><fpage>420</fpage><lpage>434</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.11.009</pub-id><pub-id pub-id-type="pmid">29249397</pub-id><pub-id pub-id-type="pmcid">PMC5835019</pub-id></element-citation></ref><ref id="B117-pharmaceuticals-16-01384"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schoenmaker</surname><given-names>L.</given-names></name><name name-style="western"><surname>Witzigmann</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kulkarni</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Verbeke</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kersten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W.</given-names></name><name name-style="western"><surname>Crommelin</surname><given-names>D.J.</given-names></name></person-group><article-title>mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability</article-title><source>Int. J. Pharm.</source><year>2021</year><volume>601</volume><fpage>120586</fpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2021.120586</pub-id><pub-id pub-id-type="pmid">33839230</pub-id><pub-id pub-id-type="pmcid">PMC8032477</pub-id></element-citation></ref><ref id="B118-pharmaceuticals-16-01384"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.</given-names></name></person-group><article-title>mRNA vaccine for cancer immunotherapy</article-title><source>Mol. Cancer</source><year>2021</year><volume>20</volume><fpage>41</fpage><pub-id pub-id-type="doi">10.1186/s12943-021-01335-5</pub-id><pub-id pub-id-type="pmid">33632261</pub-id><pub-id pub-id-type="pmcid">PMC7905014</pub-id></element-citation></ref><ref id="B119-pharmaceuticals-16-01384"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Broderick</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hickman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Otten</surname><given-names>G.</given-names></name><name name-style="western"><surname>Barnett</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kichaev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sardesai</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Geall</surname><given-names>A.</given-names></name></person-group><article-title>Enhanced Delivery and Potency of Self-Amplifying mRNA Vaccines by Electroporation in Situ</article-title><source>Vaccines</source><year>2013</year><volume>1</volume><fpage>367</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.3390/vaccines1030367</pub-id><pub-id pub-id-type="pmid">26344119</pub-id><pub-id pub-id-type="pmcid">PMC4494232</pub-id></element-citation></ref><ref id="B120-pharmaceuticals-16-01384"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ulmer</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Geall</surname><given-names>A.J.</given-names></name></person-group><article-title>Recent innovations in mRNA vaccines</article-title><source>Curr. Opin. Immunol.</source><year>2016</year><volume>41</volume><fpage>18</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2016.05.008</pub-id><pub-id pub-id-type="pmid">27240054</pub-id></element-citation></ref><ref id="B121-pharmaceuticals-16-01384"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ho</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Li</surname><given-names>F.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X.</given-names></name></person-group><article-title>Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery</article-title><source>Adv. Healthc. Mater.</source><year>2021</year><volume>10</volume><fpage>2001812</fpage><pub-id pub-id-type="doi">10.1002/adhm.202001812</pub-id><pub-id pub-id-type="pmid">33458958</pub-id><pub-id pub-id-type="pmcid">PMC7995055</pub-id></element-citation></ref><ref id="B122-pharmaceuticals-16-01384"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>T.B.</given-names></name></person-group><article-title>Personalized pancreatic cancer therapy: From the perspective of mRNA vaccine</article-title><source>Mil. Med. Res.</source><year>2022</year><volume>9</volume><fpage>53</fpage><pub-id pub-id-type="doi">10.1186/s40779-022-00416-w</pub-id><pub-id pub-id-type="pmid">36224645</pub-id><pub-id pub-id-type="pmcid">PMC9556149</pub-id></element-citation></ref><ref id="B123-pharmaceuticals-16-01384"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brisse</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vrba</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kirk</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>H.</given-names></name></person-group><article-title>Emerging Concepts and Technologies in Vaccine Development</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>583077</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.583077</pub-id><pub-id pub-id-type="pmid">33101309</pub-id><pub-id pub-id-type="pmcid">PMC7554600</pub-id></element-citation></ref><ref id="B124-pharmaceuticals-16-01384"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rausch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schwentner</surname><given-names>C.</given-names></name><name name-style="western"><surname>Stenzl</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bedke</surname><given-names>J.</given-names></name></person-group><article-title>mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer</article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>3146</fpage><lpage>3152</lpage><pub-id pub-id-type="doi">10.4161/hv.29553</pub-id><pub-id pub-id-type="pmid">25483661</pub-id><pub-id pub-id-type="pmcid">PMC4514038</pub-id></element-citation></ref><ref id="B125-pharmaceuticals-16-01384"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name></person-group><article-title>Adoptive cell transfer as personalized immunotherapy for human cancer</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>62</fpage><lpage>68</lpage><pub-id pub-id-type="doi">10.1126/science.aaa4967</pub-id><pub-id pub-id-type="pmid">25838374</pub-id><pub-id pub-id-type="pmcid">PMC6295668</pub-id></element-citation></ref><ref id="B126-pharmaceuticals-16-01384"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Finn</surname><given-names>O.J.</given-names></name></person-group><article-title>The dawn of vaccines for cancer prevention</article-title><source>Nat. Rev. Immunol.</source><year>2018</year><volume>18</volume><fpage>183</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/nri.2017.140</pub-id><pub-id pub-id-type="pmid">29279613</pub-id></element-citation></ref><ref id="B127-pharmaceuticals-16-01384"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lichty</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Breitbach</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Stojdl</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.C.</given-names></name></person-group><article-title>Going viral with cancer immunotherapy</article-title><source>Nat. Rev. Cancer</source><year>2014</year><volume>14</volume><fpage>559</fpage><lpage>567</lpage><pub-id pub-id-type="doi">10.1038/nrc3770</pub-id><pub-id pub-id-type="pmid">24990523</pub-id></element-citation></ref><ref id="B128-pharmaceuticals-16-01384"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Bryan</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Mathis</surname><given-names>J.M.</given-names></name></person-group><article-title>Oncolytic Virotherapy for Breast Cancer Treatment</article-title><source>Curr. Gene Ther.</source><year>2018</year><volume>18</volume><fpage>192</fpage><lpage>205</lpage><pub-id pub-id-type="doi">10.2174/1566523218666180910163805</pub-id><pub-id pub-id-type="pmid">30207220</pub-id><pub-id pub-id-type="pmcid">PMC7499349</pub-id></element-citation></ref><ref id="B129-pharmaceuticals-16-01384"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Drake</surname><given-names>C.G.</given-names></name></person-group><article-title>Prostate cancer as a model for tumour immunotherapy</article-title><source>Nat. Rev. Immunol.</source><year>2010</year><volume>10</volume><fpage>580</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1038/nri2817</pub-id><pub-id pub-id-type="pmid">20651745</pub-id><pub-id pub-id-type="pmcid">PMC3082366</pub-id></element-citation></ref><ref id="B130-pharmaceuticals-16-01384"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gubin</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Artyomov</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Mardis</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>R.D.</given-names></name></person-group><article-title>Tumor neoantigens: Building a framework for personalized cancer immunotherapy</article-title><source>J. Clin. Investig.</source><year>2015</year><volume>125</volume><fpage>3413</fpage><lpage>3421</lpage><pub-id pub-id-type="pmid">26258412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI80008</pub-id><pub-id pub-id-type="pmcid">PMC4588307</pub-id></element-citation></ref><ref id="B131-pharmaceuticals-16-01384"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>K.W.</given-names></name></person-group><article-title>Viruses as anticancer drugs</article-title><source>Trends Pharmacol. Sci.</source><year>2007</year><volume>28</volume><fpage>326</fpage><lpage>333</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2007.05.005</pub-id><pub-id pub-id-type="pmid">17573126</pub-id><pub-id pub-id-type="pmcid">PMC3125087</pub-id></element-citation></ref><ref id="B132-pharmaceuticals-16-01384"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kohlhapp</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Zloza</surname><given-names>A.</given-names></name></person-group><article-title>Oncolytic viruses: A new class of immunotherapy drugs</article-title><source>Nat. Rev. Drug Discov.</source><year>2015</year><volume>14</volume><fpage>642</fpage><lpage>662</lpage><pub-id pub-id-type="doi">10.1038/nrd4663</pub-id><pub-id pub-id-type="pmid">26323545</pub-id><pub-id pub-id-type="pmcid">PMC7097180</pub-id></element-citation></ref><ref id="B133-pharmaceuticals-16-01384"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rollier</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cottingham</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hill</surname><given-names>A.V.S.</given-names></name></person-group><article-title>Viral vectors as vaccine platforms: Deployment in sight</article-title><source>Curr. Opin. Immunol.</source><year>2011</year><volume>23</volume><fpage>377</fpage><lpage>382</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2011.03.006</pub-id><pub-id pub-id-type="pmid">21514130</pub-id></element-citation></ref><ref id="B134-pharmaceuticals-16-01384"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shimada</surname><given-names>M.</given-names></name></person-group><article-title>Developments in viral vector-based vaccines</article-title><source>Vaccines</source><year>2014</year><volume>2</volume><fpage>624</fpage><lpage>641</lpage><pub-id pub-id-type="doi">10.3390/vaccines2030624</pub-id><pub-id pub-id-type="pmid">26344749</pub-id><pub-id pub-id-type="pmcid">PMC4494222</pub-id></element-citation></ref><ref id="B135-pharmaceuticals-16-01384"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bloy</surname><given-names>N.</given-names></name><name name-style="western"><surname>Obrist</surname><given-names>F.</given-names></name><name name-style="western"><surname>Eggermont</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cremer</surname><given-names>I.</given-names></name><name name-style="western"><surname>Erbs</surname><given-names>P.</given-names></name><name name-style="western"><surname>Limacher</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Preville</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Trial watch: Oncolytic viruses for cancer therapy</article-title><source>Oncoimmunology</source><year>2014</year><volume>3</volume><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.4161/onci.28694</pub-id><pub-id pub-id-type="pmid">25097804</pub-id><pub-id pub-id-type="pmcid">PMC4091053</pub-id></element-citation></ref><ref id="B136-pharmaceuticals-16-01384"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prestwich</surname><given-names>R.J.D.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>K.J.</given-names></name><name name-style="western"><surname>Pandha</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Vile</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Melcher</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Errington</surname><given-names>F.</given-names></name></person-group><article-title>Oncolytic viruses: A novel form of immunotherapy</article-title><source>Expert Rev. Anticancer Ther.</source><year>2008</year><volume>8</volume><fpage>1581</fpage><lpage>1588</lpage><pub-id pub-id-type="doi">10.1586/14737140.8.10.1581</pub-id><pub-id pub-id-type="pmid">18925850</pub-id><pub-id pub-id-type="pmcid">PMC2729453</pub-id></element-citation></ref><ref id="B137-pharmaceuticals-16-01384"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>J.</given-names></name></person-group><article-title>Plasmid DNA and viral vector-based vaccines for the treatment of cancer</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><issue>(Suppl. 2)</issue><fpage>24</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.05.030</pub-id><pub-id pub-id-type="pmid">17698262</pub-id></element-citation></ref><ref id="B138-pharmaceuticals-16-01384"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanneman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dranoff</surname><given-names>G.</given-names></name></person-group><article-title>Combining immunotherapy and targeted therapies in cancer treatment</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>237</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1038/nrc3237</pub-id><pub-id pub-id-type="pmid">22437869</pub-id><pub-id pub-id-type="pmcid">PMC3967236</pub-id></element-citation></ref><ref id="B139-pharmaceuticals-16-01384"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Buqu&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kepp</surname><given-names>O.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Immunogenic cell death in cancer and infectious disease</article-title><source>Nat. Rev. Immunol.</source><year>2017</year><volume>17</volume><fpage>97</fpage><lpage>111</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.107</pub-id><pub-id pub-id-type="pmid">27748397</pub-id></element-citation></ref><ref id="B140-pharmaceuticals-16-01384"><label>140.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watanabe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Goshima</surname><given-names>F.</given-names></name></person-group><article-title>Oncolytic virotherapy by HSV</article-title><source>Adv. Exp. Med. Biol.</source><year>2018</year><volume>1045</volume><fpage>63</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">29896663</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/978-981-10-7230-7_4</pub-id></element-citation></ref><ref id="B141-pharmaceuticals-16-01384"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramesh</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ge</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ennist</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mina</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ganesh</surname><given-names>S.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D.C.</given-names></name></person-group><article-title>CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor&#8212;Armed oncolytic adenovirus for the treatment of bladder cancer</article-title><source>Clin. Cancer Res.</source><year>2006</year><volume>12</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-1059</pub-id><pub-id pub-id-type="pmid">16397056</pub-id></element-citation></ref><ref id="B142-pharmaceuticals-16-01384"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albershardt</surname><given-names>T.C.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Parsons</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Slough</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Ter Meulen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>P.</given-names></name></person-group><article-title>LV305, a dendritic cell-targeting integration-deficient ZVex TM-based lentiviral vector encoding NY-ESO-1, induces potent anti-tumor immune response</article-title><source>Mol. Ther. Oncolytics</source><year>2016</year><volume>3</volume><fpage>305</fpage><lpage>313</lpage><pub-id pub-id-type="doi">10.1038/mto.2016.10</pub-id><pub-id pub-id-type="pmid">27626061</pub-id><pub-id pub-id-type="pmcid">PMC5008268</pub-id></element-citation></ref><ref id="B143-pharmaceuticals-16-01384"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Reid</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ruo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Breitbach</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bloomston</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lim</surname><given-names>H.Y.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>C.W.</given-names></name><etal/></person-group><article-title>Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>329</fpage><lpage>336</lpage><pub-id pub-id-type="doi">10.1038/nm.3089</pub-id><pub-id pub-id-type="pmid">23396206</pub-id><pub-id pub-id-type="pmcid">PMC4268543</pub-id></element-citation></ref><ref id="B144-pharmaceuticals-16-01384"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Breitbach</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Kirn</surname><given-names>D.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.</given-names></name></person-group><article-title>The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594)</article-title><source>Oncolytic Virother.</source><year>2015</year><volume>4</volume><fpage>25</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.2147/OV.S59640</pub-id><pub-id pub-id-type="pmid">27512667</pub-id><pub-id pub-id-type="pmcid">PMC4918374</pub-id></element-citation></ref><ref id="B145-pharmaceuticals-16-01384"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parato</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Breitbach</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Le Boeuf</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Storbeck</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ilkow</surname><given-names>C.</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>J.-S.</given-names></name><name name-style="western"><surname>Falls</surname><given-names>T.</given-names></name><name name-style="western"><surname>Burns</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>V.</given-names></name><etal/></person-group><article-title>The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers</article-title><source>Mol. Ther.</source><year>2012</year><volume>20</volume><fpage>749</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1038/mt.2011.276</pub-id><pub-id pub-id-type="pmid">22186794</pub-id><pub-id pub-id-type="pmcid">PMC3321594</pub-id></element-citation></ref><ref id="B146-pharmaceuticals-16-01384"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Steinman</surname><given-names>R.M.</given-names></name></person-group><article-title>Dendritic cells and the control of immunity</article-title><source>Nature</source><year>1998</year><volume>392</volume><fpage>245</fpage><lpage>252</lpage><pub-id pub-id-type="doi">10.1038/32588</pub-id><pub-id pub-id-type="pmid">9521319</pub-id></element-citation></ref><ref id="B147-pharmaceuticals-16-01384"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Schwartzentruber</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Hwu</surname><given-names>P.</given-names></name><name name-style="western"><surname>Marincola</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Topalian</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Restifo</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Sznol</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schwarz</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Spiess</surname><given-names>P.J.</given-names></name><etal/></person-group><article-title>Impact of Cytokine Administration on the Generation of Antitumor Reactivity in Patients with Metastatic Melanoma Receiving a Peptide Vaccine</article-title><source>J. Immunol.</source><year>1999</year><volume>163</volume><fpage>1690</fpage><lpage>1695</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.163.3.1690</pub-id><pub-id pub-id-type="pmid">10415076</pub-id><pub-id pub-id-type="pmcid">PMC2249693</pub-id></element-citation></ref><ref id="B148-pharmaceuticals-16-01384"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tuyaerts</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aerts</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Corthals</surname><given-names>J.</given-names></name><name name-style="western"><surname>Neyns</surname><given-names>B.</given-names></name><name name-style="western"><surname>Heirman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Breckpot</surname><given-names>K.</given-names></name><name name-style="western"><surname>Thielemans</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bonehill</surname><given-names>A.</given-names></name></person-group><article-title>Current approaches in dendritic cell generation and future implications for cancer immunotherapy</article-title><source>Cancer Immunol. Immunother.</source><year>2007</year><volume>56</volume><fpage>1513</fpage><lpage>1537</lpage><pub-id pub-id-type="pmid">17503040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00262-007-0334-z</pub-id><pub-id pub-id-type="pmcid">PMC11030932</pub-id></element-citation></ref><ref id="B149-pharmaceuticals-16-01384"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wculek</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Cueto</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Mujal</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Krummel</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Sancho</surname><given-names>D.</given-names></name></person-group><article-title>Dendritic cells in cancer immunology and immunotherapy</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>7</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1038/s41577-019-0210-z</pub-id><pub-id pub-id-type="pmid">31467405</pub-id></element-citation></ref><ref id="B150-pharmaceuticals-16-01384"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bhatta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Bo</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Elosegui-Artola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Metabolic glycan labeling immobilizes dendritic cell membrane and enhances antitumor efficacy of dendritic cell vaccine</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>5049</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-40886-7</pub-id><pub-id pub-id-type="pmid">37598185</pub-id><pub-id pub-id-type="pmcid">PMC10439884</pub-id></element-citation></ref><ref id="B151-pharmaceuticals-16-01384"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carreno</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Magrini</surname><given-names>V.</given-names></name><name name-style="western"><surname>Becker-Hapak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kaabinejadian</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hundal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Petti</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ly</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lie</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Hildebrand</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Mardis</surname><given-names>E.R.</given-names></name><etal/></person-group><article-title>A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>803</fpage><lpage>808</lpage><pub-id pub-id-type="doi">10.1126/science.aaa3828</pub-id><pub-id pub-id-type="pmid">25837513</pub-id><pub-id pub-id-type="pmcid">PMC4549796</pub-id></element-citation></ref><ref id="B152-pharmaceuticals-16-01384"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morse</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Clay</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>Hobeika</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Osada</surname><given-names>T.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Niedzwiecki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Panicali</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schlom</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lyerly</surname><given-names>H.K.</given-names></name></person-group><article-title>Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules</article-title><source>Clin. Cancer Res.</source><year>2005</year><volume>11</volume><fpage>3017</fpage><lpage>3024</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-04-2172</pub-id><pub-id pub-id-type="pmid">15837756</pub-id></element-citation></ref><ref id="B153-pharmaceuticals-16-01384"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anguille</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smits</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Lion</surname><given-names>E.</given-names></name><name name-style="western"><surname>Van Tendeloo</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Berneman</surname><given-names>Z.N.</given-names></name></person-group><article-title>Clinical use of dendritic cells for cancer therapy</article-title><source>Lancet Oncol.</source><year>2014</year><volume>15</volume><fpage>257</fpage><lpage>267</lpage><pub-id pub-id-type="pmid">24872109</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1470-2045(13)70585-0</pub-id></element-citation></ref><ref id="B154-pharmaceuticals-16-01384"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonarakis</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Small</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Petrylak</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>D.I.</given-names></name><name name-style="western"><surname>Kibel</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>N.N.</given-names></name><name name-style="western"><surname>Dearstyne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Harmon</surname><given-names>M.</given-names></name><name name-style="western"><surname>Campogan</surname><given-names>D.</given-names></name><name name-style="western"><surname>Haynes</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Antigen-specific CD8 lytic phenotype induced by sipuleucel-T in hormone-sensitive or castration-resistant prostate cancer and association with overall survival</article-title><source>Clin. Cancer Res.</source><year>2018</year><volume>24</volume><fpage>4662</fpage><lpage>4671</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-18-0638</pub-id><pub-id pub-id-type="pmid">29858218</pub-id><pub-id pub-id-type="pmcid">PMC6481607</pub-id></element-citation></ref><ref id="B155-pharmaceuticals-16-01384"><label>155.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carballido</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fishman</surname><given-names>M.</given-names></name></person-group><article-title>Sipuleucel-T: Prototype for development of anti-tumor vaccines</article-title><source>Curr. Oncol. Rep.</source><year>2011</year><volume>13</volume><fpage>112</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1007/s11912-011-0152-5</pub-id><pub-id pub-id-type="pmid">21243538</pub-id></element-citation></ref><ref id="B156-pharmaceuticals-16-01384"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polyzoidis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ashkan</surname><given-names>K.</given-names></name></person-group><article-title>DCVax<sup>&#174;</sup>-L&#8212;Developed by Northwest Biotherapeutics</article-title><source>Hum. Vaccines Immunother.</source><year>2014</year><volume>10</volume><fpage>3139</fpage><lpage>3145</lpage><pub-id pub-id-type="doi">10.4161/hv.29276</pub-id><pub-id pub-id-type="pmcid">PMC4514134</pub-id><pub-id pub-id-type="pmid">25483653</pub-id></element-citation></ref><ref id="B157-pharmaceuticals-16-01384"><label>157.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Guo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Manjili</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Subjeck</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Sarkar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.Y.</given-names></name></person-group><article-title>Therapeutic cancer vaccines</article-title><source>Past, Present, and Future</source><edition>1st ed.</edition><comment>Advances in Cancer Research</comment><publisher-name>Elsevier Inc.</publisher-name><publisher-loc>Amsterdam, The Netherlands</publisher-loc><year>2013</year><volume>Volume 119</volume><fpage>421</fpage><lpage>475</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-407190-2.00007-1</pub-id><pub-id pub-id-type="pmcid">PMC3721379</pub-id><pub-id pub-id-type="pmid">23870514</pub-id></element-citation></ref><ref id="B158-pharmaceuticals-16-01384"><label>158.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.T.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>P.A.</given-names></name></person-group><article-title>Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy</article-title><source>Crit. Rev. Immunol.</source><year>2007</year><volume>27</volume><fpage>463</fpage><lpage>483</lpage><pub-id pub-id-type="doi">10.1615/CritRevImmunol.v27.i5.50</pub-id><pub-id pub-id-type="pmid">18197808</pub-id></element-citation></ref><ref id="B159-pharmaceuticals-16-01384"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emens</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>E.M.</given-names></name></person-group><article-title>Leveraging the activity of tumor vaccines with cytotoxic chemotherapy</article-title><source>Cancer Res.</source><year>2005</year><volume>65</volume><fpage>8059</fpage><lpage>8064</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-1797</pub-id><pub-id pub-id-type="pmid">16166275</pub-id></element-citation></ref><ref id="B160-pharmaceuticals-16-01384"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Principe</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Korc</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Munshi</surname><given-names>H.G.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>A.</given-names></name></person-group><article-title>Trials and tribulations of pancreatic cancer immunotherapy</article-title><source>Cancer Lett.</source><year>2021</year><volume>504</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2021.01.031</pub-id><pub-id pub-id-type="pmid">33549709</pub-id><pub-id pub-id-type="pmcid">PMC7940598</pub-id></element-citation></ref><ref id="B161-pharmaceuticals-16-01384"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ward</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>McNeel</surname><given-names>D.G.</given-names></name></person-group><article-title>GVAX: An allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer</article-title><source>Expert Opin. Biol. Ther.</source><year>2007</year><volume>7</volume><fpage>1893</fpage><lpage>1902</lpage><pub-id pub-id-type="doi">10.1517/14712598.7.12.1893</pub-id><pub-id pub-id-type="pmid">18034654</pub-id></element-citation></ref><ref id="B162-pharmaceuticals-16-01384"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Petricciani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Koren</surname><given-names>E.</given-names></name><name name-style="western"><surname>Morton</surname><given-names>D.</given-names></name></person-group><article-title>Analysis of the in vivo proliferative capacity of a whole cell cancer vaccine</article-title><source>Biologicals</source><year>2016</year><volume>44</volume><fpage>60</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1016/j.biologicals.2015.12.005</pub-id><pub-id pub-id-type="pmid">26806533</pub-id></element-citation></ref><ref id="B163-pharmaceuticals-16-01384"><label>163.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Di Pietro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tosti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ferrucci</surname><given-names>P.F.</given-names></name><name name-style="western"><surname>Testori</surname><given-names>A.</given-names></name></person-group><article-title>Oncophage: Step to the future for vaccine therapy in melanoma</article-title><source>Expert Opin. Biol. Ther.</source><year>2008</year><volume>8</volume><fpage>1973</fpage><lpage>1984</lpage><pub-id pub-id-type="doi">10.1517/14712590802517970</pub-id><pub-id pub-id-type="pmid">18990084</pub-id></element-citation></ref><ref id="B164-pharmaceuticals-16-01384"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacobsohn</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Wood</surname><given-names>C.G.</given-names></name></person-group><article-title>Adjuvant Therapy for Renal Cell Carcinoma</article-title><source>Semin. Oncol.</source><year>2006</year><volume>33</volume><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1053/j.seminoncol.2006.06.005</pub-id><pub-id pub-id-type="pmid">17045086</pub-id></element-citation></ref><ref id="B165-pharmaceuticals-16-01384"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Itoh</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamada</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mine</surname><given-names>T.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>M.</given-names></name></person-group><article-title>Recent advances in cancer vaccines: An overview</article-title><source>Jpn. J. Clin. Oncol.</source><year>2009</year><volume>39</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1093/jjco/hyn132</pub-id><pub-id pub-id-type="pmid">19015149</pub-id></element-citation></ref><ref id="B166-pharmaceuticals-16-01384"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ardavanis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Litton</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Shumway</surname><given-names>N.M.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Murray</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Ponniah</surname><given-names>S.</given-names></name><name name-style="western"><surname>Baxevanis</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Papamichail</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>66192</fpage><lpage>66201</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.11751</pub-id><pub-id pub-id-type="pmid">27589688</pub-id><pub-id pub-id-type="pmcid">PMC5323226</pub-id></element-citation></ref><ref id="B167-pharmaceuticals-16-01384"><label>167.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lepisto</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Zeh</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bartlett</surname><given-names>D.</given-names></name><name name-style="western"><surname>McKolanis</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Geller</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Schmotzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Potter</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Whiteside</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors</article-title><source>Cancer Ther.</source><year>2008</year><volume>6</volume><fpage>955</fpage><lpage>964</lpage><pub-id pub-id-type="pmid">19129927</pub-id><pub-id pub-id-type="pmcid">PMC2614325</pub-id></element-citation></ref><ref id="B168-pharmaceuticals-16-01384"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>K&#252;bler</surname><given-names>H.</given-names></name><name name-style="western"><surname>Scheel</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gnad-Vogt</surname><given-names>U.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schultze-Seemann</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dorp</surname><given-names>F.V.</given-names></name><name name-style="western"><surname>Parmiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hampel</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wedel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Trojan</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: A first-in-man phase I/IIa study</article-title><source>J. Immunother. Cancer</source><year>2015</year><volume>3</volume><fpage>26</fpage><pub-id pub-id-type="doi">10.1186/s40425-015-0068-y</pub-id><pub-id pub-id-type="pmid">26082837</pub-id><pub-id pub-id-type="pmcid">PMC4468959</pub-id></element-citation></ref><ref id="B169-pharmaceuticals-16-01384"><label>169.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaufman</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Deraffele</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mitcham</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coffin</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Kim-Schulze</surname><given-names>S.</given-names></name></person-group><article-title>Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma</article-title><source>Ann. Surg. Oncol.</source><year>2010</year><volume>17</volume><fpage>718</fpage><lpage>730</lpage><pub-id pub-id-type="doi">10.1245/s10434-009-0809-6</pub-id><pub-id pub-id-type="pmid">19915919</pub-id></element-citation></ref><ref id="B170-pharmaceuticals-16-01384"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hwang</surname><given-names>T.-H.</given-names></name><name name-style="western"><surname>Moon</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Stephenson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Breitbach</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Daneshmand</surname><given-names>M.</given-names></name><name name-style="western"><surname>De Silva</surname><given-names>N.</given-names></name><name name-style="western"><surname>Parato</surname><given-names>K.</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>J.-S.</given-names></name><etal/></person-group><article-title>A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma</article-title><source>Mol. Ther.</source><year>2011</year><volume>19</volume><fpage>1913</fpage><lpage>1922</lpage><pub-id pub-id-type="doi">10.1038/mt.2011.132</pub-id><pub-id pub-id-type="pmid">21772252</pub-id><pub-id pub-id-type="pmcid">PMC3188739</pub-id></element-citation></ref><ref id="B171-pharmaceuticals-16-01384"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liau</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Ashkan</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>D.D.</given-names></name><name name-style="western"><surname>Campian</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Trusheim</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Cobbs</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Heth</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Salacz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>S.</given-names></name><name name-style="western"><surname>D&#8217;andre</surname><given-names>S.D.</given-names></name><etal/></person-group><article-title>First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma</article-title><source>J. Transl. Med.</source><year>2018</year><volume>16</volume><fpage>142</fpage><pub-id pub-id-type="doi">10.1186/s12967-018-1507-6</pub-id><pub-id pub-id-type="pmid">29843811</pub-id><pub-id pub-id-type="pmcid">PMC5975654</pub-id></element-citation></ref><ref id="B172-pharmaceuticals-16-01384"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Yeo</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Lillemoe</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Biedrzycki</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kobrin</surname><given-names>B.</given-names></name><name name-style="western"><surname>Herman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sugar</surname><given-names>E.</given-names></name><name name-style="western"><surname>Piantadosi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Solt</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma: A phase II trial of safety, efficacy, and immune activation</article-title><source>Ann. Surg.</source><year>2011</year><volume>253</volume><fpage>328</fpage><lpage>335</lpage><pub-id pub-id-type="pmid">21217520</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/SLA.0b013e3181fd271c</pub-id><pub-id pub-id-type="pmcid">PMC3085934</pub-id></element-citation></ref><ref id="B173-pharmaceuticals-16-01384"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morton</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Hsueh</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Essner</surname><given-names>R.</given-names></name><name name-style="western"><surname>Foshag</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>O&#8217;Day</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bilchik</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Hoon</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Ravindranath</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nizze</surname><given-names>J.A.</given-names></name><etal/></person-group><article-title>Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes</article-title><source>Ann. Surg.</source><year>2002</year><volume>236</volume><fpage>438</fpage><lpage>449</lpage><pub-id pub-id-type="doi">10.1097/00000658-200210000-00006</pub-id><pub-id pub-id-type="pmid">12368672</pub-id><pub-id pub-id-type="pmcid">PMC1422598</pub-id></element-citation></ref><ref id="B174-pharmaceuticals-16-01384"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wood</surname><given-names>C.</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bukowski</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lacombe</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gorelov</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Gorelov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Mulders</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zielinski</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hoos</surname><given-names>A.</given-names></name><name name-style="western"><surname>Teofilovici</surname><given-names>F.</given-names></name><etal/></person-group><article-title>An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial</article-title><source>Lancet</source><year>2008</year><volume>372</volume><fpage>145</fpage><lpage>154</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(08)60697-2</pub-id><pub-id pub-id-type="pmid">18602688</pub-id></element-citation></ref><ref id="B175-pharmaceuticals-16-01384"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Testori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>J.</given-names></name><name name-style="western"><surname>Whitman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mann</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Lutzky</surname><given-names>J.</given-names></name><name name-style="western"><surname>Camacho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Parmiani</surname><given-names>G.</given-names></name><name name-style="western"><surname>Tosti</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kirkwood</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Hoos</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician&#8217;s choice of treatment for stage IV melanoma: The C-100-21 study group</article-title><source>J. Clin. Oncol.</source><year>2008</year><volume>26</volume><fpage>955</fpage><lpage>962</lpage><pub-id pub-id-type="doi">10.1200/JCO.2007.11.9941</pub-id><pub-id pub-id-type="pmid">18281670</pub-id></element-citation></ref><ref id="B176-pharmaceuticals-16-01384"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lawler</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Speranza</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Cho</surname><given-names>C.F.</given-names></name><name name-style="western"><surname>Chiocca</surname><given-names>E.A.</given-names></name></person-group><article-title>Oncolytic viruses in cancer treatment a review</article-title><source>JAMA Oncol.</source><year>2017</year><volume>3</volume><fpage>841</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2016.2064</pub-id><pub-id pub-id-type="pmid">27441411</pub-id></element-citation></ref><ref id="B177-pharmaceuticals-16-01384"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Svensson-Arvelund</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lubitz</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>Marabelle</surname><given-names>A.</given-names></name><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Brody</surname><given-names>J.D.</given-names></name></person-group><article-title>Cancer vaccines: The next immunotherapy frontier</article-title><source>Nat. Cancer</source><year>2022</year><volume>3</volume><fpage>911</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1038/s43018-022-00418-6</pub-id><pub-id pub-id-type="pmid">35999309</pub-id></element-citation></ref><ref id="B178-pharmaceuticals-16-01384"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name></person-group><article-title>The blockade of immune checkpoints in cancer immunotherapy</article-title><source>Nat. Rev. Cancer</source><year>2012</year><volume>12</volume><fpage>252</fpage><lpage>264</lpage><pub-id pub-id-type="doi">10.1038/nrc3239</pub-id><pub-id pub-id-type="pmid">22437870</pub-id><pub-id pub-id-type="pmcid">PMC4856023</pub-id></element-citation></ref><ref id="B179-pharmaceuticals-16-01384"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Topalian</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>C.G.</given-names></name><name name-style="western"><surname>Pardoll</surname><given-names>D.M.</given-names></name></person-group><article-title>Immune checkpoint blockade: A common denominator approach to cancer therapy</article-title><source>Cancer Cell</source><year>2015</year><volume>27</volume><fpage>450</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1016/j.ccell.2015.03.001</pub-id><pub-id pub-id-type="pmid">25858804</pub-id><pub-id pub-id-type="pmcid">PMC4400238</pub-id></element-citation></ref><ref id="B180-pharmaceuticals-16-01384"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheever</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Ferris</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Finn</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Hastings</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Hecht</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name><name name-style="western"><surname>Prindiville</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Viner</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>L.M.</given-names></name><etal/></person-group><article-title>The prioritization of cancer antigens: A National Cancer Institute pilot project for the acceleration of translational research</article-title><source>Clin. Cancer Res.</source><year>2009</year><volume>15</volume><fpage>5323</fpage><lpage>5337</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0737</pub-id><pub-id pub-id-type="pmid">19723653</pub-id><pub-id pub-id-type="pmcid">PMC5779623</pub-id></element-citation></ref><ref id="B181-pharmaceuticals-16-01384"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Hagan</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>New generation adjuvants&#8212;From empiricism to rational design</article-title><source>Vaccine</source><year>2015</year><volume>33</volume><fpage>B14</fpage><lpage>B20</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2015.01.088</pub-id><pub-id pub-id-type="pmid">26022561</pub-id></element-citation></ref><ref id="B182-pharmaceuticals-16-01384"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kawai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name></person-group><article-title>Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity</article-title><source>Immunity</source><year>2011</year><volume>34</volume><fpage>637</fpage><lpage>650</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.006</pub-id><pub-id pub-id-type="pmid">21616434</pub-id></element-citation></ref><ref id="B183-pharmaceuticals-16-01384"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffman</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>A.</given-names></name><name name-style="western"><surname>Seder</surname><given-names>R.A.</given-names></name></person-group><article-title>Vaccine adjuvants: Putting innate immunity to work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id><pub-id pub-id-type="pmcid">PMC3420356</pub-id></element-citation></ref><ref id="B184-pharmaceuticals-16-01384"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name></person-group><article-title>Key roles of adjuvants in modern vaccines</article-title><source>Nat. Med.</source><year>2013</year><volume>19</volume><fpage>1597</fpage><lpage>1608</lpage><pub-id pub-id-type="doi">10.1038/nm.3409</pub-id><pub-id pub-id-type="pmid">24309663</pub-id></element-citation></ref><ref id="B185-pharmaceuticals-16-01384"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kocic</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hadzi-Djokic</surname><given-names>J.</given-names></name><name name-style="western"><surname>Colic</surname><given-names>M.</given-names></name><name name-style="western"><surname>Veljkovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tomovic</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roumeliotis</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smelcerovic</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liakopoulos</surname><given-names>V.</given-names></name></person-group><article-title>The Role of Nucleases Cleaving TLR3, TLR7/8 and TLR9 Ligands, Dicer RNase and miRNA/piRNA Proteins in Functional Adaptation to the Immune Escape and Xenophagy of Prostate Cancer Tissue</article-title><source>Int. J. Mol. Sci.</source><year>2023</year><volume>24</volume><elocation-id>509</elocation-id><pub-id pub-id-type="doi">10.3390/ijms24010509</pub-id><pub-id pub-id-type="pmid">36613950</pub-id><pub-id pub-id-type="pmcid">PMC9820234</pub-id></element-citation></ref><ref id="B186-pharmaceuticals-16-01384"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhuang</surname><given-names>W.-R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nie</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lei</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>C.</given-names></name><name name-style="western"><surname>He</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zuo</surname><given-names>L.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>L.-L.</given-names></name><name name-style="western"><surname>Xie</surname><given-names>H.-Y.</given-names></name></person-group><article-title>Bacterial outer membrane vesicle based versatile nanosystem boosts the efferocytosis blockade triggered tumor-specific immunity</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>1675</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-37369-0</pub-id><pub-id pub-id-type="pmid">36966130</pub-id><pub-id pub-id-type="pmcid">PMC10039929</pub-id></element-citation></ref><ref id="B187-pharmaceuticals-16-01384"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garland</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Sheehy</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.T.</given-names></name></person-group><article-title>Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy</article-title><source>Chem. Rev.</source><year>2022</year><volume>122</volume><fpage>5977</fpage><lpage>6039</lpage><pub-id pub-id-type="doi">10.1021/acs.chemrev.1c00750</pub-id><pub-id pub-id-type="pmid">35107989</pub-id><pub-id pub-id-type="pmcid">PMC8994686</pub-id></element-citation></ref><ref id="B188-pharmaceuticals-16-01384"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>A.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>K.</given-names></name></person-group><article-title>Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy</article-title><source>J. Hematol. Oncol.</source><year>2019</year><volume>12</volume><fpage>35</fpage><pub-id pub-id-type="doi">10.1186/s13045-019-0721-x</pub-id><pub-id pub-id-type="pmid">30935414</pub-id><pub-id pub-id-type="pmcid">PMC6444510</pub-id></element-citation></ref><ref id="B189-pharmaceuticals-16-01384"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hegde</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>D.S.</given-names></name></person-group><article-title>Top 10 Challenges in Cancer Immunotherapy</article-title><source>Immunity</source><year>2020</year><volume>52</volume><fpage>17</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2019.12.011</pub-id><pub-id pub-id-type="pmid">31940268</pub-id></element-citation></ref><ref id="B190-pharmaceuticals-16-01384"><label>190.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Minn</surname><given-names>A.J.</given-names></name></person-group><article-title>Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies</article-title><source>Immunity</source><year>2018</year><volume>48</volume><fpage>417</fpage><lpage>433</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2018.03.007</pub-id><pub-id pub-id-type="pmid">29562193</pub-id><pub-id pub-id-type="pmcid">PMC6948191</pub-id></element-citation></ref><ref id="B191-pharmaceuticals-16-01384"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Puzanov</surname><given-names>I.</given-names></name><name name-style="western"><surname>VanderWalde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Andtbacka</surname><given-names>R.H.I.</given-names></name><name name-style="western"><surname>Michielin</surname><given-names>O.</given-names></name><name name-style="western"><surname>Olszanski</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Malvehy</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cebon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fernandez</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy</article-title><source>Cell</source><year>2017</year><volume>170</volume><fpage>1109</fpage><lpage>1119.e10</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.08.027</pub-id><pub-id pub-id-type="pmid">28886381</pub-id><pub-id pub-id-type="pmcid">PMC8034392</pub-id></element-citation></ref><ref id="B192-pharmaceuticals-16-01384"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gandhi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Abreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gadgeel</surname><given-names>S.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>E.</given-names></name><name name-style="western"><surname>Felip</surname><given-names>E.</given-names></name><name name-style="western"><surname>De Angelis</surname><given-names>F.</given-names></name><name name-style="western"><surname>Domine</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clingan</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hochmair</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Powell</surname><given-names>S.F.</given-names></name><etal/></person-group><article-title>Pembrolizumab plus Chemotherapy in Metastatic Non&#8211;Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>2078</fpage><lpage>2092</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1801005</pub-id><pub-id pub-id-type="pmid">29658856</pub-id></element-citation></ref><ref id="B193-pharmaceuticals-16-01384"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>J.-J.</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Cowey</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wagstaff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>381</volume><fpage>1535</fpage><lpage>1546</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1910836</pub-id><pub-id pub-id-type="pmid">31562797</pub-id></element-citation></ref><ref id="B194-pharmaceuticals-16-01384"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Motzer</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Penkov</surname><given-names>K.</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rini</surname><given-names>B.</given-names></name><name name-style="western"><surname>Albiges</surname><given-names>L.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Venugopal</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kollmannsberger</surname><given-names>C.</given-names></name><name name-style="western"><surname>Negrier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Uemura</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>1103</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1816047</pub-id><pub-id pub-id-type="pmid">30779531</pub-id><pub-id pub-id-type="pmcid">PMC6716603</pub-id></element-citation></ref><ref id="B195-pharmaceuticals-16-01384"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hu-Lieskovan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wargo</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ribas</surname><given-names>A.</given-names></name></person-group><article-title>Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>707</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.017</pub-id><pub-id pub-id-type="pmid">28187290</pub-id><pub-id pub-id-type="pmcid">PMC5391692</pub-id></element-citation></ref><ref id="B196-pharmaceuticals-16-01384"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morse</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gwin</surname><given-names>W.R.</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>D.A.</given-names></name></person-group><article-title>Vaccine Therapies for Cancer: Then and Now</article-title><source>Target. Oncol.</source><year>2021</year><volume>16</volume><fpage>121</fpage><lpage>152</lpage><pub-id pub-id-type="doi">10.1007/s11523-020-00788-w</pub-id><pub-id pub-id-type="pmid">33512679</pub-id><pub-id pub-id-type="pmcid">PMC7845582</pub-id></element-citation></ref><ref id="B197-pharmaceuticals-16-01384"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Igarashi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Sasada</surname><given-names>T.</given-names></name></person-group><article-title>Cancer Vaccines: Toward the Next Breakthrough in Cancer Immunotherapy</article-title><source>J. Immunol. Res.</source><year>2020</year><volume>2020</volume><fpage>5825401</fpage><pub-id pub-id-type="doi">10.1155/2020/5825401</pub-id><pub-id pub-id-type="pmid">33282961</pub-id><pub-id pub-id-type="pmcid">PMC7685825</pub-id></element-citation></ref><ref id="B198-pharmaceuticals-16-01384"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postow</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Sidlow</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>M.D.</given-names></name></person-group><article-title>Immune-Related Adverse Events Associated with Immune Checkpoint Blockade</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>158</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1056/NEJMra1703481</pub-id><pub-id pub-id-type="pmid">29320654</pub-id></element-citation></ref><ref id="B199-pharmaceuticals-16-01384"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dusetzina</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Winn</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Abel</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Huskamp</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Keating</surname><given-names>N.L.</given-names></name></person-group><article-title>Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia</article-title><source>J. Clin. Oncol.</source><year>2014</year><volume>32</volume><fpage>306</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1200/JCO.2013.52.9123</pub-id><pub-id pub-id-type="pmid">24366936</pub-id></element-citation></ref><ref id="B200-pharmaceuticals-16-01384"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Abreu</surname><given-names>D.</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cs&#337;szi</surname><given-names>T.</given-names></name><name name-style="western"><surname>F&#252;l&#246;p</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gottfried</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peled</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tafreshi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cuffe</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Pembrolizumab versus Chemotherapy for PD-L1&#8211;Positive Non&#8211;Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>1823</fpage><lpage>1833</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1606774</pub-id><pub-id pub-id-type="pmid">27718847</pub-id></element-citation></ref><ref id="B201-pharmaceuticals-16-01384"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Larkin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chiarion-Sileni</surname><given-names>V.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>R.</given-names></name><name name-style="western"><surname>Grob</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Cowey</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Lao</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Schadendorf</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dummer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Smylie</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rutkowski</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>373</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1504030</pub-id><pub-id pub-id-type="pmid">26027431</pub-id><pub-id pub-id-type="pmcid">PMC5698905</pub-id></element-citation></ref><ref id="B202-pharmaceuticals-16-01384"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zraik</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>He&#223;-Busch</surname><given-names>Y.</given-names></name></person-group><article-title>Management of chemotherapy side effects and their long-term sequelae</article-title><source>Urol. Ausg. A</source><year>2021</year><volume>60</volume><fpage>862</fpage><lpage>871</lpage><pub-id pub-id-type="doi">10.1007/s00120-021-01569-7</pub-id><pub-id pub-id-type="pmid">34185118</pub-id></element-citation></ref><ref id="B203-pharmaceuticals-16-01384"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Obeid</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tesniere</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ghiringhelli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Fimia</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Apetoh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perfettini</surname><given-names>J.-L.</given-names></name><name name-style="western"><surname>Castedo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mignot</surname><given-names>G.</given-names></name><name name-style="western"><surname>Panaretakis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Casares</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Calreticulin exposure dictates the immunogenicity of cancer cell death</article-title><source>Nat. Med.</source><year>2007</year><volume>13</volume><fpage>54</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1038/nm1523</pub-id><pub-id pub-id-type="pmid">17187072</pub-id></element-citation></ref><ref id="B204-pharmaceuticals-16-01384"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wainwright</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Dey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lesniak</surname><given-names>M.S.</given-names></name></person-group><article-title>Targeting tregs in malignant brain cancer: Overcoming IDO</article-title><source>Front. Immunol.</source><year>2013</year><volume>4</volume><fpage>116</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2013.00116</pub-id><pub-id pub-id-type="pmid">23720663</pub-id><pub-id pub-id-type="pmcid">PMC3654236</pub-id></element-citation></ref><ref id="B205-pharmaceuticals-16-01384"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ma</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xin</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Su</surname><given-names>R.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>W.</given-names></name></person-group><article-title>Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitorbased immunotherapy</article-title><source>Theranostics</source><year>2022</year><volume>12</volume><fpage>4965</fpage><lpage>4979</lpage><pub-id pub-id-type="doi">10.7150/thno.73152</pub-id><pub-id pub-id-type="pmid">35836810</pub-id><pub-id pub-id-type="pmcid">PMC9274752</pub-id></element-citation></ref><ref id="B206-pharmaceuticals-16-01384"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sasso</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lollo</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pitorre</surname><given-names>M.</given-names></name><name name-style="western"><surname>Solito</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pinton</surname><given-names>L.</given-names></name><name name-style="western"><surname>Valpione</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bastiat</surname><given-names>G.</given-names></name><name name-style="western"><surname>Mandruzzato</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bronte</surname><given-names>V.</given-names></name><name name-style="western"><surname>Marigo</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy</article-title><source>Biomaterials</source><year>2016</year><volume>96</volume><fpage>47</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.biomaterials.2016.04.010</pub-id><pub-id pub-id-type="pmid">27135716</pub-id></element-citation></ref><ref id="B207-pharmaceuticals-16-01384"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hauner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Maisch</surname><given-names>P.</given-names></name><name name-style="western"><surname>Retz</surname><given-names>M.</given-names></name></person-group><article-title>Nebenwirkungen der Chemotherapie</article-title><source>Urol. Ausg. A</source><year>2017</year><volume>56</volume><fpage>472</fpage><lpage>479</lpage><pub-id pub-id-type="doi">10.1007/s00120-017-0338-z</pub-id><pub-id pub-id-type="pmid">28251254</pub-id></element-citation></ref><ref id="B208-pharmaceuticals-16-01384"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farkona</surname><given-names>S.</given-names></name><name name-style="western"><surname>Diamandis</surname><given-names>E.P.</given-names></name><name name-style="western"><surname>Blasutig</surname><given-names>I.M.</given-names></name></person-group><article-title>Cancer immunotherapy: The beginning of the end of cancer?</article-title><source>BMC Med.</source><year>2016</year><volume>14</volume><elocation-id>73</elocation-id><pub-id pub-id-type="doi">10.1186/s12916-016-0623-5</pub-id><pub-id pub-id-type="pmid">27151159</pub-id><pub-id pub-id-type="pmcid">PMC4858828</pub-id></element-citation></ref><ref id="B209-pharmaceuticals-16-01384"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Emens</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Cruz</surname><given-names>C.</given-names></name><name name-style="western"><surname>Eder</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Braiteh</surname><given-names>F.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tolaney</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Kuter</surname><given-names>I.</given-names></name><name name-style="western"><surname>Nanda</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cassier</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Delord</surname><given-names>J.P.</given-names></name><etal/></person-group><article-title>Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients with Metastatic Triple-Negative Breast Cancer: A Phase 1 Study</article-title><source>JAMA Oncol.</source><year>2019</year><volume>5</volume><fpage>74</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1001/jamaoncol.2018.4224</pub-id><pub-id pub-id-type="pmid">30242306</pub-id><pub-id pub-id-type="pmcid">PMC6439773</pub-id></element-citation></ref><ref id="B210-pharmaceuticals-16-01384"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hinshaw</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Shevde</surname><given-names>L.A.</given-names></name></person-group><article-title>The tumor microenvironment innately modulates cancer progression</article-title><source>Cancer Res.</source><year>2019</year><volume>79</volume><fpage>4557</fpage><lpage>4567</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-3962</pub-id><pub-id pub-id-type="pmid">31350295</pub-id><pub-id pub-id-type="pmcid">PMC6744958</pub-id></element-citation></ref><ref id="B211-pharmaceuticals-16-01384"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abshire</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lang</surname><given-names>M.K.</given-names></name></person-group><article-title>The Evolution of Radiation Therapy in Treating Cancer</article-title><source>Semin. Oncol. Nurs.</source><year>2018</year><volume>34</volume><fpage>151</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1016/j.soncn.2018.03.006</pub-id><pub-id pub-id-type="pmid">29606538</pub-id></element-citation></ref><ref id="B212-pharmaceuticals-16-01384"><label>212.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dewan</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Galloway</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Kawashima</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dewyngaert</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Babb</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Formenti</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Demaria</surname><given-names>S.</given-names></name></person-group><article-title>Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody</article-title><source>Clin. Cancer Res.</source><year>2009</year><volume>15</volume><fpage>5379</fpage><lpage>5388</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-09-0265</pub-id><pub-id pub-id-type="pmid">19706802</pub-id><pub-id pub-id-type="pmcid">PMC2746048</pub-id></element-citation></ref><ref id="B213-pharmaceuticals-16-01384"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Golden</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Demaria</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schiff</surname><given-names>P.B.</given-names></name><name name-style="western"><surname>Chachoua</surname><given-names>A.</given-names></name><name name-style="western"><surname>Formenti</surname><given-names>S.C.</given-names></name></person-group><article-title>An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer</article-title><source>Cancer Immunol. Res.</source><year>2013</year><volume>1</volume><fpage>365</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1158/2326-6066.CIR-13-0115</pub-id><pub-id pub-id-type="pmid">24563870</pub-id><pub-id pub-id-type="pmcid">PMC3930458</pub-id></element-citation></ref><ref id="B214-pharmaceuticals-16-01384"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weichselbaum</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y.X.</given-names></name></person-group><article-title>Radiotherapy and immunotherapy: A beneficial liaison?</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2017</year><volume>14</volume><fpage>365</fpage><lpage>379</lpage><pub-id pub-id-type="doi">10.1038/nrclinonc.2016.211</pub-id><pub-id pub-id-type="pmid">28094262</pub-id></element-citation></ref><ref id="B215-pharmaceuticals-16-01384"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>A.</given-names></name><name name-style="western"><surname>Probst</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Vuong</surname><given-names>V.</given-names></name><name name-style="western"><surname>Landshammer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Muth</surname><given-names>S.</given-names></name><name name-style="western"><surname>Yagita</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schwendener</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pruschy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Knuth</surname><given-names>A.</given-names></name><name name-style="western"><surname>van den Broek</surname><given-names>M.</given-names></name></person-group><article-title>Radiotherapy Promotes Tumor-Specific Effector CD8+ T Cells via Dendritic Cell Activation</article-title><source>J. Immunol.</source><year>2012</year><volume>189</volume><fpage>558</fpage><lpage>566</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1200563</pub-id><pub-id pub-id-type="pmid">22685313</pub-id></element-citation></ref><ref id="B216-pharmaceuticals-16-01384"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barker</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Paget</surname><given-names>J.T.E.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Harrington</surname><given-names>K.J.</given-names></name></person-group><article-title>The tumour microenvironment after radiotherapy: Mechanisms of resistance and recurrence</article-title><source>Nat. Rev. Cancer</source><year>2015</year><volume>15</volume><fpage>409</fpage><lpage>425</lpage><pub-id pub-id-type="doi">10.1038/nrc3958</pub-id><pub-id pub-id-type="pmid">26105538</pub-id><pub-id pub-id-type="pmcid">PMC4896389</pub-id></element-citation></ref><ref id="B217-pharmaceuticals-16-01384"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Twyman-Saint Victor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rech</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Maity</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rengan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pauken</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Stelekati</surname><given-names>E.</given-names></name><name name-style="western"><surname>Benci</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>B.</given-names></name><name name-style="western"><surname>Dada</surname><given-names>H.</given-names></name><name name-style="western"><surname>Odorizzi</surname><given-names>P.M.</given-names></name><etal/></person-group><article-title>Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer</article-title><source>Nature</source><year>2015</year><volume>520</volume><fpage>373</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1038/nature14292</pub-id><pub-id pub-id-type="pmid">25754329</pub-id><pub-id pub-id-type="pmcid">PMC4401634</pub-id></element-citation></ref><ref id="B218-pharmaceuticals-16-01384"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lugade</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Gerber</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>R.C.</given-names></name><name name-style="western"><surname>Frelinger</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Lord</surname><given-names>E.M.</given-names></name></person-group><article-title>Local Radiation Therapy of B16 Melanoma Tumors Increases the Generation of Tumor Antigen-Specific Effector Cells That Traffic to the Tumor</article-title><source>J. Immunol.</source><year>2005</year><volume>174</volume><fpage>7516</fpage><lpage>7523</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.174.12.7516</pub-id><pub-id pub-id-type="pmid">15944250</pub-id></element-citation></ref><ref id="B219-pharmaceuticals-16-01384"><label>219.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Antonia</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Villegas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Daniel</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vicente</surname><given-names>D.</given-names></name><name name-style="western"><surname>Murakami</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hui</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yokoi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chiappori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>De Wit</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Durvalumab after Chemoradiotherapy in Stage III Non&#8211;Small-Cell Lung Cancer</article-title><source>N. Engl. J. Med.</source><year>2017</year><volume>377</volume><fpage>1919</fpage><lpage>1929</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1709937</pub-id><pub-id pub-id-type="pmid">28885881</pub-id></element-citation></ref><ref id="B220-pharmaceuticals-16-01384"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Humeau</surname><given-names>J.</given-names></name><name name-style="western"><surname>Buqu&#233;</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors</article-title><source>Nat. Rev. Clin. Oncol.</source><year>2020</year><volume>17</volume><fpage>725</fpage><lpage>741</lpage><pub-id pub-id-type="doi">10.1038/s41571-020-0413-z</pub-id><pub-id pub-id-type="pmid">32760014</pub-id></element-citation></ref><ref id="B221-pharmaceuticals-16-01384"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shuel</surname><given-names>S.L.</given-names></name></person-group><article-title>Targeted cancer therapies</article-title><source>Can. Fam. Physician</source><year>2022</year><volume>68</volume><fpage>515</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.46747/cfp.6807515</pub-id><pub-id pub-id-type="pmid">35831091</pub-id><pub-id pub-id-type="pmcid">PMC9842142</pub-id></element-citation></ref><ref id="B222-pharmaceuticals-16-01384"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>R.-Y.</given-names></name><name name-style="western"><surname>Eppolito</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lele</surname><given-names>S.</given-names></name><name name-style="western"><surname>Shrikant</surname><given-names>P.</given-names></name><name name-style="western"><surname>Matsuzaki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Odunsi</surname><given-names>K.</given-names></name></person-group><article-title>LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>27359</fpage><lpage>27377</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4751</pub-id><pub-id pub-id-type="pmid">26318293</pub-id><pub-id pub-id-type="pmcid">PMC4694995</pub-id></element-citation></ref><ref id="B223-pharmaceuticals-16-01384"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beatty</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Gladney</surname><given-names>W.L.</given-names></name></person-group><article-title>Immune escape mechanisms as a guide for cancer immunotherapy</article-title><source>Clin. Cancer Res.</source><year>2015</year><volume>21</volume><fpage>687</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-14-1860</pub-id><pub-id pub-id-type="pmid">25501578</pub-id><pub-id pub-id-type="pmcid">PMC4334715</pub-id></element-citation></ref><ref id="B224-pharmaceuticals-16-01384"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holohan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Van Schaeybroeck</surname><given-names>S.</given-names></name><name name-style="western"><surname>Longley</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Johnston</surname><given-names>P.G.</given-names></name></person-group><article-title>Cancer drug resistance: An evolving paradigm</article-title><source>Nat. Rev. Cancer</source><year>2013</year><volume>13</volume><fpage>714</fpage><lpage>726</lpage><pub-id pub-id-type="doi">10.1038/nrc3599</pub-id><pub-id pub-id-type="pmid">24060863</pub-id></element-citation></ref><ref id="B225-pharmaceuticals-16-01384"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zitvogel</surname><given-names>L.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Smyth</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name></person-group><article-title>Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>74</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.06.014</pub-id><pub-id pub-id-type="pmid">23890065</pub-id></element-citation></ref><ref id="B226-pharmaceuticals-16-01384"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yun</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Yoon</surname><given-names>A.R.</given-names></name></person-group><article-title>Current clinical landscape of oncolytic viruses as novel cancer immunotherapeutic and recent preclinical advancements</article-title><source>Front. Immunol.</source><year>2022</year><volume>13</volume><fpage>953410</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2022.953410</pub-id><pub-id pub-id-type="pmid">36091031</pub-id><pub-id pub-id-type="pmcid">PMC9458317</pub-id></element-citation></ref><ref id="B227-pharmaceuticals-16-01384"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parato</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Senger</surname><given-names>D.</given-names></name><name name-style="western"><surname>Forsyth</surname><given-names>P.A.J.</given-names></name><name name-style="western"><surname>Bell</surname><given-names>J.C.</given-names></name></person-group><article-title>Recent progress in the battle between oncolytic viruses and tumours</article-title><source>Nat. Rev. Cancer</source><year>2005</year><volume>5</volume><fpage>965</fpage><lpage>976</lpage><pub-id pub-id-type="doi">10.1038/nrc1750</pub-id><pub-id pub-id-type="pmid">16294217</pub-id></element-citation></ref><ref id="B228-pharmaceuticals-16-01384"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>N.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Giese</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Merghoub</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>L.</given-names></name></person-group><article-title>Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>e002569</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-002569</pub-id><pub-id pub-id-type="pmid">34593618</pub-id><pub-id pub-id-type="pmcid">PMC8487208</pub-id></element-citation></ref><ref id="B229-pharmaceuticals-16-01384"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><etal/></person-group><article-title>Oncolytic Parapoxvirus induces Gasdermin E-mediated pyroptosis and activates antitumor immunity</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>224</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-35917-2</pub-id><pub-id pub-id-type="pmid">36641456</pub-id><pub-id pub-id-type="pmcid">PMC9840172</pub-id></element-citation></ref><ref id="B230-pharmaceuticals-16-01384"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Enekegho</surname><given-names>L.</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>D.</given-names></name></person-group><article-title>Smart Oncolytic Adenovirotherapy to Induce Killing of Cancer Cells and Elicit Antitumor Immunity</article-title><source>Eureka</source><year>2022</year><volume>7</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.29173/eureka28752</pub-id></element-citation></ref><ref id="B231-pharmaceuticals-16-01384"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zuo</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>M.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>L.</given-names></name><name name-style="western"><surname>He</surname><given-names>B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Dong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name></person-group><article-title>An engineered oncolytic vaccinia virus encoding a single-chain variable fragment against TIGIT induces effective antitumor immunity and synergizes with PD-1 or LAG-3 blockade</article-title><source>J. Immunother. Cancer</source><year>2021</year><volume>9</volume><fpage>e002843</fpage><pub-id pub-id-type="doi">10.1136/jitc-2021-002843</pub-id><pub-id pub-id-type="pmid">34949694</pub-id><pub-id pub-id-type="pmcid">PMC8705214</pub-id></element-citation></ref><ref id="B232-pharmaceuticals-16-01384"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Das</surname><given-names>K.</given-names></name><name name-style="western"><surname>Belnoue</surname><given-names>E.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hofer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Danklmaier</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nolden</surname><given-names>T.</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>L.-M.</given-names></name><name name-style="western"><surname>Angerer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kimpel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hoegler</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>5195</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-25506-6</pub-id><pub-id pub-id-type="pmid">34465781</pub-id><pub-id pub-id-type="pmcid">PMC8408233</pub-id></element-citation></ref><ref id="B233-pharmaceuticals-16-01384"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>B.</given-names></name><name name-style="western"><surname>Shu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>P.</given-names></name></person-group><article-title>In Situ Tumor Vaccine Expressing Anti-CD47 Antibody Enhances Antitumor Immunity</article-title><source>Front. Oncol.</source><year>2022</year><volume>12</volume><fpage>897561</fpage><pub-id pub-id-type="doi">10.3389/fonc.2022.897561</pub-id><pub-id pub-id-type="pmid">35837100</pub-id><pub-id pub-id-type="pmcid">PMC9273963</pub-id></element-citation></ref><ref id="B234-pharmaceuticals-16-01384"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hofer</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carboni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Di Berardino Besson</surname><given-names>W.</given-names></name><name name-style="western"><surname>von Laer</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wollmann</surname><given-names>G.</given-names></name><name name-style="western"><surname>Derouazi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santiago-Raber</surname><given-names>M.L.</given-names></name></person-group><article-title>Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect</article-title><source>Cancers</source><year>2021</year><volume>13</volume><elocation-id>6107</elocation-id><pub-id pub-id-type="doi">10.3390/cancers13236107</pub-id><pub-id pub-id-type="pmid">34885215</pub-id><pub-id pub-id-type="pmcid">PMC8656755</pub-id></element-citation></ref><ref id="B235-pharmaceuticals-16-01384"><label>235.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartlett</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Sathaiah</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ravindranathan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>Z.S.</given-names></name></person-group><article-title>Oncolytic viruses as therapeutic cancer vaccines</article-title><source>Mol. Cancer</source><year>2013</year><volume>12</volume><fpage>103</fpage><pub-id pub-id-type="doi">10.1186/1476-4598-12-103</pub-id><pub-id pub-id-type="pmid">24020520</pub-id><pub-id pub-id-type="pmcid">PMC3847443</pub-id></element-citation></ref><ref id="B236-pharmaceuticals-16-01384"><label>236.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>K.W.</given-names></name></person-group><article-title>Oncolytic Virotherapy: A Contest between Apples and Oranges</article-title><source>Mol. Ther.</source><year>2017</year><volume>25</volume><fpage>1107</fpage><lpage>1116</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.03.026</pub-id><pub-id pub-id-type="pmid">28392162</pub-id><pub-id pub-id-type="pmcid">PMC5417845</pub-id></element-citation></ref><ref id="B237-pharmaceuticals-16-01384"><label>237.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukuhara</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ino</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Todo</surname><given-names>T.</given-names></name></person-group><article-title>Oncolytic virus therapy: A new era of cancer treatment at dawn</article-title><source>Cancer Sci.</source><year>2016</year><volume>107</volume><fpage>1373</fpage><lpage>1379</lpage><pub-id pub-id-type="doi">10.1111/cas.13027</pub-id><pub-id pub-id-type="pmid">27486853</pub-id><pub-id pub-id-type="pmcid">PMC5084676</pub-id></element-citation></ref><ref id="B238-pharmaceuticals-16-01384"><label>238.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pol</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kroemer</surname><given-names>G.</given-names></name><name name-style="western"><surname>Galluzzi</surname><given-names>L.</given-names></name></person-group><article-title>First oncolytic virus approved for melanoma immunotherapy</article-title><source>Oncoimmunology</source><year>2016</year><volume>5</volume><fpage>e1115641</fpage><pub-id pub-id-type="doi">10.1080/2162402X.2015.1115641</pub-id><pub-id pub-id-type="pmid">26942095</pub-id><pub-id pub-id-type="pmcid">PMC4760283</pub-id></element-citation></ref><ref id="B239-pharmaceuticals-16-01384"><label>239.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harrington</surname><given-names>K.</given-names></name><name name-style="western"><surname>Freeman</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>B.</given-names></name><name name-style="western"><surname>Harper</surname><given-names>J.</given-names></name><name name-style="western"><surname>Soria</surname><given-names>J.C.</given-names></name></person-group><article-title>Optimizing oncolytic virotherapy in cancer treatment</article-title><source>Nat. Rev. Drug Discov.</source><year>2019</year><volume>18</volume><fpage>689</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1038/s41573-019-0029-0</pub-id><pub-id pub-id-type="pmid">31292532</pub-id></element-citation></ref><ref id="B240-pharmaceuticals-16-01384"><label>240.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goradel</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Arashkia</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ebrahimi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Ghorghanlu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Negahdari</surname><given-names>B.</given-names></name></person-group><article-title>Oncolytic virotherapy: Challenges and solutions</article-title><source>Curr. Probl. Cancer</source><year>2021</year><volume>45</volume><fpage>100639</fpage><pub-id pub-id-type="doi">10.1016/j.currproblcancer.2020.100639</pub-id><pub-id pub-id-type="pmid">32828575</pub-id></element-citation></ref><ref id="B241-pharmaceuticals-16-01384"><label>241.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mondal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Guo</surname><given-names>J.</given-names></name><name name-style="western"><surname>He</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D.</given-names></name></person-group><article-title>Recent advances of oncolytic virus in cancer therapy</article-title><source>Hum. Vaccines Immunother.</source><year>2020</year><volume>16</volume><fpage>2389</fpage><lpage>2402</lpage><pub-id pub-id-type="doi">10.1080/21645515.2020.1723363</pub-id><pub-id pub-id-type="pmcid">PMC7644205</pub-id><pub-id pub-id-type="pmid">32078405</pub-id></element-citation></ref><ref id="B242-pharmaceuticals-16-01384"><label>242.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niemann</surname><given-names>J.</given-names></name><name name-style="western"><surname>K&#252;hnel</surname><given-names>F.</given-names></name></person-group><article-title>Oncolytic viruses: Adenoviruses</article-title><source>Virus Genes</source><year>2017</year><volume>53</volume><fpage>700</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1007/s11262-017-1488-1</pub-id><pub-id pub-id-type="pmid">28702840</pub-id></element-citation></ref><ref id="B243-pharmaceuticals-16-01384"><label>243.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moaven</surname><given-names>O.</given-names></name><name name-style="western"><surname>Mangieri</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Stauffer</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Anastasiadis</surname><given-names>P.Z.</given-names></name><name name-style="western"><surname>Borad</surname><given-names>M.J.</given-names></name></person-group><article-title>Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy</article-title><source>JCO Precis. Oncol.</source><year>2021</year><volume>1</volume><fpage>733</fpage><lpage>743</lpage><pub-id pub-id-type="doi">10.1200/PO.21.00003</pub-id><pub-id pub-id-type="pmid">34250395</pub-id><pub-id pub-id-type="pmcid">PMC8232397</pub-id></element-citation></ref><ref id="B244-pharmaceuticals-16-01384"><label>244.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gubin</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Schuster</surname><given-names>H.</given-names></name><name name-style="western"><surname>Caron</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ward</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Noguchi</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ivanova</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hundal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Arthur</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Krebber</surname><given-names>W.J.</given-names></name><etal/></person-group><article-title>Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens</article-title><source>Nature</source><year>2014</year><volume>515</volume><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="doi">10.1038/nature13988</pub-id><pub-id pub-id-type="pmid">25428507</pub-id><pub-id pub-id-type="pmcid">PMC4279952</pub-id></element-citation></ref><ref id="B245-pharmaceuticals-16-01384"><label>245.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>S.Q.</given-names></name><name name-style="western"><surname>Fellowes</surname><given-names>A.</given-names></name><name name-style="western"><surname>Doig</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ellul</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bosma</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Irwin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vedururu</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>A.Y.-C.</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Assessing the clinical value of targeted massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients</article-title><source>Br. J. Cancer</source><year>2015</year><volume>112</volume><fpage>1411</fpage><lpage>1420</lpage><pub-id pub-id-type="doi">10.1038/bjc.2015.80</pub-id><pub-id pub-id-type="pmid">25742471</pub-id><pub-id pub-id-type="pmcid">PMC4402458</pub-id></element-citation></ref><ref id="B246-pharmaceuticals-16-01384"><label>246.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGranahan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Swanton</surname><given-names>C.</given-names></name></person-group><article-title>Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future</article-title><source>Cell</source><year>2017</year><volume>168</volume><fpage>613</fpage><lpage>628</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.01.018</pub-id><pub-id pub-id-type="pmid">28187284</pub-id></element-citation></ref><ref id="B247-pharmaceuticals-16-01384"><label>247.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Van Allen</surname><given-names>E.M.</given-names></name></person-group><article-title>Genomic determinants of cancer immunotherapy</article-title><source>Curr. Opin. Immunol.</source><year>2016</year><volume>41</volume><fpage>32</fpage><lpage>38</lpage><pub-id pub-id-type="doi">10.1016/j.coi.2016.05.010</pub-id><pub-id pub-id-type="pmid">27254251</pub-id></element-citation></ref><ref id="B248-pharmaceuticals-16-01384"><label>248.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>&#321;uksza</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riaz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Balachandran</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Solovyov</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rizvi</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Merghoub</surname><given-names>T.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>T.A.</given-names></name><etal/></person-group><article-title>A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy</article-title><source>Nature</source><year>2017</year><volume>551</volume><fpage>517</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1038/nature24473</pub-id><pub-id pub-id-type="pmid">29132144</pub-id><pub-id pub-id-type="pmcid">PMC6137806</pub-id></element-citation></ref><ref id="B249-pharmaceuticals-16-01384"><label>249.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O&#8217;Donnell</surname><given-names>T.J.</given-names></name><name name-style="western"><surname>Rubinsteyn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bonsack</surname><given-names>M.</given-names></name><name name-style="western"><surname>Riemer</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Laserson</surname><given-names>U.</given-names></name><name name-style="western"><surname>Hammerbacher</surname><given-names>J.</given-names></name></person-group><article-title>MHCflurry: Open-Source Class I MHC Binding Affinity Prediction</article-title><source>Cell Syst.</source><year>2018</year><volume>7</volume><fpage>129</fpage><lpage>132.e4</lpage><pub-id pub-id-type="doi">10.1016/j.cels.2018.05.014</pub-id><pub-id pub-id-type="pmid">29960884</pub-id></element-citation></ref><ref id="B250-pharmaceuticals-16-01384"><label>250.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kalaora</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Feferman</surname><given-names>T.</given-names></name><name name-style="western"><surname>Barnea</surname><given-names>E.</given-names></name><name name-style="western"><surname>Greenstein</surname><given-names>E.</given-names></name><name name-style="western"><surname>Reshef</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tirosh</surname><given-names>I.</given-names></name><name name-style="western"><surname>Reuben</surname><given-names>A.</given-names></name><name name-style="western"><surname>Patkar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Levy</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Combined analysis of antigen presentation and T-cell recognition reveals restricted immune responses in melanoma</article-title><source>Cancer Discov.</source><year>2018</year><volume>8</volume><fpage>1366</fpage><lpage>1375</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-17-1418</pub-id><pub-id pub-id-type="pmid">30209080</pub-id><pub-id pub-id-type="pmcid">PMC6453138</pub-id></element-citation></ref><ref id="B251-pharmaceuticals-16-01384"><label>251.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjerregaard</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hadrup</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Szallasi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Eklund</surname><given-names>A.C.</given-names></name></person-group><article-title>MuPeXI: Prediction of neo-epitopes from tumor sequencing data</article-title><source>Cancer Immunol. Immunother.</source><year>2017</year><volume>66</volume><fpage>1123</fpage><lpage>1130</lpage><pub-id pub-id-type="doi">10.1007/s00262-017-2001-3</pub-id><pub-id pub-id-type="pmid">28429069</pub-id><pub-id pub-id-type="pmcid">PMC11028452</pub-id></element-citation></ref><ref id="B252-pharmaceuticals-16-01384"><label>252.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>P.F.</given-names></name></person-group><article-title>Cancer immunotherapy targeting neoantigens</article-title><source>Semin. Immunol.</source><year>2016</year><volume>28</volume><fpage>22</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2015.11.002</pub-id><pub-id pub-id-type="pmid">26653770</pub-id><pub-id pub-id-type="pmcid">PMC4862880</pub-id></element-citation></ref><ref id="B253-pharmaceuticals-16-01384"><label>253.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubensky</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>S.G.</given-names></name></person-group><article-title>Adjuvants for cancer vaccines</article-title><source>Semin. Immunol.</source><year>2010</year><volume>22</volume><fpage>155</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.1016/j.smim.2010.04.007</pub-id><pub-id pub-id-type="pmid">20488726</pub-id></element-citation></ref><ref id="B254-pharmaceuticals-16-01384"><label>254.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>J.Z.</given-names></name><name name-style="western"><surname>Jou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>E.</given-names></name></person-group><article-title>Vaccine strategies for human papillomavirus-associated head and neck cancers</article-title><source>Cancers</source><year>2022</year><volume>14</volume><elocation-id>33</elocation-id><pub-id pub-id-type="doi">10.3390/cancers14010033</pub-id><pub-id pub-id-type="pmid">35008197</pub-id><pub-id pub-id-type="pmcid">PMC8750601</pub-id></element-citation></ref><ref id="B255-pharmaceuticals-16-01384"><label>255.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heathman</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Nienow</surname><given-names>A.W.</given-names></name><name name-style="western"><surname>McCall</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Coopman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kara</surname><given-names>B.</given-names></name><name name-style="western"><surname>Hewitt</surname><given-names>C.J.</given-names></name></person-group><article-title>The translation of cell-based therapies: Clinical landscape and manufacturing challenges</article-title><source>Regen. Med.</source><year>2015</year><volume>10</volume><fpage>49</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.2217/rme.14.73</pub-id><pub-id pub-id-type="pmid">25562352</pub-id></element-citation></ref><ref id="B256-pharmaceuticals-16-01384"><label>256.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pollock</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coffman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>S.V.</given-names></name><name name-style="western"><surname>Farid</surname><given-names>S.S.</given-names></name></person-group><article-title>Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture</article-title><source>Biotechnol Prog.</source><year>2017</year><volume>33</volume><fpage>854</fpage><lpage>866</lpage><pub-id pub-id-type="doi">10.1002/btpr.2492</pub-id><pub-id pub-id-type="pmid">28480535</pub-id><pub-id pub-id-type="pmcid">PMC5575510</pub-id></element-citation></ref><ref id="B257-pharmaceuticals-16-01384"><label>257.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Peter Goedegebuure</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gillanders</surname><given-names>W.E.</given-names></name></person-group><article-title>Personalized cancer vaccines: Targeting the cancer mutanome</article-title><source>Vaccine</source><year>2017</year><volume>35</volume><fpage>1094</fpage><lpage>1100</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.05.073</pub-id><pub-id pub-id-type="pmid">27449681</pub-id><pub-id pub-id-type="pmcid">PMC5448976</pub-id></element-citation></ref><ref id="B258-pharmaceuticals-16-01384"><label>258.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hilf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kuttruff-Coqui</surname><given-names>S.</given-names></name><name name-style="western"><surname>Frenzel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Bukur</surname><given-names>V.</given-names></name><name name-style="western"><surname>Stevanovi&#263;</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gouttefangeas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Platten</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tabatabai</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dutoit</surname><given-names>V.</given-names></name><name name-style="western"><surname>Van Der Burg</surname><given-names>S.H.</given-names></name><etal/></person-group><article-title>Actively personalized vaccination trial for newly diagnosed glioblastoma</article-title><source>Nature</source><year>2019</year><volume>565</volume><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0810-y</pub-id><pub-id pub-id-type="pmid">30568303</pub-id></element-citation></ref><ref id="B259-pharmaceuticals-16-01384"><label>259.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kloor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Von Knebel Doeberitz</surname><given-names>M.</given-names></name></person-group><article-title>The immune biology of microsatellite-unstable cancer</article-title><source>Trends Cancer</source><year>2016</year><volume>2</volume><fpage>121</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2016.02.004</pub-id><pub-id pub-id-type="pmid">28741532</pub-id></element-citation></ref><ref id="B260-pharmaceuticals-16-01384"><label>260.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yarchoan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Lutz</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Laheru</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Jaffee</surname><given-names>E.M.</given-names></name></person-group><article-title>Targeting neoantigens to augment antitumour immunity</article-title><source>Nat. Rev. Cancer</source><year>2017</year><volume>17</volume><fpage>209</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1038/nrc.2016.154</pub-id><pub-id pub-id-type="pmid">28233802</pub-id><pub-id pub-id-type="pmcid">PMC5575801</pub-id></element-citation></ref><ref id="B261-pharmaceuticals-16-01384"><label>261.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palucka</surname><given-names>K.</given-names></name><name name-style="western"><surname>Banchereau</surname><given-names>J.</given-names></name></person-group><article-title>Dendritic-Cell-Based Therapeutic Cancer Vaccines</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.004</pub-id><pub-id pub-id-type="pmid">23890062</pub-id><pub-id pub-id-type="pmcid">PMC3788678</pub-id></element-citation></ref><ref id="B262-pharmaceuticals-16-01384"><label>262.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saung</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Ke</surname><given-names>X.</given-names></name><name name-style="western"><surname>Howard</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>H.Q.</given-names></name></person-group><article-title>Particulate carrier systems as adjuvants for cancer vaccines</article-title><source>Biomater. Sci.</source><year>2019</year><volume>7</volume><fpage>4873</fpage><lpage>4887</lpage><pub-id pub-id-type="doi">10.1039/C9BM00871C</pub-id><pub-id pub-id-type="pmid">31528923</pub-id></element-citation></ref><ref id="B263-pharmaceuticals-16-01384"><label>263.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rizvi</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Hellmann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kvistborg</surname><given-names>P.</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Havel</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>124</fpage><lpage>128</lpage><pub-id pub-id-type="doi">10.1126/science.aaa1348</pub-id><pub-id pub-id-type="pmid">25765070</pub-id><pub-id pub-id-type="pmcid">PMC4993154</pub-id></element-citation></ref><ref id="B264-pharmaceuticals-16-01384"><label>264.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Postow</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Callahan</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Wolchok</surname><given-names>J.D.</given-names></name></person-group><article-title>Immune checkpoint blockade in cancer therapy</article-title><source>J. Clin. Oncol.</source><year>2015</year><volume>33</volume><fpage>1974</fpage><lpage>1982</lpage><pub-id pub-id-type="doi">10.1200/JCO.2014.59.4358</pub-id><pub-id pub-id-type="pmid">25605845</pub-id><pub-id pub-id-type="pmcid">PMC4980573</pub-id></element-citation></ref><ref id="B265-pharmaceuticals-16-01384"><label>265.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sharma</surname><given-names>P.</given-names></name><name name-style="western"><surname>Allison</surname><given-names>J.P.</given-names></name></person-group><article-title>The future of immune checkpoint therapy</article-title><source>Science</source><year>2015</year><volume>348</volume><fpage>56</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1126/science.aaa8172</pub-id><pub-id pub-id-type="pmid">25838373</pub-id></element-citation></ref><ref id="B266-pharmaceuticals-16-01384"><label>266.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Snyder</surname><given-names>A.</given-names></name><name name-style="western"><surname>Makarov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Merghoub</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zaretsky</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Desrichard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Walsh</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Postow</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>T.S.</given-names></name><etal/></person-group><article-title>Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma</article-title><source>N. Engl. J. Med.</source><year>2014</year><volume>371</volume><fpage>2189</fpage><lpage>2199</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1406498</pub-id><pub-id pub-id-type="pmid">25409260</pub-id><pub-id pub-id-type="pmcid">PMC4315319</pub-id></element-citation></ref><ref id="B267-pharmaceuticals-16-01384"><label>267.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mitchell</surname><given-names>S.A.</given-names></name></person-group><article-title>Cancer-Related Fatigue: State of the Science</article-title><source>PMR</source><year>2010</year><volume>2</volume><fpage>364</fpage><lpage>383</lpage><pub-id pub-id-type="doi">10.1016/j.pmrj.2010.03.024</pub-id><pub-id pub-id-type="pmid">20656618</pub-id></element-citation></ref><ref id="B268-pharmaceuticals-16-01384"><label>268.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vanpouille-Box</surname><given-names>C.</given-names></name><name name-style="western"><surname>Alard</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aryankalayil</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Sarfraz</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Inghirami</surname><given-names>G.</given-names></name><name name-style="western"><surname>Coleman</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Formenti</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Demaria</surname><given-names>S.</given-names></name></person-group><article-title>DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity</article-title><source>Nat. Commun.</source><year>2017</year><volume>8</volume><fpage>15618</fpage><pub-id pub-id-type="doi">10.1038/ncomms15618</pub-id><pub-id pub-id-type="pmid">28598415</pub-id><pub-id pub-id-type="pmcid">PMC5472757</pub-id></element-citation></ref><ref id="B269-pharmaceuticals-16-01384"><label>269.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Tendeloo</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Van de Velde</surname><given-names>A.</given-names></name><name name-style="western"><surname>Van Driessche</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cools</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anguille</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ladell</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gostick</surname><given-names>E.</given-names></name><name name-style="western"><surname>Vermeulen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pieters</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nijs</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Induction of complete and molecular remissions in acute myeloid leukemia by Wilms&#8217; tumor 1 antigen-targeted dendritic cell vaccination</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2010</year><volume>107</volume><fpage>13824</fpage><lpage>13829</lpage><pub-id pub-id-type="doi">10.1073/pnas.1008051107</pub-id><pub-id pub-id-type="pmid">20631300</pub-id><pub-id pub-id-type="pmcid">PMC2922237</pub-id></element-citation></ref><ref id="B270-pharmaceuticals-16-01384"><label>270.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenblatt</surname><given-names>J.</given-names></name><name name-style="western"><surname>Glotzbecker</surname><given-names>B.</given-names></name><name name-style="western"><surname>Mills</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vasir</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tzachanis</surname><given-names>D.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Joyce</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Wellenstein</surname><given-names>K.</given-names></name><name name-style="western"><surname>Keefe</surname><given-names>W.</given-names></name><name name-style="western"><surname>Schickler</surname><given-names>M.</given-names></name><etal/></person-group><article-title>PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo t-cell responses to autologous dendritic cell/myeloma fusion vaccine</article-title><source>J. Immunother.</source><year>2011</year><volume>34</volume><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="doi">10.1097/CJI.0b013e31821ca6ce</pub-id><pub-id pub-id-type="pmid">21577144</pub-id><pub-id pub-id-type="pmcid">PMC3142955</pub-id></element-citation></ref><ref id="B271-pharmaceuticals-16-01384"><label>271.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maude</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Laetsch</surname><given-names>T.W.</given-names></name><name name-style="western"><surname>Buechner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rives</surname><given-names>S.</given-names></name><name name-style="western"><surname>Boyer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bittencourt</surname><given-names>H.</given-names></name><name name-style="western"><surname>Bader</surname><given-names>P.</given-names></name><name name-style="western"><surname>Verneris</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Stefanski</surname><given-names>H.E.</given-names></name><name name-style="western"><surname>Myers</surname><given-names>G.D.</given-names></name><etal/></person-group><article-title>Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>378</volume><fpage>439</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1709866</pub-id><pub-id pub-id-type="pmid">29385370</pub-id><pub-id pub-id-type="pmcid">PMC5996391</pub-id></element-citation></ref><ref id="B272-pharmaceuticals-16-01384"><label>272.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuster</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Bishop</surname><given-names>M.R.</given-names></name><name name-style="western"><surname>Tam</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Waller</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Borchmann</surname><given-names>P.</given-names></name><name name-style="western"><surname>McGuirk</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>J&#228;ger</surname><given-names>U.</given-names></name><name name-style="western"><surname>Jaglowski</surname><given-names>S.</given-names></name><name name-style="western"><surname>Andreadis</surname><given-names>C.</given-names></name><name name-style="western"><surname>Westin</surname><given-names>J.R.</given-names></name><etal/></person-group><article-title>Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma</article-title><source>N. Engl. J. Med.</source><year>2019</year><volume>380</volume><fpage>45</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1804980</pub-id><pub-id pub-id-type="pmid">30501490</pub-id></element-citation></ref><ref id="B273-pharmaceuticals-16-01384"><label>273.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartmann</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sch&#252;&#223;ler-Lenz</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bondanza</surname><given-names>A.</given-names></name><name name-style="western"><surname>Buchholz</surname><given-names>C.J.</given-names></name></person-group><article-title>Clinical development of CAR T cells&#8212;Challenges and opportunities in translating innovative treatment concepts</article-title><source>EMBO Mol. Med.</source><year>2017</year><volume>9</volume><fpage>1183</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.15252/emmm.201607485</pub-id><pub-id pub-id-type="pmid">28765140</pub-id><pub-id pub-id-type="pmcid">PMC5582407</pub-id></element-citation></ref><ref id="B274-pharmaceuticals-16-01384"><label>274.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sanmamed</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Fern&#225;ndez-Land&#225;zuri</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rodr&#237;guez</surname><given-names>C.</given-names></name><name name-style="western"><surname>Z&#225;rate</surname><given-names>R.</given-names></name><name name-style="western"><surname>Lozano</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Zubiri</surname><given-names>L.</given-names></name><name name-style="western"><surname>Perez-Gracia</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Mart&#237;n-Algarra</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gonz&#225;lez</surname><given-names>A.</given-names></name></person-group><article-title>Quantitative cell-free circulating BRAFV600E mutation analysis by use of droplet digital PCR in the follow-up of patients with melanoma being treated with BRAF inhibitors</article-title><source>Clin. Chem.</source><year>2015</year><volume>61</volume><fpage>297</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1373/clinchem.2014.230235</pub-id><pub-id pub-id-type="pmid">25411185</pub-id></element-citation></ref><ref id="B275-pharmaceuticals-16-01384"><label>275.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Mellman</surname><given-names>I.</given-names></name></person-group><article-title>Oncology meets immunology: The cancer-immunity cycle</article-title><source>Immunity</source><year>2013</year><volume>39</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.07.012</pub-id><pub-id pub-id-type="pmid">23890059</pub-id></element-citation></ref><ref id="B276-pharmaceuticals-16-01384"><label>276.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shae</surname><given-names>D.</given-names></name><name name-style="western"><surname>Becker</surname><given-names>K.W.</given-names></name><name name-style="western"><surname>Christov</surname><given-names>P.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lytton-Jean</surname><given-names>A.K.R.</given-names></name><name name-style="western"><surname>Sevimli</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ascano</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>M.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Balko</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy</article-title><source>Nat. Nanotechnol.</source><year>2019</year><volume>14</volume><fpage>269</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/s41565-018-0342-5</pub-id><pub-id pub-id-type="pmid">30664751</pub-id><pub-id pub-id-type="pmcid">PMC6402974</pub-id></element-citation></ref><ref id="B277-pharmaceuticals-16-01384"><label>277.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guedan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ruella</surname><given-names>M.</given-names></name><name name-style="western"><surname>June</surname><given-names>C.H.</given-names></name></person-group><article-title>Emerging Cellular Therapies for Cancer</article-title><source>Annu. Rev. Immunol.</source><year>2019</year><volume>37</volume><fpage>145</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-042718-041407</pub-id><pub-id pub-id-type="pmid">30526160</pub-id><pub-id pub-id-type="pmcid">PMC7399614</pub-id></element-citation></ref><ref id="B278-pharmaceuticals-16-01384"><label>278.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Melero</surname><given-names>I.</given-names></name><name name-style="western"><surname>Berman</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Aznar</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Korman</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Gracia</surname><given-names>J.L.P.</given-names></name><name name-style="western"><surname>Haanen</surname><given-names>J.</given-names></name></person-group><article-title>Evolving synergistic combinations of targeted immunotherapies to combat cancer</article-title><source>Nat. Rev. Cancer</source><year>2015</year><volume>15</volume><fpage>457</fpage><lpage>472</lpage><pub-id pub-id-type="doi">10.1038/nrc3973</pub-id><pub-id pub-id-type="pmid">26205340</pub-id></element-citation></ref><ref id="B279-pharmaceuticals-16-01384"><label>279.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Palucka</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Coussens</surname><given-names>L.M.</given-names></name></person-group><article-title>The Basis of Oncoimmunology</article-title><source>Cell</source><year>2016</year><volume>164</volume><fpage>1233</fpage><lpage>1247</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.01.049</pub-id><pub-id pub-id-type="pmid">26967289</pub-id><pub-id pub-id-type="pmcid">PMC4788788</pub-id></element-citation></ref><ref id="B280-pharmaceuticals-16-01384"><label>280.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Thi</surname><given-names>V.L.D.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Billerbeck</surname><given-names>E.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>H.-H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>L.A.V.</given-names></name><name name-style="western"><surname>Sarbanes</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Intrinsic Immunity Shapes Viral Resistance of Stem Cells</article-title><source>Cell</source><year>2018</year><volume>172</volume><fpage>423</fpage><lpage>438.e25</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2017.11.018</pub-id><pub-id pub-id-type="pmid">29249360</pub-id><pub-id pub-id-type="pmcid">PMC5786493</pub-id></element-citation></ref><ref id="B281-pharmaceuticals-16-01384"><label>281.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatti-Mays</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Redman</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Collins</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bilusic</surname><given-names>M.</given-names></name></person-group><article-title>Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations</article-title><source>Hum. Vaccines Immunother.</source><year>2017</year><volume>13</volume><fpage>2561</fpage><lpage>2574</lpage><pub-id pub-id-type="doi">10.1080/21645515.2017.1364322</pub-id><pub-id pub-id-type="pmcid">PMC5703410</pub-id><pub-id pub-id-type="pmid">28857666</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="pharmaceuticals-16-01384-f001" orientation="portrait"><label>Figure 1</label><caption><p>The timeline of tumor vaccines&#8217; development.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-16-01384-g001.jpg"/></fig><fig position="float" id="pharmaceuticals-16-01384-f002" orientation="portrait"><label>Figure 2</label><caption><p>The regulation mechanisms of the tumor microenvironment on tumor cells: TGF-&#946;, transforming growth factor-beta; IL, interleukin; VEGF, vascular endothelial growth factor; TNF-&#945;, tumor necrosis factor-&#945;; IFN-&#947;, interferon-&#947;; M-CSF, macrophage colony-stimulating factor; Tregs, regulatory T cells. Created with <uri>BioRender.com</uri>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-16-01384-g002.jpg"/></fig><fig position="float" id="pharmaceuticals-16-01384-f003" orientation="portrait"><label>Figure 3</label><caption><p>(<bold>A</bold>) Cellular immune response against cancer (step 1 to step 7); APCs, antigen-presenting cells; APC, antigen-presenting cell. (<bold>B</bold>) Humoral immunity response against cancer (step 1 to step 4). A&#8211;C; antibody-dependent cell-mediated cytotoxicity; a&#8211;c: complement-dependent cytotoxicity; MAC, membrane attack complex. Created with <uri>BioRender.com</uri>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-16-01384-g003.jpg"/></fig><fig position="float" id="pharmaceuticals-16-01384-f004" orientation="portrait"><label>Figure 4</label><caption><p>Therapeutic pipeline for personalized vaccines. Created with <uri>BioRender.com</uri>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="pharmaceuticals-16-01384-g004.jpg"/></fig></floats-group></article></pmc-articleset>